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 Summary 
SUMMARY 
Approximately 35 million of people were living with Human Immunodeficiency Virus (HIV) and 2 million 
were newly infected in 2012. Prevention measures and a higher coverage of antiretroviral therapy 
(ART) resulted in a decline of HIV incidence by more than 50% in 26 countries between 2001 and 2012. 
In addition, the observed impact of ART on community-level HIV incidence mainly on clinical trials has 
influenced clinical guidelines to start treatment early and to set up test-and-treat strategies or treatment 
as prevention (TasP) in some countries. However, it is a matter of debate if these policies would be 
cost-effectively in different settings. It is imperative that local governments become better informed with 
timely data about the characteristics of the local HIV epidemics, because they could influence the 
development of effective preventive policies. In this project we wanted to gain a deeper understanding 
of the dynamics of the HIV-1 epidemic in Belgium and Colombia, using viral sequences, socio-
demographic and clinical data, complemented with statistical and phylogenetic approaches. These two 
countries share an increasing incidence and prevalence of HIV-1 infection in recent years, but differ in 
the HIV health care and availability of relevant data.  Consequently, different research questions were 
triggered for each country.  
Unlike Belgium, there was limited information available about the molecular epidemiology of HIV-1 in 
Colombia and the spread of subtypes. In chapter 3, we focused on viral diversity and how the virus 
spread geographically and temporally in Colombia. Subtype B still predominated between 2002 and 
2007 in the country. Additionally, phylogenetic analyses showed that multiple introductions occurred in 
the early 80s and suggested a link between the Colombian and Spanish epidemics. Bogotá, the capital, 
was the main exporter of the HIV epidemic, and other important cities within Colombia acted as sinks. 
These findings suggest an important role of tourism in the spread of HIV, but further studies should 
investigate the complete dynamics of this epidemic.  
Since Transmitted drug resistance (TDR) can impact the efficacy of first-line ART and its use in 
prevention strategies such as the prevention of mother-to-child transmission or TasP, we focused our 
efforts to retrieve any data on TDR in the Colombian epidemic and zoomed out our evaluation at 
regional level in chapter 4. A systematic review was performed using published literature and viral 
sequences available from Colombia and other Latin American and Caribbean countries. The overall 
TDR prevalence was stable and some countries had more than 5%. The reported prevalence of TDR 
was around 6% in Colombia, but there were no data about trends or related factors. These findings 
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imply that surveillance of TDR should be frequently performed in countries such as Brazil or Venezuela 
or warranted in settings with scarce data such as Colombia, Central America and the Andean region.  
We investigated the evolution in TDR prevalence for the different drug classes and its association with 
other socio- demographic factors at the AIDS Reference Center and AIDS Reference Laboratory in UZ 
Leuven as a first step in the study of the epidemic in Belgium. The TDR and viral diversity prevalence 
were stable in Leuven between 1998 and 2012, while a parabolic trend was observed for TDR against 
non-nucleoside reverse transcriptase inhibitors. We were not able to identify a specific population 
significantly  associated with TDR or with spread of TDR, but men who have sex with men and 
originating from Belgium seemed to play an important role. The high number of chronically infected 
individuals in the cohort and the number of patients included in transmission clusters suggest that 
national collaborative studies should be prioritized to formulate policies that target earlier HIV diagnosis 
and prevention of transmission.  
As a methodological step, we evaluated the performance of automated subtyping tools with the aim to 
classify quickly the large amount of sequences used in different analyses in the Belgian and Colombian 
cohorts. Since our laboratory developed REGA version 3 (REGAv3), we compared our tool with the 
previous version REGA version 2 and six other tools. We found that most of the tools accurately 
identified subtype C and B, the most frequent clades worldwide. However, the performance was 
variable for other subtypes. COMET, jpHMM, REGAv3, and SCUEAL had good performance for pure 
subtypes using the pol region whereas COMET and REGAv3 also had good performance when 
analyzing most of the CRFs. Consequently, we recommended the use of two subtyping tools for 
surveillance and clinical purposes, and this was the strategy we also used to classify subtypes in other 
chapters. 
Finally, this thesis constitutes the initial step to characterize both epidemics. The complete 
understanding of these two local HIV epidemics will be useful for designing prevention strategies as 
well as for improving HIV health care programs. 
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 Resumen 
RESUMEN 
Aproximadamente 35 millones de personas vivían con el Virus de la Inmunodeficiencia Humana (VIH) y 
2 millones de casos de nuevas infecciones ocurrieron en el 2012. Medidas de prevención y una mayor 
cobertura de la terapia antirretroviral (TAR) permitió una disminución de la incidencia del VIH en más 
de un 50% en 26 países entre 2001 y 2012. Además, el impacto observado de la TAR en la incidencia 
del VIH a nivel  de salud pública en los ensayos clínicos ha influido en las guías clínicas para iniciar un 
tratamiento antirretroviral más temprano y la creación de estrategias como “test and treat” (testear-
diagnosticar y tratar) o tratamiento como prevención (TasP; del Ingles Treatment as Prevention) en 
algunos países. Sin embargo, es debatible si estas estrategias serían costo-efectivas en diferentes 
entornos. Por lo tanto, es imperativo que los gobiernos a nivel local estén mejor informados sobre las 
características específicas de la epidemia por VIH con datos actualizados, ya que pueden influir en el 
desarrollo de políticas de prevención eficaces. En este proyecto nuestro objetivo es describir la 
dinámica de la epidemia del VIH-1 en Bélgica y Colombia, utilizando secuencias virales, datos socio-
demográficos y clínicos, complementados con métodos estadísticos y filogenéticos. Estos dos países 
comparten un incremento de la incidencia y prevalencia de la infección por VIH-1 en los últimos años, 
pero difieren en la prestación de servicios de salud y la disponibilidad de  información pertinente. Dado 
estas diferencias, las preguntas de investigación fueron diferentes para cada país  
A diferencia de Bélgica, había poca información disponible acerca de la epidemiología molecular del 
VIH-1 en Colombia y la consecuente propagación de los subtipos. En el capítulo 3, nos hemos 
centrado en la diversidad viral y cómo el virus se propagó temporalmente y geográficamente en 
Colombia. El subtipo B predominó en el país entre los años 2002 y 2007. Además, los análisis 
filogenéticos mostraron que múltiples introducciones se produjeron entre finales de los años 70s y 
principios de los 80s e indicaron que las epidemias de Colombia y España estaban relacionadas. A 
nivel nacional, Bogotá, la capital, fue el principal exportador de la epidemia del VIH, y otras ciudades 
importantes actuaron como importadores del virus. Estos hallazgos sugieren un papel importante del 
turismo en la propagación del VIH, pero nuevos estudios son necesarios para investigar la dinámica de 
esta epidemia. 
La farmacorresistencia transmitida (TDR; del Ingles Transmitted drug resistance) puede afectar la 
eficacia de la TAR de primera línea y su uso en las estrategias de prevención, tales como la 
prevención de la transmisión de madre a hijo o TasP. Por lo consiguiente, nuestro objetivo era obtener 
todos los datos de TDR disponibles en Colombia y extenderlos a nivel regional en el capítulo 4. Una 
revisión sistemática fue realizada con la literatura publicada y secuencias virales disponibles en bases 
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de datos públicas que incluyeran información acerca de Colombia y otros países de América Latina y el 
Caribe. La prevalencia de TDR se mantuvo estable y en algunos países la prevalencia fue mayor al 
5%. Para Colombia, la prevalencia de TDR fue alrededor del 6% en Colombia, pero no hubo datos 
sobre tendencias o factores socioeconómicos o clínicos relacionados. Estos resultados implican que la 
vigilancia de TDR se debe realizar con frecuencia en países como Brasil o Venezuela o es requerida 
urgentemente en países con escasez de datos, tales como Colombia, América Central y la región 
Andina. 
Como un primer paso en el estudio de la epidemia en Bélgica, investigamos la evolución de la 
prevalencia de TDR para las diferentes clases de drogas y su asociación con otros factores socio-
demográficos en el Centro de Referencia del SIDA y del Laboratorio de Referencia de SIDA en UZ 
Leuven. La prevalencia de la diversidad viral y TDR fueron estables en Lovaina entre los años 1998 y 
2012, mientras que se observó una tendencia parabólica de resistencia contra los inhibidores no 
nucleósidos de la transcriptasa reversa. Aunque no se identificó significamente una población 
específica asociada con TDR o con la propagación de TDR, se evidenció una posible asociación con 
los hombres que tienen relaciones sexuales con hombres, nacidos en Bélgica. El elevado número de 
personas con infección crónica en la cohorte y que participan en grupos de transmisión, sugiere que se 
debe priorizar a nivel nacional estudios colaborativos los cuales ayuden a la formulación de políticas de 
salud pública para fortalecer el diagnóstico y prevención de la transmisión del VIH. 
Como paso metodológico, se compararon las herramientas automatizadas que clasifican los subtipos 
virales, con el propósito de identificar rápidamente la gran cantidad de secuencias utilizadas en los 
diferentes análisis realizados en las cohortes de Bélgica y Colombia. Como nuestro laboratorio diseñó 
REGA versión 3 (REGAv3), nuestro objetivo era comparar nuestra herramienta con la anterior versión 
y otras seis herramientas usadas frecuentemente o reportadas para clasificar subtipos. Como resultado 
se evidenció que la mayoría de herramientas identificaron los subtipos B y C, los cuales son los más 
frecuentes a nivel mundial. Sin embargo, la clasificación de otros subtipos fue variable. Cuando la 
región pol fue analizada, COMET, jpHMM, REGAv3 y SCUEAL identificaron los subtipos virales 
mientras que COMET y REGAv3 clasificaron las formas recombinantes circulantes. Por lo tanto, 
nosotros recomendamos el uso de por lo menos dos herramientas para identificar subtipos virales en la 
práctica clínica o en estudios de vigilancia epidemiológica molecular. Esta estrategia fue también 
usada para clasificar los subtipos en otros capítulos de esta tesis. 
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 Resumen 
Por último, esta tesis constituye el primer paso para caracterizar las dos epidemias. La descripción 
detallada de estas dos epidemias de VIH a nivel local será de utilidad para el diseño de estrategias de 
prevención, así como para mejorar los programas de atención de salud del VIH. 
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 Samenvatting 
SAMENVATTING 
In 2012 waren er wereldwijd ongeveer 35 miljoen mensen met een HIV besmetting en liepen er 2 
miljoen mensen die besmetting op. Preventieve maatregelen en een groter bereik van antiretrovirale 
behandeling (ART) resulteerde tussen 2001 en 2012 in een daling van de HIV incidentie met meer dan  
50% in 26 landen. Het geobserveerde effect van ART op de incidentie van HIV in de bevolking zorgde 
voor een bijsturing van klinische richtlijnen in de richting van vroegtijdige behandeling en het opzetten 
van een test-en-behandel strategie of behandelen als preventie (“treatment as prevention”, (TasP)) in 
sommige landen. Het is echter nog niet duidelijk of deze aanpak in verschillende omstandigheden 
kosteneffectief zal zijn. Daarom moeten lokale overheden beter geinformeerd worden met actuele 
gegevens over de kernmerken van de lokale HIV epidemies, omdat zij de ontwikkeling van 
doeltreffende preventieve maatregelen kunnen beïnvloeden. Het doel van deze studie was een beter 
begrip van de dynamiek van de HIV-1 epidemie in België en Colombia, met behulp van virale 
sequentie, socio-demografische en klinische gegevens, aangevuld met statistische en fylogenetische 
benaderingen.  In beide landen is in de voorbije jaren zowel de incidentie als de prevalentie van HIV-1 
infecties gestegen, maar zijn er verschillen in desbetreffende gezondheidszorg en de beschikbaarheid 
van relevante gegevens. Deze verschillen resulteerden in verschillende onderzoeksvragen voor beide 
landen. 
Anders dan in België, was er in Colombia slechts beperkt informatie beschikbaar over de moleculaire 
epidemiologie van HIV-1 en de verspreiding van subtypes. In hoofdstuk 3 ligt de focus op virale 
diversiteit in Colombia en de verspreiding van het virus in tijd en ruimte aldaar.  Tussen 2002 rn 2007 
had subtype B er nog de overhand. Fylogenetische analyse toonde aan dat meerdere introducties 
plaatsvonden in het begin van de jaren 1980 en suggereerde een verband tussen de epidemies in 
Colombia en in Spanje. De hoofdstad Bogota was the voornaamste exporteur van de HIV epidemie, 
terwijl andere belangrijke steden in Colombia als importeur functioneerden.  Deze resulaten suggereren 
dat toerisme een belangrijke rol speelde in de verspreiding van HIV, maar meer onderzoek is nodig om 
de volledige dynamiek van deze epidemie te ontrafelen. 
Omdat TDR de effectiviteit van eerstelijns ART kan beïnvloeden en aldus ook zijn toepassing in 
strategieën zoals preventie van verticale transmissie of TasP, hebben we er ons op toegelegd om zo 
veel mogelijk gegevens over de aanwezigheid van TDR in de Colombiaanse epidemie te verzamelen 
en daarna het probleem op grotere, regionale schaal te bekijken in hoofdstuk 4. We voerden een 
systematische review door van de gepubliceerde literatuur en de beschikbare virale sequenties van 
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Colombia en andere Latijns-Amerikaanse en Caraïbische landen. De prevalentie van totale TDR was 
stabiel, maar overtrof in sommige landen de 5%. De gerapporteerde prevalentie van TDR was in 
Colombia rond de 6%, maar er waren geen gegevens over trends of geassocieerde factoren.  Deze 
vaststellingen betekenen dat monitoring van TDR frequent moet uitgevoerd worden in landen zoals 
Brazilië of Venezuela, of aanbevolen moet worden op plaatsen met slechts beperkte gegevens, zoals in 
Colombia, in Centraal Amerika en in het Andesgebied. 
We onderzochten de evolutie van de prevalentie van overdracht van resistent HIV-1 (‘Transmission of 
drug resistance” or TDR) voor de verschillende klassen van remmers en zijn associatie met andere 
socio-demografische factoren in het AIDS Referentie Centrum and AIDS Referentie Laboratorium van 
UZ Leuven, als een eerste stap in de studie van de epidemie in België. TDR en virale diversiteit waren 
tussen 1998 en 2012 stabiel in België, maar voor TDR tegen niet-nucleoside reverse transcriptase 
inhibitoren observeerden we een parabolische trend.  We konden geen specifieke populatie 
identificeren die significant geassocieerd was met TDR of de verspreiding van TDR, maar de 
combinatie van MSM en Belgische origine leek een belangrijke rol te spelen.  Het grote aantal 
chronisch geïnfecteerden in de cohorte en het aantal patiënten in transmissie clusters suggereren dat 
de voorrang moet verleend worden aan collaboratief onderzoek op nationale schaal, om zo 
maatregelen te formuleren met als doelwit vroegere diagnose en preventie van transmissie van HIV. 
In een methodologische studie evalueerden we de prestatie van geautomatiseerde subtyping tools, met 
als doel een snelle klassificatie van de grote hoeveelheden sequenties die gebruikt zijn in de 
verschillende analyses in de cohortes uit België en Colombia.  Omdat ons laboratorium REGA versie 3 
(REGAv3) ontwikkeld heeft, vergeleken we onze tool met de vorige versie, REGA versie 2 en zes 
andere tools.  We zagen dat de meeste tools subtypes C en B, de claden die wereldwijd het meest 
voorkomen, accuraat konden identificeren.  Voor de andere subtypes verschilde de prestatie van tool 
tot tool.  COMET, jpHMM, REGAv3 en SCUEAL presteerden goed voor zuivere subtypes wanneer de 
pol regio werd geanalyseerd, terwijl COMET en REGAv3 ook goed resultaat opleverden bij de analyse 
van de meeste CRFs.  We raadden daarom aan om telkens twee subtyping tools te gebruiken in het 
kader van surveillance studies en klinische monitoring, en dat is ook de strategie die we zelf toepasten 
in de andere hoofdstukken. 
Deze thesis is een eerste stap in de richting van de karakteristaie van beide epidemies.  Een volledig 
begrip van deze twee lokale HIV epidemies zal bijdragen tot het ontwerpen van preventieve strategieën 
en tot het verbeteren van programma’s in de HIV gezondheidszorg. 
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 Chapter 1: General Introduction 
1.1 HISTORY 
The first cases of human immunodeficiency virus (HIV) infections were described in 1981 when 
Kaposi’s sarcoma and pneumonia by Pneumocystis carinii (now Pneumocystis jiroveci) were reported 
in the United States of America (USA) [1, 2]. With the increasing number of opportunistic infections and 
cancers in previous healthy people and the impairment of cell-mediated immunity, the acronym 
Acquired Immunodeficiency Syndrome (AIDS) was introduced one year later. Subsequently, a 
retrovirus was identified in 1983 by the French group headed by Luc Montagnier [3, 4]. In 1987, the 
hope of a treatment became reality with the use of zidovudine (ZDV), which decreased mortality and 
opportunistic infections [5]. Subsequently, mono- and bi-therapies were prescribed with the introduction 
of didanosine (ddI) and zalcitabine (ddC). The first evidence of resistance was reported in 1989 with the 
identification of mutations within reverse transcriptase [6, 7], together with the transient effect of mono-
therapy in preventing disease progression [8]. It was not until 1996 that Highly Active Antiretroviral 
Therapy (HAART) was used that eventually resulted into a decrease of mortality and morbidity [9].  
 
1.2 WORLDWIDE STATISTICS 
According to the Joint United Nations Programme on HIV/AIDS (UNAIDS) and the World Health 
Organization (WHO) an estimated 35.3 million people were living with HIV in 2012 (Figure 1.1), 1.6 
million of people died and 2.3 million were infected. The annual number of new infections has 
decreased by 50% in 26 countries between 2001 and 2012 [10]. The highest prevalence is still 
concentrated in sub-Saharan Africa, which has been the most affected region by the epidemic, followed 
by the Caribbean where HIV’s incidence has decreased since the 2000s [10]. However, other 
epidemics like the ones in Belgium and Colombia are characterized with an increase in the number of 
new infections during the last years. Since these epidemics are the subject of this thesis, they will be 
discussed in detail in chapter 6.   
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FIGURE 1. 1. PREVALENCE OF HIV WORLDWIDE  
Figure 1.1: Prevalence of HIV worldwide. HIV prevalence is shown in shades of red according to 
UNAIDS-WHO report 2013. The estimated number of people living with HIV (*), number of new HIV 
infections (^) and number of AIDS-related deaths (†) in each geographical region are displayed. 
Adapted from UNAIDS [10]. 
 
1.3 THE HUMAN IMMUNODEFICIENCY VIRUS 
According to the International Committee on Taxonomy of Viruses, HIV is classified into the genus 
Lentivirus, subfamily Orthoretrovirinae, and family Retroviridae [11]. Retroviruses cause chronic 
infections with a range of pathogenic manifestations such as cancer, immunodeficiency and central 
nervous system diseases. Retroviruses are characterized with a similar morphology, genomic structure 
5’LTR-gag-pol-env-3’LTR and replicative cycle [12]. 
 1.3.1 MORPHOLOGY AND GENOMIC STRUCTURE  
The HIV mature virion is roughly spherical with a diameter of approximately 120 nm (Figure 1.2). The 
envelope is a lipid bilayer that is derived from the membrane of the host cell and that contains host 
proteins such as major histocompatibility antigens, actin and ubiquitin (yellow). At the viral surface 
spikes are formed by glycoproteins gp120 that interact with transmembrane proteins gp41 (blue).  The 
inner surface of the envelope is lined with about 2,000 copies of matrix protein p17 (dark green). The 
cone-shaped capsid is located in the center of the virus and is formed by capsid protein p24 (brown). It 
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contains the essential enzymes protease (PR), reverse transcriptase (RT), integrase (IN) and two 
identical copies of unspliced positive single stranded ribonucleic acid (RNA) molecules that are bound 
to the nucleocapsid proteins p7 (red with white) [13].  
 
The length of the HIV proviral genome is around 9,700 nucleotides.  Multiple reading frames lead to 
nine partly overlapping genes. Three genes encode the structural and enzymatic proteins commonly 
found in retroviruses. The group specific antigen (gag) gene encodes the precursor p55 that is 
subsequently cleaved by PR, into the structural proteins matrix (MA or p17), capsid (CA or p24), 
nucleocapsid (NC or p7) and p6. The polymerase (pol) gene encodes PR (p11), RT (p66/p51), and IN 
(p31). The env gene encodes surface gp120 and transmembrane gp41 glycoproteins [12].  
 
 
FIGURE 1. 2. MOFPHOLOGY OF HIV 
Figure 1.2: Morphology of HIV. Adapted from http://www.hiv.lanl.gov  
Two other genes are essential for virus propagation and replication, for instance tat (transactivator of 
HIV gene expression) and rev (regulatory factor). Four accessory or auxiliary genes are not essential in 
vitro but are necessary for spread and disease progression in vivo: vif (viral infectivity factor), vpr (viral 
protein R in HIV-1 and its homolog vpx in HIV-2), vpu (viral protein U), and nef (before named negative 
factor). Finally, the long terminal repeats (LTR) are necessary for transcription regulation [12]. 
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FIGURE 1. 3. GENOMIC STRUCTURE OF HIV 
Figure 1.3: Genomic structure of HIV.  The relative locations of the open reading frames 
gag, pol, env, vif, vpr, vpu, nef, tat and rev are shown. The blue lines indicate the positions 
according to HXB2 strain. Adapted from [14]. 
 1.3.2 REPLICATION CYCLE 
The entry of HIV requires the presence of the cluster of differentiation 4  (CD4), present on T-
lymphocytes, macrophages, dendritic cells and brain microglia. The replication cycle includes ten 
important steps that are divided in two phases (Figure 1.4). The early phase includes binding to 
integration, whereas the late phase begins with transcription and ends with viral maturation [13]. 
EARLY PHASE 
The interaction between gp120 and the amino-terminal domain of CD4 causes the binding between 
virus and target cell. Afterwards, conformational changes allow the binding between gp120 and the 
chemokine receptors CXC-chemokine receptor 4 (CXCR4) and the CC-chemokine receptor 5 (CCR5). 
The CCR5 co-receptor is generally used in early stages of the infection and CXCR4 in the late stages. 
Based on the use of these co-receptors, the tropism of viruses could be classified as X4, R5, R5+X4 
and R5X4, which is important for therapeutic options. The interaction between CD4-gp120-
CCR5/CXCR4 triggers conformational changes within gp41, which promotes the physical approach 
between viral and cellular membranes and fusion [12-14]. 
 
Entry of the HIV core into the cytoplasm causes the disintegration of the capsid with the aim to release 
the viral proteins. This process is known as uncoating.  RT catalyzes the reverse transcription of two 
RNA molecules into one double-stranded deoxyribonucleic acid (DNA). The newly synthesized viral 
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DNA is imported within the nucleus as part of the preintegration complex that additionally includes 
viral proteins such as MA, IN, RT and Vpr [13].  
 
Subsequently, the IN catalyzes the integration of proviral DNA into the host cell genome. This provirus 
serves as template for the synthesis of RNA that encodes the structural, enzymatic, regulatory and 
accessory proteins. The provirus is the basis for viral latency and reservoirs. Latency occurs when the 
CD4 cell turns into a resting status and limited transcription occurs. Activation of the resting cell results 
into complete transcription and a productive infection [15]. Viral reservoirs are a small pool of cells 
within lymphoid tissue and the brain, that provides a long-lived source of rebound viraemia [16]. 
LATE PHASE 
Transcription is initiated at the LTR site, in which Tat is an essential transcriptional activator to 
increase viral RNA synthesis. This process generates three types of RNA: (i) unspliced or genomic 
RNA that is the messenger RNA (mRNA) for Gag and Gag-Pol precursors; (ii) singly spliced mRNAs 
that encodes Env precursor, Vpu, Vif and Vpr; and (iii) multiply spliced mRNAs that are translated into 
Tat, Nef and Rev [12, 17]. With the aim to translate all types of mRNA, the unspliced and singly spliced 
mRNAs need to be transported to the cytoplasm by Rev. Indeed, Rev acts by binding the rev 
responsive element, promoting the nuclear export and cycling between nucleus and cytoplasm of 
unspliced and singly spliced mRNA [12, 18]. 
 
Following the translation of the proteins, the assembly involves the Gag precursor polyprotein pr55, 
which binds to the plasma membrane and promotes the interaction of gag-gag proteins, encapsidation 
of RNA and the incorporation of Env proteins in the host membrane. Env precursor is translated in the 
rough endoplasmic reticulum and cleaved by host protease in the Golgi apparatus [17]. The budding of 
the immature virus includes interactions between host factors, and the p6 domain within Gag to hijack 
the endosomal machinery and release it. Viral maturation requires the cleavage of Gag and Pol 
polyproteins by PR in order to re-assemble the virion. A single cell can produce thousands of virus 
particles until the apoptosis of the host cell. Meanwhile new virus particles could start another 
replication cycle [12, 14].  
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FIGURE 1. 4. REPLICATION CYCLE 
Figure 1.4: Replication cycle.  Adapted from [19]. 
 
1.4 MOLECULAR EPIDEMIOLOGY 
The evolution of HIV is the consequence of several viral intrinsic mechanisms: the lack of proofreading 
activity of RT, the high mutation rate of 3.4 x 10-5 mutations per base pair per replication cycle [20, 21], 
the high viral production of 1010 virions per day [22, 23], the process of recombination with 7 to 30 
crossovers per genome per round of replication, the flexible conformation of HIV proteins, the short 
generation time between 24-48 hours [24] and Apolipoprotein B mRNA editing enzyme, catalytic 
polypeptide-like (APOBEC) editing [25].  1.4.1 PHYLOGENETIC ANALYSES ON THE SURVEILLANCE OF HIV 
Phylogenetics describes evolution and relationships among genes or genes fragments, by inferring their 
common ancestor. Therefore, it is necessary for phylogenetic analyses that sequences under 
investigation are from the same gene and without evidence of recombination [26].  Phylogenetic tools 
have been used in molecular epidemiology to investigate the origin of HIV and to classify subtypes [27] 
and their introduction and dissemination in different regions.  
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Phylogenetic analyses include the pre-processing of data from datasets or databases, such as the 
retrieval of particular fragments of a gene and an alignment to put homologous residues arranged in 
columns with the assistance of software packages such as ClustalW and Muscle [26, 28, 29]. The 
reconstruction of a tree could be performed by two different algorithm methods: optimality search 
criterion and clustering. Each one can use different kind of data such as discrete characters 
(morphological, physiological characteristics, nucleotides or amino acids) or a distance matrix of 
pairwise genetic dissimilarities [30].  Usually pairwise distance methods are complemented with 
evolutionary models that provide a statistical description of the substitution of nucleotides or amino 
acids in the sequence [26]. The most common used methods in phylogenetics of HIV are the distance 
pairwise method that uses clustering called Neighbor-joining (NJ) and the character state algorithm that 
use optimality criterion called Maximum likelihood (ML). Nonparametric bootstrap is used to determine 
the phylogenetic branch support in both methods [31]. However, the approximate likelihood ratio test 
(aLRT) is another fast alternative instead of nonparametric bootstrap when ML method is used [32]. 
The choice of the method depends on the kind of analyses, for instance NJ method works well for 
subtyping HIV sequences [33] (see section 1.4.4), whereas ML method is used in cluster transmission 
analyses because the exhaustive searching of different tree topologies (see section 1.7)  [26, 34-39]. 
 
Whereas NJ or ML methods construct one tree, Bayesian methods integrate all plausible trees and 
provide confidence intervals (or Bayesian credible intervals) for any evolutionary relationship [26]. This 
is summarized in the maximum clade credibility (MCC) tree that also shows different traits, for instance 
the posterior distribution or probability. These techniques have several applications, for instance cluster 
transmission analyses (see section 1.7) [40-43], time-scaled phylogenies [44-48], and lately, 
phylogeographic diffusion models [49-51]. Phylogeography is based on the measurable imprint on the 
genome of rapidly evolving viruses that occurs simultaneously with the geographical dispersal over a 
specific period [52, 53]. Therefore it can provide insights about the viral introduction and dissemination 
in a region or the impact of human mobility on the spread of the HIV epidemic [51, 52]. 1.4.2 ORIGIN OF HIV 
Based upon clinical records, colonial literature and phylogenetic analyses of primate and human 
lentiviruses, the origin of HIV has been related with bushmeat hunting and keeping primates as pets 
[54-56]. HIV-1 group M (major) and group N (nonoutlier) originated from Simian Immunodeficiency 
Virus (SIV) (Figure 1.5), which was isolated from a subspecies of chimpanzee in West Africa, more 
specifically from Pan troglodytes troglodytes [57]. The origin of HIV-1 group O (outlier) and P (putative) 
was the SIV from gorillas in the same region [57-59].  
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FIGURE 1. 5. CLASSIFICATION OF HIV 
Figure 1.5: Classification of HIV. HIV is classified in types 1 (green) and 2 (blue).  HIV-1 is divided in 
groups M, N, O and P. The group M includes nine subtypes, subtype A and F are divided in sub-
subtypes e.g. A1 or F1. Some examples of circulating recombinant forms (CRFs) are shown in violet.  
HIV-2 is classified in eight groups (A-H), but only the most frequent groups A and B are shown [27, 58]. 
Tree adapted from [60]. 
 
The origin of HIV-1 group M was dated between 1900s and 1930s (Figure 1.6) [59, 61-64]. Two recent 
articles support its origin in the early 1900s. One included the phylogenetic analysis including the two 
oldest samples obtained from patients in Kinshasa, Democratic Republic of Congo [64]. According to a 
study including phylogenetic analysis, computational simulations and review of colonial literature [59], 
the main driver of the spread of HIV in the early 20th century was linked to sexual transmitted diseases, 
especially ulcerative diseases, in the heterosexual risk transmission group, whereas the increase of city 
population size and the low frequency of circumcision at that time had little effect in the initial viral 
spread [59].  
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HIV-2 originated from interspecies transmission between Sooty mangabey monkeys (Cercocebus atys 
atys) and humans. Each HIV-2 group (A-H) originated from independent cross-species transmission 
events from this monkey species infected with SIV [65]. HIV-2 group A originated around 1930s and 
group B around 1935s (Figure 1.6) [51, 63, 66, 67]. 
 
 
 
FIGURE 1. 6. ESTIMATED TIME LINE OF THE GLOBAL SPREAD OF HIV 
Figure 1.6: Estimated time line of the global spread of HIV. Adapted from [60]. Additional subtype B 
data were adapted from [47, 48, 68-70] 
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 1.4.3 MOLECULAR EPIDEMIOLOGY 
Group M is the predominant circulating HIV-1 group, that is classified in subtypes A-D, F-H, J and K 
(Figure 1.5) [27]. The circulating recombinant forms (CRFs) are recombinants for which the full length 
sequences are fully characterized and specific breakpoints can be found in at least three people 
epidemiologically unlinked [27]. These are denominated according to the subtypes that compose the 
recombinant, and numbered according to the order of description (Figure 1.5). Up to date, there are 61 
CRFs described in HIV-1 and one in HIV-2 (http://www.hiv.lanl.gov, accessed in February 2014). 
Additionally, inter-subtype recombination is common resulting into unique recombinant forms (URFs) 
within single patients [23].  
 
The rare HIV-1 groups N, O and P have been identified mainly in Cameroon [58, 71, 72]. HIV-2 groups 
A and B have spread in West Africa causing 1-2 million of cases, whereas the other HIV-2 groups (C-H) 
have been rarely isolated [10, 73, 74].  
 
To estimate HIV diversity large amounts of published and unpublished data were summarized and 
weighted according to the number of people living with HIV in each country by the WHO network of HIV 
Isolation and Characterization [75]. Subtype C was responsible for about 50% of HIV-1 infections 
worldwide between 2000 and 2007 (Figure 1.7). It was dominant in Southern and East Africa, India and 
Oceania. Subtype B was the most frequent subtype in Western and Central Europe and America. 
Regarding the molecular epidemiology of Belgium and Colombia, subtype B is predominant in both 
countries [76-79]. However, the percentage of subtype B is around 50% according to the last 
nationwide survey carried out in Belgium until 2006 [78]. In contrast, subtype B accounts for around 
99% of the HIV infections in Colombia until 2002 [76, 77, 79]. The epidemiology of these two countries 
will be further discussed in chapter 6. 
 
Several studies have reported on the origin of subtypes around the world [45, 61, 80, 81]. The most 
studied and prevalent subtype in America and Europe is B. The subtype B epidemic started to spread 
from Central Africa to Haiti around 1966 (1962-1970), before dispersing in a single migration to the USA 
around 1969 (1966-1972) and to Trinidad and Tobago around 1973 (1970-1976). Phylogenetic analysis 
showed that single chance events, ecological interactions and specific population bottlenecks and 
founder effects influenced the spread of subtype B in the Americas [48]. A recent study also suggested 
that the epidemic in South America was influenced by migration and multiple introductions from 
Caribbean but also by immigration to USA [69].  The spread of subtype B  in Europe was related with 
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North American men who have sex with men (MSM) and intravenous drug users (IVDU) [82-84]. Most 
of the migratory pathways of subtype B in Europe are bidirectional. However, some countries are 
sources and others are sinks. For instance, tourism could partially explain the viral dispersal from 
Greece, Portugal, Serbia and Spain to Central Europe. Similarly, Austria, Belgium and Luxembourg 
have an imported epidemic due to the highest immigration from other European countries [83]. 
Concerning the origin of subtype B in Colombia and migration pathways, there is not information 
available (see chapter 3). On the other hand, multiple introductions from Africa and Asia were involved 
in the spread of non-B subtypes in Europe [60], and links with former colonies in Central-Africa 
influenced from the start the relative high prevalence of non-B subtypes in Belgium, Portugal and 
France [85].  
 
 
FIGURE 1. 7. EPIDEMIOLOGY OF SUBTYPES WORLDWIDE 
Figure 1.7:  Epidemiology of subtypes worldwide. Subtype C (blue), subtype B (orange) and 
subtype A (red) are the three most prevalent subtypes worldwide. The prevalence of subtypes varies 
with geographical localization.   Adapted from [74]. Data for Colombia and Belgium were adapted from 
[75, 76, 78, 79]. 
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The currently most prevalent subtype C originated around 1958 (1949-1960) [80]. A rapid spread in 
South Africa followed by the introductions to India and China could explain the high prevalence of this 
subtype (Figures 1.6 and 1.7) [60]. In the 1990s, it was also introduced to Brazil directly via East Africa 
[86], or via an intermediate step in UK [45]. Other multiple introductions have been reported for Italy, 
mainly from South America and India [87]. Although other few non-B subtypes have been studied [46, 
47, 66, 88, 89], the increasing availability of more data from these subtypes is expected to unravel the 
routes of the HIV-1 spread. 
 1.4.4 METHODS OF SUBTYPING HIV 
Although serological and genotypic methods have been used to identify HIV strains, the gold standard 
to classify subtypes is based upon the manual phylogenetic analysis of full-length viral sequences. 
Subtypes are phylogenetically equidistant, generating a starlike tree (Figure 1.5). The genetic variation 
between subtypes is usually 25-35% depending on the genes compared, whereas within a subtype it 
can be 15-20% [23]. Some subtypes have sub-subtypes with a smaller genetic distance (e.g. A1-A4 
and F1-F2). The classification of HIV is based on phylogenetic analyses, in which the clustering pattern 
of viral sequences provides information about genetic similarity and evolutionary rate [27]. This 
classification is dynamic because it could change with the availability of new sequences. However, it is 
expensive to sequence the full-length viral genome and the analysis is time consuming. Since most 
available sequences are obtained within the framework of drug resistance testing, automatic tools have 
been developed with the aim to identify subtypes based upon PR and RT fragments [90-92]. In 
addition, the automated subtyping tools enable the quick classification of one to hundreds of 
sequences.  
 
According to the methodology used to assign an HIV-1 clade to a query sequence, automatic tools can 
be divided into three main types. First, similarity-based tools use an alignment between the reference 
and the query sequence and calculate the match. Examples include the NCBI subtyping tool [93], 
Stanford [94], Geno2pheno [95] and EuResist (http://engine.euresist.org/data_analysis/ 
viral_sequence/new). Second, statistical-based tools use prediction by partial matching compression 
algorithm like COntext-based Modeling for Expeditious Typing COMET [96], position-specific scoring 
matrices plus a statistical model such as STAR [97] or jumping profile Hidden Markov Models such as 
jpHMM [98]. Third, phylogeny-based tools like REGA [99] and SCUEAL [100].  Currently, it is not clear 
which tool is better to classify B or non B subtypes.  
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1.5 STAGES OF HIV-1 INFECTION 
HIV is present in blood, genital fluids and breast milk. Transmission events are mainly the consequence 
of exposure to HIV at mucosal surfaces (80%) and the remaining transmissions are caused by 
percutaneous or intravenous inoculation. The per-act HIV transmission depends on the type of 
exposure. For instance, it is around 92.5% for blood transfusion, 22.5% for mother to child transmission 
(MTCT), 0.63% for IVDU, and 0.23% for percutaneous needle stick injury. Sexual transmission risk 
depends on the type of intercourse. Indeed, the per-act HIV transmission risk for receptive anal 
intercourse is 1.38%, for insertive anal intercourse 0.11%, for receptive penile-vaginal intercourse 
0.08%, and for insertive penile-vaginal intercourse 0.04% [101]. The sexual transmission risk increases 
with genital ulcer diseases and high viral load, and during acute or late state of the disease, and 
decreases with circumcision, male condom use, and use of antiretroviral therapy (ART) [101].     
 
Genetic diversity may affect the transmissibility [102, 103]. Subtype C seems to be more transmissible 
than subtypes A and D according to studies performed in pregnant women [104, 105] but not in 
heterosexual couples [106]. In Kenya, the MTCT rate was higher among women infected with subtype 
D than with subtype A [107], whereas in Tanzania subtype A was more likely to be transmitted than 
subtype D [104]. A study performed in discordant couples revealed a higher rate of heterosexual 
transmission of subtype A than subtype D [108] which seems to be in agreement with the higher 
number of infections of subtype A worldwide (Figure 1.7).  In another study, CRF01_AE seemed also to 
be more transmissible than subtype B in IVDU [109]. 
 
After exposure, HIV initially replicates in mucosal, submucosal and lymphoreticular tissues and 
therefore it is not detected in plasma yet. The clinical manifestations of acute infection could be 
asymptomatic, similar to flu-like syndrome with pharyngitis, non-tender lymphadenopathies or 
mucocutaneous ulcerations by Candida spp, Epstein-Barr virus or Herpes simplex virus (acute retroviral 
syndrome) [110]. Other less frequent signs or symptoms can be presented such as generalized 
maculopapular rash, hematologic disturbances like anemia or thrombocytopenia, neurological disorders 
like aseptic meningitis and reactivation of Varicella-zoster virus [111]. 
 
The phases of HIV-1 infection can be categorized based on the sequential positivity of diagnostic 
assays (Fiebig stages I-VI, Figure 1.8A). The period between infection and the detection of viral RNA is 
named eclipse, and can last 7 to 21 days.  At the end of the eclipse phase, HIV reaches the gut-
associated lymphoid tissue, as well as other lymphoid tissues, and a peak viraemia concomitantly with 
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a decrease of CD4 T cells is observed [112]. In the initial phase of acute infection, the algorithm for the 
diagnosis of HIV-1 infection includes detection of viral RNA, p24 antigen or fourth generation combined 
HIV antigen/antibody immunoassay [113, 114]. The viral burden is high during acute infection. 
Therefore, transmission of HIV is mainly driven by recently infected individuals, who account for 5 to 
50% of the transmissions [34, 102, 103, 115-117]. The seroconversion occurs in Fiebig stage III when 
viral-specific antibodies are detected in serum [118]. The viral load gradually decreases over 12-20 
weeks and reaches a viral set point [119, 120]. Meanwhile the pressure of adaptive immune responses 
selects mutants and virus diversification occurs. 
 
The Fiebig scale depends on the used test methods [121]. Ideally, these methods should be able to 
detect all subtypes, although some assays have a lower performance [122]. False-negative results 
have been reported in fourth-generation immunoassays in subtypes A, C, F, H, CRF01_AE and O. 
Similarly, false negatives for subtypes B, C and F have been described for gp41 immunoassays [123, 
124]. These results are the consequence of differences in viral epitopes [123, 125]. Rapid HIV tests 
have also shown low sensitivity for D, F, H, CRF01_AG, O and HIV-2 [122, 125-128]. In general, viral 
load assays perform well for B and non B subtypes, but the assays based on integrase seem to perform 
better on viral strains belonging to M, O and N than assays using primers and probes in the gag gene 
[122, 129] . 
 
The early chronic infection phase is frequently asymptomatic but some individuals do display clinical 
manifestations like persistent generalized lymphadenopathy. The duration of the clinically latent phase 
is variable but it could last between 1 and 10 years (Figure 1.8). In the meantime the CD4 count 
declines on average with 50 cells /mm3 per year, which is influenced by the viral burden [130]. The final 
AIDS stage is reached when there are less than 200 CD4 cells /mm3 or opportunistic infections and 
malignancies occur [111, 131]. When the CD4 count reaches 50 cells/mm3 and ART is not provided, 
the median survival is 12 to 18 months [132]. 
 
Some patients are the exception of the described profile in clinical progression and are named long-
term nonprogressors. They can be infected for more than 10 years without any clinical symptom and 
CD4 count above 500 cells/mm3 without receiving ART [133]. Similarly, the “elite controllers” are 
characterized with a spontaneous virological control defined as viraemias below 50 copies/mL [134]. 
The genetic background and differences in immunological response, such as cytotoxic T cell response 
and HLA class I alleles, have been described as possible causes of this particular phenomenon [133].  
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Despite 30 years of research, the impact of subtypes on disease progression is still a matter of debate 
due to conflicting data and the presence of several confounding factors [107, 135]. Several reports from 
Uganda, Tanzania, Kenya and London have shown a faster progression in people infected with subtype 
D than with other subtypes [136-138]. The dual or X4 tropism of subtype D, the more frequent formation 
of syncytium and the higher replication capacity of the pol region are factors that could explain the 
faster decrease of CD4, compared with other subtypes [137, 139, 140]. A cohort study performed in 
London could not detect differences in disease progression between subtypes A, B, C and CRF02_AG 
[141].  However, a systematic review showed that subtype C is also aggressive, followed by G, 
CRF01_AE, and CRF02_AG mainly in developing countries [135]. Recent reports on larger study 
populations also showed the rapid disease progression associated with subtype C, which may be 
related to the increased replication capacity [142, 143]. Similarly, CRF01_AE is associated with X4 
tropism and consequently low CD4 count in MSM [144, 145]. The viral load has also been compared 
between different cohorts. People infected with CRF01_AE had threefold higher viral load after three 
months of seroconversion when compared to subtype B, but no difference was found after one year 
[146]. Two reports showed higher viral loads in subtype D infections [137, 139] but other two did not 
[141, 147], which raise the question whether other factors such as comorbidities, co-infections, 
constitution and socio-economic conditions could impact the different response and disease 
progression [135, 147]. A recent systematic review pointed to the heterogeneity of the outcome 
measures and suggested to use subtype A as comparator and the inclusion of some typical outcome 
measurements such as relative risk, odds ratio (OR) or hazard ratio [135]. The standardization of future 
studies might enable the pooling of different datasets and provide valuable information for clinicians in 
developing countries where 88% of the individuals infected with non-B subtypes are living. 
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FIGURE 1. 8. PATHOGENESIS OF HIV-1 
Figure 1.8: Pathogenesis of HIV-1. A) The Fiebig stages are represented by roman numbers and are 
classified according to a positive result for viral RNA measured by PCR (I), for p24 antigen (II) and for 
antibodies immunoglobulin M (IgM) measured by enzyme linked immunosorbent assay (ELISA) but not 
by western blot (III), for antibodies detected by ELISA and by western blot (still indeterminate) (IV), for 
antibodies detected by ELISA and by western blot (positive, but still p31 negative) (V), for antibodies 
detected by ELISA and by western blot (positive including for p31) (VI). B) The relationship between 
viral load (red line) and CD4+T cell (blue line) over time in an untreated patient. R5 virus is usually 
found during the early stages of the infection, whereas X4 viruses in the chronic stage.  Abbreviation: 
DC:  Dentritic cell, PCR: Polymerase chain reaction. Figures adapted from [120, 148]. 
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1.6 ANTIRETROVIRAL THERAPY 
Currently, there are six different classes and 28 drugs approved by USA Food and Drug Administration. 
The classes are nucleoside/nucleotide reverse transcriptase inhibitors (NRTI), NNRTI, protease 
inhibitors (PI), fusion inhibitors (FI), coreceptor antagonists (CRA) and integrase inhibitors (INI). These 
drugs must be combined in HAART that contains three active drugs, or at least two fully active 
compounds in case of salvage regimen [149, 150]. See table 1.1.  
 
HAART could display suboptimal results due to side effects or toxicity, prior ineffective ART, infection 
with a drug resistant strain or suboptimal adherence [151]. The latter factor is the major reason of initial 
therapy failure.  At least 95% of the doses must be taken with the aim to completely suppress viral 
replication [152, 153], although certain regimens based upon NNRTI and boosted-PIs could tolerate 
lapses due to their high potency and longer half-lives [154, 155]. Otherwise, residual replication could 
result into resistance and therapy failure. Treatment failure can be defined clinically (occurrence or 
recurrence of opportunistic infections or malignancies), immunologically (failure to achieve and maintain 
an adequate CD4 response despite virologic suppression) or virologically (inability to achieve or 
maintain suppression of viral load <50 copies/mL) [114, 156].  As viral load is the most important 
measure of response to therapy, the most recent WHO guidelines have included the assessment of 
viral load in the follow-up of patients treated in low-middle income countries. In this guideline, virological 
failure was defined as a persistent HIV viral load above 1,000 copies/mL, measured in two consecutive 
tests within an interval of 3 months [157]. Given these definitions and the roll-out of ART in resource-
limited settings, it is essential to have access to viral load assays that can accurately quantify the extent 
of viral replication for all subtypes and viral variants, as lower sensitivities affect clinical decision making 
and could compromise subsequent therapeutic lines [122, 129].  
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Drug 
class Drugs 
Release 
year Activity Mechanisms of resistance 
NRTI 
 
Zidovudine (ZDV) 1987 
NRTI are mimetics of  
nucleosides/nucleotides 
and bind to the active site of 
the polymerase domain of 
RT, once incorporated they 
inhibit the synthesis of viral 
DNA.  
 
(i) Thymidine analogue 
mutations promote ATP and 
pyrophosphate-mediated 
excision of the incorporated 
nucleoside analogue. (ii) 
Mutations interfere with the 
binding and/or incorporation 
of the nucleoside analogue 
into the growing viral DNA 
chain.  
 
  Didanosine (ddI) 1991 
  Zalcitabine (ddC) 1992 
  Stavudine (d4T) 1994 
  Lamivudine (3TC) 1995 
  Abacavir (ABC) 1998 
  Tenofovir (TDF) 2001 
  
Emtricitabine (FTC) 2003 
 
NNRTI Nevirapine (NVP) 1996 NNRTI are designed to bind 
to an allosteric hydrophobic 
pocket within RT, modifying 
its structure and impairing 
its catalytic activities.  
 
Mutations reduce affinity of 
the inhibitors for the binding 
site at the enzyme. Single 
mutations generally are 
sufficient to induce 
resistance.  
 
 
Delavirdine (DLV) 1997 
 
Efavirenz (EFV) 1998 
 
Etravirine (ETR) 2008 
 
Rilpivirine (RPV) 2011 
PI Saquinavir (SQV) 1995 
 
Except for TPV, PI are 
mimetics of viral peptides 
and bind to the PR active 
site, preventing viral 
maturation.  
 
Mutations reduce affinity of 
the inhibitors for the enzyme. 
PIs require accumulation of 
multiple mutations to reduce 
susceptibility. Major 
mutations impair binding 
affinity whereas minor 
mutations often improve 
replication capacity. 
  Ritonavir (RTV) 1996 
  Indinavir (IDV) 1996 
  Nelfinavir (NFV) 1997 
  Amprenavir (APV) 1999 
  Lopinavir (LPV) 2000 
  Atazanavir (ATV) 2003 
  Fosamprenavir (FPV) 2003 
  Tipranavir (TPV) 2005 
  Darunavir (DRV) 2006 
 
FI Enfuvirtide (T20) 2003 
T20 is a small peptide that 
binds to gp41 and prevents 
the fusion between viral 
envelope and cellular 
membranes.  
Mutations affect a domain of 
gp41 whose interaction 
promotes membrane fusion.  
   
CRA Maraviroc (MVC) 2007 MVC binds to CCR5 and 
prevents gp120 attachment 
to CCR5. 
Change in coreceptor use 
(mainly due to genotypic 
changes within V3 loop) or 
mutations that allow binding 
of CCR5-MVC complex. 
 
INI 
 
Raltegravir (RAL) 
Elvitegravir (ETG) 
Dolutegravir (DTG) 
 
2007 
2012 
2013 
 
INI bind to the viral 
integrase and prevent the 
integration of the viral 
double-stranded cDNA into 
the host cellular genome.  
Mutations affect the vicinity 
of the INIs-binding pocket in 
the catalytic core domain of 
the enzyme. 
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Table 1.1: Activity and resistance mechanism of antiretroviral drugs approved by United States 
Food and Drug Administration. Abbreviations: ATP: Adenosine triphosphate. Adapted from [149, 
150, 158]. 1.6.1 TREATMENT GOALS INDIVIDUAL LEVEL 
Since ART is not able to eradicate HIV infection due to long-term viral reservoirs, the aim of therapy is 
the preservation or restoration of the immune system. Therefore, the main goal is the suppression of 
HIV viral load with the consequent reduction of HIV-associated morbidity and improvement of the 
quality of life and prolongation of survival [114]. 
At the individual-level, the viral repression requires a highly potent ART with the use of three active 
drugs from at least two different classes [114, 156]. The clinical evaluation of the patient, the laboratory 
tests and the readiness of the patient to start ART will guide clinicians to choose the first line therapy 
(Table 1.2). The regimen in high-income countries is individualized because upon the availability of 
more antiretrovirals, genotyping resistance testing and HLA-B*5701 tests. The detection of this allele is 
associated with the hypersensitivity to ABC, which includes mainly rash, fever, gastrointestinal and 
respiratory symptoms that could become severe and potentially life-threatening [159]. Moreover, the 
guidelines are moving towards an earlier start of ART according to the CD4 count given the increasing 
evidence of the association of viremia with cardiovascular, kidney and liver diseases, cancer or other 
neurological complications. The exceptions are USA, Brazil and France, where ART is recommended 
for all patients diagnosed with HIV [114, 160-162]. 
In middle and low-income countries where the scaling-up of ART should be optimized, the WHO 
recommends to start therapy with one preferred first-line regimen based on the balance between cost-
effectiveness and clinical evidence (Table 1.2) [157]. Moreover, laboratory tests such as baseline 
resistance testing or HLA-B*5701 are not recommended. Instead, the scaling up of viral load testing is 
considered to be a priority. Nevertheless, every country can adapt these WHO guidelines to the local 
setting.  For instance, the Colombian guideline includes ABC or boosted PI as first-line therapy, 
whereas baseline resistance testing is not recommended [163]. It is only recommended when 
therapeutic failure occurs (definition according to European or USA guidelines described previously). 
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COMMUNITY LEVEL 
The community-level goal of ART is based on the prevention of HIV transmission. For instance, ART 
has been used since mid-90s in HIV-infected pregnant women to prevent perinatal transmission 
because it decreases the risk of transmission from 20% to 0.1% or 0.5% when viral load is suppressed 
after the 28th week of gestation [164, 165]. Several studies showed that ART reduced the community 
viral load since the mid-00 and they suggested that ART could therefore decrease HIV incidence [166-
168]. This concept was conclusive after the HIV Prevention Trial Network (HPTN) 052 randomized 
study identified a 96% of reduction of HIV transmission in serodiscordant couples under ART [169]. 
Mathematical models also suggest that the use of ART may decrease the incidence of HIV [170]. 
Therefore, the recommendation to start ART regardless of the CD4 count (concept known as Treatment 
as Prevention (TasP)) has been implemented in USA, French and Brazilian guidelines [114, 161, 162].  
However, the success of this strategy will depend on earlier HIV diagnosis or improved test and treat 
strategies that propose universal testing and treatment. Even more, the engagement in care and 
adherence are key factors to reach a decrease in new infections. For instance, an observational study 
developed in an upper-middle income country like China showed a 26% reduction of transmission in 
heterosexual couples. In this study, resistance, non-adherence, probably lower linkage and retention in 
care partially explained the lower effect of ART on transmission when compared with the HPTN-052 
trial [171]. 
  
 
Guideline  
AIDS  
or HIV-
Related 
Symptoms 
CD4+ Cell Count Recommended First line ARV regimen Alternative first line ARV regimen 
< 350 350-500 > 500 NRTI NNRTI PI INI NRTI NNRTI PI INI 
EACS Yes Yes Consider Consider 
ABC/3TC 
or 
TDF/FTC 
EFV or 
RPV 
ATV/r or 
DRV/r RAL 
TDF/3TC 
or 
ZDV/3TC 
NVP 
FPV/r or 
LPV/r or 
SQV/r 
EVG‡/COBI 
USA 
DHHS Yes Yes Yes Yes TDF/FTC* 
EFV or 
RPV 
ATV/r or 
DRV/r 
RAL or 
EVG/COBI 
or DTG 
ABC/3TC  -  
ATV/r or 
DRV/r or 
FPV/r or 
LPV/r 
RAL 
IAS-USA Yes Yes Yes Yes 
ABC/3TC 
or 
TDF/FTC 
EFV ATV/r or DRV/r RAL 
ABC/3TC 
or 
TDF/FTC 
or 
ZDV/3TC 
NVP DRV/r or LPV/r 
RAL or 
EVG/COBI 
or DTG 
WHO Yes Yes Yes Not addressed TDF/FTC* EFV  -   -  
TDF/FTC* 
or 
ZDV/3TC 
NVP or 
EFV †  -  
Colombia Yes Yes Yes Not addressed 
ABC/3TC 
or 
TDF/FTC 
EFV ATV/r or DRV/r RAL ZDV/3TC NVP 
ATV/r or 
LPV/r  or 
FPV/r  
- 
Table 1.2: When and what to start first line ART for adults. Several considerations such as pregnancy (EFV), HIV viral load (RPV, ABC), CD4 count (NVP), 
HLA-B*5701 negative (ABC), other medications, comorbidities, co-infections, intolerance to other drugs should be considered to initiate ART. *3TC may be 
replaced for FTC or vice versa, except for EVG/Cobi which is available as fixed-dose combination with TDF/FTC and RPV/TDF/FTC, † PI and ABC are used in 
special circumstances such as toxicities, drug interactions, drug supply, etcetera. Abbreviations: EACS: European AIDS Clinical Society, DHHS: Department of 
Health and Human Services, IAS: International Antiviral Society.  Adapted from [114, 156, 157, 160, 163]. 
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ART as prevention is also used in HIV-negative people with strategies such as pre-exposure 
prophylaxis (PrEP), microbicides and post-exposure prophylaxis (PEP). The latter strategy was the first 
one to be implemented. A case-control study in the middle 90’s showed that the administration of ZDV 
after exposure decreased the risk of HIV infection by 81% in health-care personnel [172]. However, the 
effect of PEP depends on the type of exposure and the host-source co-factors such as viral load and 
co-infections. The time of ART initiation should be as soon as possible because it aims to prevent a 
systemic infection that occurs approximately between 48-72 hours [173, 174]. It should last 4 weeks 
according to studies in animal models [175]. The efficacy of PEP has not been evaluated in-depth 
because randomized trials would be unethical. However, observational studies suggest that PEP in 
non-occupational exposure was tolerated but suboptimal adherence, unreported or subsequent 
exposures limit the evaluation of the public health impact of this measurement [176]. Despite the limited 
evidence, PEP is included in several guidelines. The specific ART combination depends on the 
source’s clinical history, but if it is unknown the preferred ART regimen after for non-occupational 
exposures includes NRTI+PI like TDF/FTC or ZDV/3TV +LPV/r in Europe and USA [156, 177]. In 
addition, USA guideline recommends other regimens for occupational exposures. In this instance, the 
recommended ART is TDF+FTC+RAL but also other alternatives such as NRTI (ZDV+3TC), NNRTI 
(ETV or RPV), and PI (DRV/r, ATV/r, and LPV/r) can be used [178]. In contrast, WHO recommends the 
first-line therapy available in the country [157]. 
PrEP implies the intake of oral ART before the exposure in individuals who are at risk of getting HIV, 
which includes TDF+FTC, once daily. Studies showed a reduction of 92% of the risk of infection in 
MSM (iPREX study, [179]) and 90% in serodiscordant couples (Partners PrEP study, [180-182]) when 
levels of ART were detectable. However, this reduction is highly dependent on adherence. In the iPrEx 
study, a 50% reduction was reported ZKHQ WKHDGKHUHQFHZDV [183]. Other studies confirmed 
the impact of adherence and logistics problems. Low compliance resulted in a reduction of 62% in 
heterosexuals (TDF2study, [184]), no reduction in trials that included females (FEM-PrEP trial or 
VOICE, [185, 186]), or inconclusive data (West Africa trial, [187]). On the other hand, TDF showed an 
efficacy of 50% in IVDU. When only adherent participants with drug levels detectable in plasma were 
considered, the efficacy increased to 73.5% (Bankok TDF study, [188]). Given the results of these trials, 
PrEP has been included in the USA guideline for populations at risk of acquiring HIV infection [189], 
whereas the WHO guideline recommends PrEP only for serodiscordant couples or in men and 
transgender women when other prevention choices are needed [157]. European guideline does not 
address PrEP because the discrepant results of effectiveness and the need of more evidence in 
specific populations [176, 190]. 
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Finally, microbicides are still in research and are not yet approved for broader use in clinical practice. 
Since 1987 broad spectrum of microbicides with contraceptive properties were investigated but the 
results showed no benefit [191]. Since the 2000s, the use of ART in a gel formulation was investigated 
but results were conflicting. For instance, the CAPRISA study showed that 1% TDF gel reduced the risk 
of HIV acquisition by 39%, and this reduction reached even 54% when the adherence was >80% [192]. 
However, the VOICE study that also included TDF in gel was stopped because of the low adherence 
and futility [186]. Another alternative that is still subject of on-going microbicide trials is dapivirine, a 
NNRTI that had poor oral bioavailability. The studies using diaphragms or intra-vaginal rings/tablets are 
however in early phases [193]. Similarly, rectal microbicides are still in early study phases (MTN-017 
trial) [194]. 
CURE 
Several initiatives were taken to find a cure for HIV without success [195]. Up until now, there is no 
curative treatment nor vaccine [196], although hopes for a cure have risen after the case report of the 
Berlin patient in 2008. This patient had an allogeneic bone marrow transplantation with a dysfunctional 
CC-chemokine receptor 5 (CCR5), which is crucial for HIV entry (mutation known as CCR5 ǻ32/ ǻ32 
deletion) [197].  After the discontinuation of HAART, the HIV-1 virus has been undetectable in 
peripheral blood, bone marrow, cerebrospinal fluid, brain or rectal mucosa up to now, which implied a 
sterilizing cure of HIV for the first time [198]. In 2012, other two patients heterozygous for ccr5Ǽ32 
mutation had apparent functional cure or long-term control of HIV replication after allogeneic bone 
narrow transplantation. However, these patients continued ART despite the chemotherapy, and 
achieved undetectable viral load in plasma and reservoirs for more than two years [199-201]. When 
ART was subsequently interrupted, a virological rebound was observed in these so-called Boston 
patients [202]. In 2013, a case known as the Mississippi baby showed a possible functional cure after 
the administration of aggressive ART soon after birth, and later interruption of treatment by the mother 
[203, 204]. Although HIV remained undetectable in the baby for more than two years without ART, the 
same mother’s HIV strain was detected and the CD4 decreased according with an official 
announcement last July. Other strategy such as ART in primary infection has led to the discovery of 
post-treatment controllers.  ART was discontinued after a median of 36 months, but nevertheless they 
achieved sustainable undetectable viremia for several years [205, 206], even if some of them were 
characterized with poorer CD8+ T cell responses and unfavorable genetic backgrounds (e.g. HLA-B*35 
and HLA-B*07 that are associated with faster disease progression) [207]. More basic and clinical 
research is needed to evaluate these strategies [208]. 
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1.6.2 RESISTANCE 
Although clinicians have access to potent drugs that could result in long-term viral suppression, they 
currently face problems with patients not responding to therapy because of drug resistant HIV. The 
main cause of HIV drug resistance is acquired or secondary resistance. Antiviral drug resistance arises 
in patients whose therapy or adherence is suboptimal, resulting in residual replication and allowing an 
increase in genetic variability and the selection of variants with reduced drug susceptibility. Minority 
drug resistant variants can ultimately replace the previously dominant susceptible population and result 
in resistance to ART [149, 209]. A less common source of resistance is transmitted drug resistance 
(TDR), also called primary resistance, when an untreated patient is infected with a resistant variant, 
either from a treated patient with inadequate viral suppression and acquired resistance or from another 
untreated patient with a virus carrying resistant strains. DETECTION OF RESISTANCE 
According to the USA and European guidelines, the resistance test should be performed in the earliest 
sample of chronic naive patients or if not available, before starting therapy [114, 156, 209]. In the case 
of acute infected individuals, the test is recommended even if ART is deferred [156] but, the USA 
guideline considers that it should be repeated before starting ART [114]. Resistance testing should also 
be performed at virologic failure, to evaluate whether resistance is the cause of failure, and to assess 
which drugs are still active. According to the European guidelines, resistance testing can be considered 
when a successful NNRTI-regimen is inappropriately interrupted [209]. The resistance test should also 
be used to guide PEP, on a sample from the source [114, 156, 209]. All guidelines advice to use 
resistance testing when a pregnant women is going to start ART or has detectable viral load [114, 209]. 
The test is usually successful when viral load is > 300-500 copies/mL, but specialized laboratories can 
perform the test with lower viral loads [156]. 
 
Drug resistance can be detected phenotypically or genotypically [114, 209]. Phenotypic assays 
measure the ability of a virus to grow in vitro in different concentrations of an inhibitor. Gene fragments, 
usually RT and PR, are inserted into a clone, which generates viruses that express these genes.  
Replication of these viruses is compared with the replication of a reference HIV strain. The drug 
concentration that inhibits viral replication by 50% (IC50) is calculated and the results are reported as a 
fold-change in drug susceptibility with respect to the reference strain [114]. On the other hand, 
genotypic assays identify drug resistance mutations in the viral sequence. It is the preferred test in 
routine practice due to easier implementation, lower costs, better clinical validation and faster turn-
around time [209, 210].  
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Genotyping testing is widely used for RT and PR because the antiretrovirals that target those genes 
have been used for a long time. However, there are situations where also resistance testing for IN and 
env is recommended or considered. In the case of IN, the use of resistance test is recommended when 
patients are failing to these drugs [114, 209]. However, performing baseline genotypic testing is not 
advised because the transmission of INI-resistance is still rare [114, 209]. Regarding env, resistance 
testing is performed on gp41 to evaluate the susceptibility of a virus to T20, which is rarely used 
nowadays. On the other hand, resistance testing is not performed for MVC because resistance is also 
rare [114]. However, before starting therapy with MVC or when virological failure occurs, a co-receptor 
tropism assay should be performed, which can be phenotypic or genotypic [114, 156]. Phenotypic 
assays include the MT-2 assay, which is the co-culture of MT-2 cells with the patient’s mononuclear 
cells, X4-tropic viruses are detected because they induce syncytia in the infected cells [211]. Another 
method includes the amplification of the env gene, the generation of recombinant viruses and the 
infection with these recombinants of human cell lines expressing X4 or R5 co-receptors.  There are 
commercial and non commercial examples such as Trofile, XTrackC/PhenX-R, and the Toulouse 
Tropism Test. Phenotypic methods, however, have the disadvantage that require high biosafety 
standards [211]. On the contrary, the tropism genotype testing includes the amplification of the third 
hypervariable loop (V3) of the co-receptor binding site using population sequencing or next-generation 
sequencing (NGS). This sequence is analyzed with a web-based bioinformatic algorithm that predicts 
the use of a co-receptor. According to the USA guideline, a phenotypic assay is usually preferred 
because it has better performance than the genotypic assay [114], whereas European guidelines 
recommend both assays given their good concordance [211].  
 
Within the framework of HIV drug resistance surveillance, an expert committee and the WHO have 
developed a Surveillance Drug Resistance Mutations (SDRM) list to enable an accurate assessment of 
TDR and comparisons of TDR trends. The list has been updated periodically and excludes highly 
polymorphic amino acid variants [212]. Within the framework of clinical interpretation of resistance, 
several interpretation algorithms have been developed with the aim to predict susceptibility and 
consequently therapy response.  The most commonly used genotypic interpretation algorithms are 
based on expert rule-based, and are HIV Drug Resistance Database (HIVdb; available at 
http://hivdb.stanford.edu) [94], REGA (available at http://sierra2.stanford.edu/sierra/servlet/JSierra? 
action=hivalgs or http://rega.kuleuven.be/cev/avd/software/software/rega-algorithm) and Agence 
National de Recerche sur le SIDA (ANRS; available at http://www.hivfrenchresistance.org) [213, 214].  
These algorithms are based on rules designed by experts who retrieved information from publications 
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and databases [209], and attempt to predict virological response. The advantages of these systems 
include an easy clinical application, but they depend on the quality of the available scientific research 
and applicability of the chosen rules.  Since different algorithms are based on slightly different 
considerations, discordances between algorithms exist, yet overall, the three algorithms perform equally 
well in comparative studies [215, 216]. Other interpretation algorithms are based on phenotype-
genotype correlations, such as Geno2pheno (available at http://www.geno2pheno.org/index.php) [209]. 
This algorithm is trained on a database containing correlated genotypic and phenotypic resistance test 
results, complemented with information of clinical response. As such, the algorithm does not depend on 
the judgment of an expert which may be biased, for example by previous scientific literature [95]. 
Nevertheless, they also depend on the available data and the reliability may be affected by new 
combinations of mutations [209]. EPIDEMIOLOGY OF HIV RESISTANCE  
TDR can occur through sexual, parenteral and vertical routes and can depend on several factors like 
type of drugs used, viral subtype, ratio of wild-type to resistant variants, and viral load [217]. TDR can 
disappear gradually over months or years but can remain archived in proviral DNA [218]. The rate of 
disappearance can depend on viral fitness, selective drug pressure, type of mutations or 
superinfections. For instance, M184IV as a singleton is usually underestimated due to the rapid 
replacement and fitness cost [219, 220], in contrast to K103N or some thymidine analogue mutations 
(TAMs) that can persist over time [221].   
The epidemiology of HIV drug resistance has been assessed in drug-naive and treated patients. The 
prevalence numbers can vary because several factors: intrinsic characteristics of the population 
analyzed (age, risk factor of transmission, geographical and socioeconomic factors), design of the study 
(method of sampling, type of study, inclusion or exclusion criteria), clinical characteristics (recent or 
chronic infection in naive patients, immunological status, viral load), determination of resistance (type of 
sample, method of sequencing, quality of the sequence, rules used for analysis of mutations), ART-
related factors in the treated population (mono- or bitherapy history, HAART scale up, delay of start 
therapy, availability of new compounds, pharmacogenetics, toxicity, adherence problems, percentages 
of drug failure)  and viral factors (subtype, viral fitness) [222-224]. 
 
The highest prevalence of acquired drug resistance was observed in Western Europe and North 
America where drugs had been prescribed in the format of mono- or bitherapy. Prevalence of drug 
resistance in these areas were between 70-80% [216, 225]. However, in the last years drug resistance 
in treated patients have decreased and resistance to novel drugs remains limited [226-229]. For 
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instance 1% of the cases in 2008 did not have other therapeutic options in seven countries from 
Western Europe, but nowadays almost every patient has an alternative therapy due to less extensive 
resistance profiles and the availability of new approved antiretrovirals [230]. 
 
Initially, a low prevalence of TDR was observed in high-income countries [231-234]. Subsequently, TDR 
levels increased up to 20% in the era of mono- and biotherapy [183, 235, 236]. Therefore, prospective 
and representative population-based studies were set up to monitor the extent and dynamics of TDR in 
Western Europe, USA and Canada [237-240]. They revealed lower prevalence values around 8-9% 
and recent studies have shown a stable trend of overall TDR in Western Europe and USA [241-243]. In 
contrast, according to a systematic review that included studies with sampling years until 2008 TDR 
decreased in Europe and increased in USA [244]. Additionally, regional differences were shown for 
TDR associated with the different drug classes [244].  For instance, no significant trends were reported 
in Belgium, and Sweden [78, 245], a slight increase of TDR related with NRTI was described in UK and 
Italy [246, 247], a slight NNRTI increase was described in Germany [248] and a significant decrease of 
TDR for PI was shown in France [249]. These regional differences highlight the importance to study 
local epidemics and suggest even contiguous areas may have different TDR prevalence values.  
 
In low and middle income countries, the WHO has created a strategy for prevention and follow-up of 
TDR, which include an international expert committee board for training, technical assistance, 
standardized protocols, laboratory quality assurance, analysis of results, and recommendations for 
guidelines and public health actions [250]. Consequently, TDR studies with the WHO recommendations 
have been set up in Africa, Asia and Latin America. TDR was still under 5% in most of the African 
countries according to a systematic review that included articles published until 2008 [251]. Another 
meta-analysis using WHO data and studies up to July 2011 showed regional differences in Africa, for 
instance TDR increased at 29% rate per year in East Africa and 14% in Southern Africa whereas a non-
significant increase was found in West and Central Africa [252]. Recent reports suggested that trends of 
TDR still are increasing based on new surveys and mathematical models [253]. In contrast, Asia seems 
to have the prevalence of TDR under 5% [244, 252], although still some countries lack surveys up to 
now [254].  Finally, the overall TDR in Latin America was stable and around 7% in studies with 
sampling dates up to 2009 [244, 252]. However, regional differences have been observed (see chapter 
4), which suggest different TDR trends between countries that are important to evaluate.  
Concerning the two countries analyzed in this thesis, Belgian cohorts have been included in pan-
European studies such as SPREAD, or EUROSIDA. Therefore, the drug resistance patterns in treated 
populations are expected to be similar to other Western European countries as mentioned above. The 
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prevalence of TDR was 9.5% between 2003 and 2006 [78], and the trends seemed stable according to 
the pan-European studies including Belgian data [239, 241]. On the other hand, limited information is 
available for Colombia. The prevalence of acquired resistance was 82.1% between 2000-2007, and 
resistance for RT inhibitors was increasing at that time [255]. The prevalence of TDR was 5.8% in a 
nationwide study in 2006 [256] (see chapter 4), and 6.6% in the city of Cali between 2008 and 2010 
[257]. A detail discussion of these studies is going to be presented in chapter 6.  IMPACT OF RESISTANCE 
Resistance could impact the future options of ART, the CD4 count, mortality and viral fitness amongst 
other factors. Regarding primary resistance, patients had three times higher risk of virological failure 
within one year when the virus carried TDR and was resistant to at least one prescribed drug [258]. 
However, if the patient received a fully active ART regimen, the risk of virological failure was not 
different from patients without TDR, although it was increased slightly for NNRTI based regimens. 
Consequently, poor virological response due to TDR may influence the decline of CD4 counts [258, 
259].  
The impact of TDR on the clinical prognosis highlights the importance to perform routinely resistance 
testing in order to select three active antiretroviral drugs. However, basing individualized treatment on 
drug resistance testing is a strategy of high-income countries, whereas low and middle income 
countries use resistance surveillance studies to design treatment guidelines as a population public 
health approach [260]. The WHO guideline for the latter countries recommends standard first and 
second line therapies based on price, availability, potency of the drugs, the most likely profile of 
secondary resistance, and individualized monitoring of viral load [157, 261]. For instance, this guideline 
proposed ART sequencing strategies such as TDF+NNRTI based-regimens given that resistance to 
TDF does not impact ZDV activity, then ZDV+PI can be used as second-line regimen without the 
performance of resistance test [157, 261]. 
 
Regarding acquired resistance, high-income countries reported a decrease in resistance that 
furthermore could be easily treated with new antiretroviral drugs [230]. In contrast, some low and 
middle-income countries could face limited alternative therapeutic options together with limited 
resources for the follow-up of patients. The extent of HIV suppression ranged between 70% to 90% 
after one year of first-line treatment [262-264], which resulted in mainly NRTI and NNRTI resistance. 
However, it is predicted that ZDV would be active for second line therapy whereas the activity for NVP 
or EFV would be low (less than 30% of the patients) [263]. In a meta-analysis of 19 studies, second-line 
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virological failure was reported in 23% of the patients after one year, although failure may have been 
related with lack of adherence rather than resistance given the low frequency of mutations [265]. 
 
Finally, viral fitness is the ability of the virus to infect, replicate and produce infectious progeny in a 
given host environment [266]. In general, a resistant virus reduces the transmission efficiency by 
approximately 20% [267], but this effect depends on the mutation or the combination of mutations. For 
instance the M184IV reduces the viral fitness, whereas NNRTI mutations do not [268]. Under ART, the 
viral fitness could also be increased by accumulation of compensatory mutations [269], whereas these 
compensatory mutations especially in PR contribute to higher viral load and decline of CD4 counts in 
untreated individuals [270]. 
 IMPACT OF GENETIC DIVERSITY 
The time to develop drug resistance and the drug resistance pathways can vary between subtypes. 
Group O and HIV-2 display high-level of resistance to NNRTI and T20 [271-273]. Additionally, natural 
polymorphisms are frequently present in non-B subtypes. Although they can act as secondary 
mutations, they should not be considered as evidence for TDR [212] (see section of resistance). Natural 
polymorphisms are often the cause of discrepancies between algorithms as they can trigger certain 
rules in drug resistance interpretation systems [209, 274]. A global collaboration determined that 55 
mutations related with subtype B drug-resistance were found in at least one non-B subtype and 80% of 
them were significantly associated with ART. Conversely, of 67 non-B resistance mutations only 61 
were also associated with treatment in subtype B [275]. One example are the studies of single doses 
NVP for prevention of MTCT, that suggest more frequent resistance in patients with subtype C 
compared with subtype A [276, 277]. Some examples of mutations or polymorphism are shown in the 
table 1. 3. 
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Drug 
class Subtype  Mutation Observations 
NRTIs 
C 
K65R High frequency under ddI+d4T, 
it has been associated with 
Y181C 
  
T69N, V75I, V118I, L210N, T215S 
 
 
F L210W, Q151M  Low prevalence  
 
CRF06_cpx TAMs High propensity vs CRF02_AG 
 
HIV-2 L210N, T215S, K219N 
Develops resistance faster than 
HIV-1 
NNRTIs A Y181C Less frequent than B 
 
C, CRF01_AE V106M Under NNRTI background 
 
C G190A Natural polymorphism 
 
G A98S Secondary resistance 
 
HIV-2 Y181I, Y188L, G190A, K101A, V106I, V179I Natural cross-resistance NNRTI 
 O Y181C, A98S, K103R, V179E Natural cross-resistance NNRTI 
PIs A, CRF37_cpx V11I Lower genetic barrier to DRV 
 
A, G, CRF02_AG I13V 2ndR, less frequent in B (13%) 
 
G, CRF01_AE K20I 
2ndR, less frequent in B, A and 
F 
 
Non-B M36I 2ndR, less frequent in B (13%) 
 
C D30N Less frequent than B 
 
CRF01_AE, 
CRF02_AG 
 
Not observed, frequent in B 
 
G I82M/T/S The PMP V82I leads it. Not in B 
 
C,F,G,  M89I/V The PMP L89M leads it. No in B 
 
A,C, G L90M More frequent than B 
 
F 
 
Rare 
 
C I93L Less frequent in B (33%) 
 
HIV-2 
I47A 
L10I/V, K20V, V32I, M36I, M46I, 
L63E/K, A71V. G73A, V77T, 
V81IL 
Develops resistance faster for 
LPV 
Lower potency of PIs than HIV-
1 
 
EIs O,HIV-2 
 
Natural resistance 
 B R263K Resistance to DTG 
 C G118R Resistance to RAL if L74M is present 
INIs C,CRF01_AE, 
CRF02_AG 
G140S, G140C 
 
Higher genetic barrier to INIs 
 
CRF01_AE, 
CRF02_AG 
V151I Higher genetic barrier to INIs 
 
Table 1.3: Mutations or polymorphisms (PMP) present in non-B subtypes. Secondary resistance 
(2ndR) means presence of the mutation in treated patients. The nomenclature of mutations consists of 
the amino acid in the wild-type virus (first letter with the amino acid standard abbreviation), the position 
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in the genome (the number) and the mutated amino acid (second letter). Adapted from [158, 209, 277-
280]. 
 
The pathways also vary between subtypes. For example the development of resistance to NFV is 
related with mutation D30N in subtype B and with L90M in subtype G and C [158]. The N88D seems to 
favor the selection of D30N in subtype B [281]. The treatment response of non-B subtypes seems to be 
equal to B subtypes according to several studies developed in Europe [74, 122, 209, 281-283].  
 
1.7 DYNAMICS OF HIV EPIDEMIC 
 
Nowadays, with the renewed interest in TasP as an effective prevention strategy [169] and its 
implementation in certain countries [114, 161, 162], there is an increasing concern about the 
generalizability and transferability of this measurement in different settings [284]. Since 
sociodemographic, behavioral and cultural drivers can vary between regions, the study of local HIV 
epidemics becomes important to design prevention policies [285]. Therefore, it is necessary to 
determine and evaluate testing and diagnosis rates, the origin of infections (local, national and 
international), engagement and follow-up in care, adherence to ART and consequent suppression of 
viral load. Additionally, the characteristics of the population engaged in transmission (the ones who 
transmit and are at risk for HIV infection) should be explored. Then, modeling of the epidemic can be 
carried out with relevant information to evaluate whether or not TasP is cost-effective as a public health 
policy [176, 286]. 
 
The continuous evaluation and improvement of the HIV care cascade is one of the main steps to obtain 
a maximum and sustained benefit from TasP. The care cascade of care continuum includes five major 
stages: HIV diagnosis, getting linked to care, retention in care, getting ART, and suppression of viral 
load [287]. The study of the cascade aims to inform in which step it is necessary to improve health care 
management, and usually is surveyed by Public Entities. For instance, the state of the HIV engagement 
cascade in USA started a controversy about the test-and-treat strategy implemented in this country. 
CDC together with other studies estimated that around 25% of one million people living with HIV 
(PLHIV) were undetectable or adherent to ART [287, 288], which implies that TasP will have little 
impact if the access to health care is not improved. However, in France and UK around 50% of PLHIV 
 34 |  
 
 The Dynamics of Local HIV-1 Epidemics 
were adherent or undetectable in 2010 [289, 290], indicating a better engagement in Europe (see 
chapter 6). 
 
Since HIV transmission occurs mainly via sexual contacts, the study of sexual transmission networks is 
relevant to characterize the populations that contribute to the spread of HIV. Social networks have their 
roots in sociology during the 1930s [291], but they can be limited due to methodological and ethical 
issues such as interviews, disclosure and partner notifications [292]. Therefore, phylogenetics have 
become important tools in evaluating transmission networks or clusters within large datasets of HIV 
sequences because it is known that they can reconstruct known transmission histories [34, 35, 37-43, 
117, 292-295].  
 
Recently, the interest in phylogenetic analyses like phylogeography (see section 1.4.1) and 
transmission clusters has increased given the priority to know whether TasP could be applied at 
community-level in different settings [284, 293]. In this context, phylogenetic analyses may provide 
information for modeling studies, prevention trials and observational studies that evaluate the impact of 
this prevention strategy [296]. Phylogeography informs about the virus mobility that can give some 
insights about the role of migration and travel in a specific population or subtype, as has been shown 
for subtype B in Europe  [51, 83] (see section 1.4.3). The study of transmission clusters sheds light on 
the transmission patterns between heterosexuals, MSM or IVDU [41, 42]; the factors involved in 
transmission, with or without drug resistance [38, 245, 294]; the evolutionary rate within a period of time 
in a specific epidemic, which is useful to study outbreaks in particular risk groups [297], and in general 
on the relationships between biological, demographical and social determinants [293]. The description 
of TDR and TDR transmission networks is of particular importance because TDR can impact the 
efficacy of first-line regimens and future therapy options (see section 1.6.5) [293]. High frequencies of 
transmission clusters and TDR have been mainly described in MSM and IVDU [39, 245, 294]. These 
clusters usually include NRTI drug resistance mutations like TAMs [294, 298-300], although NNRTI and 
PI mutations have also been described [301-303]. Differences between countries have been observed, 
a recent study in Belgium showed for instance that 18 out of 33 patients (55%) with TDR were involved 
in transmission clusters and were mainly infected with subtype B [40], whereas in Northern Greece 17 
out of 46 (37%) TDR patients were part of clusters, mainly of subtype A [304]. Differences within 
countries can also occur. In this respect, mainly TAMs and few NNRTI mutations such as G190A and 
V106A were observed in Gent [40], whereas a cluster with K103N was recently reported in Namur 
[303]. 
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It is important to bear in mind that the definition of clusters is still a matter of debate. The statistical 
criteria could differ and often include high bootstrap values (>95%) and low genetic distances (0.010-
0.045) when ML trees are inferred [35, 37-39, 305]. Lower values have been used if clusters are 
confirmed with Bayesian techniques, with bootstrap values >70-90% but posterior distribution of 1 in the 
0&&WUHHDQGKLJKHUWKUHVKROGVIRUJHQHWLFGLVWDQFH[40, 43, 304]. To evaluate the impact of 
cluster definition, some studies have performed sensitivity analyses [36, 306]. The inclusion of controls 
from the local HIV epidemic, and the exclusion of convergent evolution are also important parameters in 
the evaluation of transmission clusters [307, 308]. It is important to point out that transmission cluster 
analyses provide some epidemiological insights on the HIV epidemic, but they do not prove 
transmission given the underlying assumptions of phylogenetic analyses. For conclusive evidence, it 
would be necessary to have all controls from the local HIV epidemic, which is not feasible. The use of 
two different genes and two close different samples could enforce the results, but not enough data is 
yet available in clinical databases for this approach [307]. In conclusion, phylogenetic analyses have 
some limitations but can be valuable tools in the proper evaluation of public health, therapeutic or 
behavioral interventions when complemented with epidemiological, clinical, and demographical data 
[293]. 
 
Finally, the in-depth characterization of local epidemics can assist in the improvement of health care 
and can predict whether or not particular prevention policies could be effective. Different mathematical 
models have already been developed for sub-Saharan Africa or United States, where they have shown 
the differential impact of PrEP on TDR and HIV transmission [309-311] in different settings,  and of  
TasP [170, 312-316] on HIV transmission. However, the assumptions on the characteristics of the 
epidemic may influence greatly the results [314, 317]. 
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1.8 RATIONALE AND OBJECTIVES 
 
With the aforementioned evidence about the impact of ART on morbidity and mortality at personal level 
[9], and on HIV transmission at community level [169], and the subsequent implementation of test-and-
treat strategies in some countries [114, 161, 162], debate continues about the generalizability and 
transferability of this policy to other settings. In an attempt to resolve whether or not TasP could be 
applied in our local epidemics, we focused our research on Belgium and Colombia, within the 
framework of a collaborative project between KU Leuven, Belgium and Universidad del Rosario, 
Colombia. These countries share the concern with other countries that new infections are still 
increasing [318, 319], in contrast to several other countries where a 50% reduction of new HIV 
infections have been observed [10]. However, Belgium and Colombia differ in standard of care and 
availability of relevant data. In Belgium, the notification system for HIV provides some rough  
information about the HIV care cascade [320] and a European study has already revealed that 
international mobility constitutes one of the main sources of HIV-1 subtype B infections in Belgium [83]. 
The level and patterns of TDR have been evaluated until 2006 [78], but no updated data is yet available 
and still limited information is yet available on the characteristics of the population who transmit the 
virus, necessary for a targeted approach to prevention policies. Although Colombia has a notification 
system, underreporting may hamper an accurate assessment of the HIV care cascade [319]. 
Additionally, only little information is yet available for the in-depth study of the molecular HIV 
epidemiology or the extent of drug resistance and potential clinical impact. Therefore, the general goal 
of our studies was to study these two HIV-1 epidemics with the aim to understand their dynamics, using 
socio-demographic, clinical and virological data. 
 
One of the main types of analysis in this thesis was the identification of subtypes and recombinants. 
Given the large datasets involved in surveillance studies, the most reliable manual phylogenetic 
analyses are too cumbersome. Automated subtyping tools can quickly subtype one to thousands of 
sequences, but their reliability is variable. We felt the need for a reliable strategy that was based on the 
use of one or more of the automatic tools and as few manual phylogenetic analyses as possible, which 
could be used in our subsequent studies. As our laboratory developed the REGA subtyping tool [99] 
and an update was recently implemented, we first set out to evaluate the performance of the REGA 
version 3 compared to the previous version of REGA and six other subtyping tools. To have a large 
amount of data and non-B subtypes, a large Portuguese database was used together with publicly 
available sequences. We did not include Belgian or Colombian sequences because at this stage their 
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number was too small for our purpose. From these results we designed a testing algorithm, which was 
subsequently used for subtype classification throughout this thesis. 
 
Because data on viral diversity and viral mobility was lacking for the Colombian epidemic, we set up a 
collaborative project to retrieve viral sequences from treated HIV-1 patients sampled between 2002 and 
2007. Therapy-naive patients were not included because baseline resistance testing is not routinely 
performed [163]. We included seven sampling regions, the largest sample available to our knowledge in 
this country. The viral diversity was investigated as well as the geographically and temporally viral 
spread in the country. Our results provided some insights about how the subtype B epidemic in 
Colombia is related with the global epidemic and how the different regions interacted in its spread within 
the country.  We only set out to study viral diversity and viral mobility since clinical data that could have 
brought valuable information for prevention policies were not available. 
 
TDR impacts on the selection of therapies for first line treatment, prevention of MTCT, and the potential 
use of TasP [260]. Therefore, we wanted to evaluate any available information useful for the Colombian 
setting. We systematically reviewed all sources with relevant information on TDR in Colombia and 
extended our search to other Latin American countries [163, 321]. When we started this research, the 
trends of TDR were still unknown in Latin American and Caribbean countries, and the fear of an 
increase in TDR was stated at the Conference of Opportunistic Infections and Retroviruses (CROI) in 
2011 (available at www.retroconference.org) [322-325]. In this systematic review, we additionally 
evaluated the specific resistance patterns and factors that could influence TDR between 1996 and 2011 
by using published data  and viral sequences in public databases. As a result, this review also allowed 
to identify gaps in information and to define the future research agenda in our collaborative project in 
Colombia.  
 
For the Belgian epidemic, a lot of information was already available, with one main question remaining: 
how does TDR spread in the local epidemic. Since we did not have access to the entire Belgian 
epidemic, an initial step in studying transmission of TDR in Belgium was focused on the smaller 
epidemic of the Leuven area. We used data from the AIDS Reference Center and AIDS Reference 
Laboratory in UZ Leuven, situated in the province Flemish Brabant. This center collected clinical and 
socio-demographic information since 1997 and the cohort included a total of ~1,184 HIV-1 patients until 
December of 2012.  The availability of socio-demographic information, clinical records, and dense 
sampling allowed us to have a better understanding of the local HIV epidemic dynamics, specifically for 
the spread of TDR. UZ Leuven took part in the Belgian SPREAD study that evaluated the TDR 
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prevalence between 2003 and 2006 [78]. This survey showed stable trends of the overall TDR and per 
antiretroviral group. It also identified that patients infected in Belgium and infected with subtype B were 
more likely to have TDR. As UZ Leuven contributed only a small subset of their patient population to 
SPREAD (23 out of 283 patients), and HIV care and access to ART has changed substantially since 
then, we wanted to investigate the evolution in TDR prevalence for the different drug classes and the 
association with other socio-demographic factors over a period of 15 years (1998-2012). Since the 
identification of populations at risk for TDR could be useful for developing prevention policies, we 
focused our analysis on the identification of socio-demographic characteristics associated with TDR 
and with the spread of TDR by using statistical and phylogenetic tools, such as transmission cluster 
analyses.  
 
In summary, we aimed to characterize the HIV-1 epidemic of the Belgian and Colombian cohorts using 
an integrated approach that includes socio-demographic information, clinical data, and viral sequences, 
analyzed with statistical and phylogenetic approaches. Taking into account the rational described 
above, our specific objectives were: 
x To evaluate the performance of automated subtyping tools used in the clinical settings or 
surveillance of the HIV-1 molecular epidemiology, in order to set up a subtyping strategy for the 
rest of the thesis  
x To establish the molecular epidemiology of HIV-1 and how the virus spread geographically and 
temporally in Colombia between 2002 and 2007 
x To describe the trends and prevalence of TDR in Colombia, Latin America and Caribbean 
countries; and the factors associated between 1999 and 2011 
x To determine the temporal trend of TDR prevalence in Belgium, the factors associated with 
TDR, its transmission, and clinical impact between 1998-2012 
 
Finally, we hoped that our efforts would be useful in designing prevention strategies as well as in 
improving HIV care programs for these specific local settings because the extrapolation of data from 
other regions might result in incorrect conclusions and ineffective interventions [285].  
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2.1 SUMMARY 
Background: To investigate differences in pathogenesis, diagnosis and resistance pathways between 
HIV-1 subtypes, an accurate subtyping tool for large datasets is needed. We aimed to evaluate the 
performance of automated subtyping tools to classify the different subtypes and circulating recombinant 
forms using pol, the most sequenced region in clinical practice. We also present the upgraded version 3 
of the REGAv3. 
Methodology:  HIV-1 pol sequences (PR+RT) for 4674 patients retrieved from the Portuguese HIV 
Drug Resistance Database, and 1872 pol sequences trimmed from full-length genomes retrieved from 
the Los Alamos database were classified with statistical-based tools such as COMET, jpHMM and 
STAR; similarity-based tools such as NCBI and Stanford; and phylogenetic-based tools such as REGA 
version 2 (REGAv2), REGAv3, and SCUEAL. The performance of these tools, for pol, and for PR and 
RT separately, was compared in terms of reproducibility, sensitivity and specificity with respect to the 
gold standard, which was manual phylogenetic analysis of the pol region. 
Results: The sensitivity and specificity for subtypes B and C was more than 96% for seven tools, but 
was variable for other subtypes such as A, D, F and G. With regard to the most common CRFs, the 
sensitivity and specificity for CRF01_AE was ~99% with statistical-based tools, with phylogenetic-based 
tools and with Stanford, one of the similarity based tools. CRF02_AG was correctly identified for more 
than 96% by COMET, REGAv3, Stanford and STAR. All the tools reached a specificity of more than 
97% for most of the subtypes and the two main CRFs (CRF01_AE and CRF02_AG). Other CRFs were 
identified only by COMET, REGAv2, REGAv3, and SCUEAL and with variable sensitivity. When 
analyzing sequences for PR and RT separately, the performance for PR was generally lower and 
variable between the tools. Similarity and statistical-based tools were 100% reproducible, but this was 
lower for phylogenetic-based tools such as REGA (~99%) and SCUEAL (~96%). 
Conclusions:  REGAv3 had an improved performance for subtype B and CRF02_AG compared to 
REGAv2 and is now able to also identify all epidemiologically relevant CRFs. In general the best 
performing tools, in alphabetical order, were COMET, jpHMM, REGAv3, and SCUEAL when analyzing 
pure subtypes in the pol region, and COMET and REGAv3 when analyzing most of the CRFs. Based 
on this study, we recommend to confirm subtyping with 2 well performing tools, and be cautious with 
the interpretation of short sequences.   
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2.2 INTRODUCTION 
At the end of 2011 there were 34 million of people living with HIV [1]. Most infections are caused by HIV 
type 1 group Major (HIV-1 group M), which can be further classified into several clades based on 
genetic diversity. To date, nine distinct subtypes named A-D,F-H, J, K [2] and 58 CRFs 
(http://www.hiv.lanl.gov/; accessed March 2013) have been identified.  While subtype B has been 
widely studied and is predominant in North America, Europe and Australia, it only causes approximately 
10 percent of the infections globally [3], while subtype C is causing nearly half of global infections, 
followed by subtype A with 12% of global infections [3]. In addition, infections with recombinant forms 
such as CRFs and URFs have been increasing over the past decades and are now responsible for a 
total of 20% of the global infections. The distribution of infections caused by CRFs varies regionally; for 
example, while CRF02_AG (8% global infections) is mostly prevalent in West and Central Africa , 
CRF01_AE (5% global infections) is more frequent in South and East Asia [3]. Additionally, CRF06_cpx 
has been identified in West Africa and some European countries, BC recombinants such as CRF07 
_BC are frequent in China, and BF recombinants, particularly CRF12_BF, prevail in Brazil and 
Argentina [3].  
 
Due to the fast pace of evolution and frequent recombination of HIV-1 [4, 5], accurate subtyping of the 
growing arsenal of genetic data arising from epidemiological and antiretroviral resistance studies has 
become increasingly challenging. Importantly, different HIV-1 clades show differences in pathogenesis 
and present distinct resistance pathways, which in turn may lead to different clinical outcomes. For 
example, subtype D seems to be more transmissible and is associated with faster disease progression 
[6]. Moreover, subtypes A, C, F and G have some natural polymorphisms in PR and RT which 
contribute to resistance in subtype B [7-11]. However, it is often difficult to compare epidemiological and 
clinical impact studies since different subtyping methods are used and the classification of HIV-1 clades 
frequently seems to differ according to the method employed [12].  
Although the gold standard for classification of HIV-1 is based on phylogenetic analysis of full-length 
genome sequences [2], this method is not widely used in clinical settings. Since most available data are 
derived from genotypic assays for resistance to PR and RT inhibitors and this region has proven to 
contain enough phylogenetic signal [13], manual phylogenetic analysis (MPhy) on pol region can be 
safely used to identify subtypes [14, 15]. However, for large datasets, automated tools are needed 
since manual subtyping is cumbersome. There are three main types of automated tools based on the 
method used to assign an HIV-1 clade to a query sequence. First, similarity-based tools include the 
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NCBI subtyping tool [16], Stanford [17], Geno2pheno [18] and EuResist  
(http://engine.euresist.org/data_analysis/viral_sequence/ new). Second, statistical-based tools use 
partial matching compression algorithms such as COntext-based Modeling for Expeditious Typing –
COMET- [19], position-specific scoring matrices plus a statistical model such as STAR [20] or jumping 
profile Hidden Markov Models such as jpHMM [21]. Finally, there are phylogenetic-based tools such as 
REGA [22, 23] and SCUEAL [24].  
 
A major objective of this paper was to compare the latest Rega subtyping tool with other available tools.  
The Rega subtyping tool has as philosophy to use phylogenetic analysis in order to take into account 
the epidemiological and evolutionary relationships among subtypes, such that it approaches the gold 
standard to classify subtypes [2]. The algorithms used in earlier versions of REGA have been 
previously described [22, 25]. REGAv2  had a high number of unassigned sequences, in part because 
of the limited number of CRFs included in the reference dataset [26], and the philosophy to achieve a 
high specificity at the cost of sensitivity. To overcome these limitations, the new REGAv3 uses an 
improved decision-tree algorithm geared towards increasing the recognition of pure subtypes and 
recombinants (see further details http://bioafrica.mrc.ac.za:8080/rega-genotype-3.0.2/hiv/typingtool 
/decisiontrees). The reference dataset has also been improved to include more divergent strains per 
subtype and to classify up to CRF47_BF (See further details http://bioafrica.mrc.ac.za:8080/rega-
genotype-3.0.2/hiv/typingtool/method). 
 
In this paper we aim to determine the performance of REGAv3 in the identification of HIV-1 clades, and 
to compare its sensitivity, specificity and reproducibility with its previous version REGAv2 and six other 
publicly available automated subtyping tools (COMET, jpHMM, NCBI, SCUEAL, Stanford and STAR).  
Another goal of this paper was to give guidance as to which HIV-1 subtyping tool would be better for 
use in a clinical and a surveillance context.  
 
2.3 MATERIAL AND METHODS 
2.3.1 STUDY POPULATION AND SUBTYPING TOOLS 
With the objective of emphasizing the classification of prevalent non B subtypes, we used two datasets 
(see figure 2.1). The clinical dataset was retrieved from the Portuguese Resistance database and 
consisted of 4676 pol sequences obtained for routine resistance testing and pooled from 22 Portuguese 
hospitals, (mean length: 1295 nucleotides (nts); min: 993 nts, max: 1311 nts). Sequences were 
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obtained by population sequencing using the ViroSeq 2.0 toolkit (Abbott Laboratories, Abbott Park, IL, 
USA). (Sequences are available through Euresist http://www.euresist.org). The Los Alamos dataset 
herein named as LANL dataset, was retrieved using the following search criteria:  “subtype” AND 
genomic region: “complete genome” AND “one sequence per patient” and we excluded CRFs that could 
not be shown to have epidemiological relevance and with less than 5 full length genome sequences at 
the time the analyses were initiated (CRF03_AB, CRF04_cpx, CRF05_DF, CRF08_BC, CRF09_cpx, 
CRF10_CD, CRF11_cpx, CRF13_cpx, and all CRFs later than CRF15_01B)  [3]. As a result, the LANL 
dataset included 1872 pol sequences (1300 nts), that were trimmed from full genome sequences 
publicly available in Los Alamos database (http://www.hiv.lanl.gov/ ; Date of access: October 2011) 
(accession numbers are shown in the supplementary material number 2.1). In addition, each sequence 
of the LANL dataset was divided in PR (mean length: 300 nts) and RT (mean length: 1000 nts) with the 
objective of evaluating the differences in the performance for identifying PR and RT separately. 
 
Only sequences that passed the quality control check were included: the quality of the sequences was 
evaluated by using the quality tool of Los Alamos database (available in 
http://www.hiv.lanl.gov/content/sequence/QC/index.html) and the parameters of Stanford database 
which are: a maximum number of four for PR and six for RT stop codons +no frame-shifts + no 
unpublished amino acid insertions or deletions + no highly ambiguous nucleotides (B,D,H,V,N) [27].  As 
a result, 2 sequences were rejected from the clinical dataset, and the final number of sequences was 
4674. 
 
Both datasets were analyzed by the following 8 subtyping tools:  COMET version 2 
(http://comet.retrovirology.lu), jpHMM (http://jphmm.gobics.de/submission_hiv.html), NCBI subtyping 
tools using the reference dataset from 2009  (http://www.ncbi.nlm.nih.gov/projects/genotyping 
/formpage.cgi), Stanford HIVdb version 6.0.10 (http://sierra2.stanford.edu/sierra/servlet/ 
JSierra?action=sequenceInput), SCUEAL (http://www.datamonkey.org/dataupload_scueal.php), STAR 
(http://www.vgb.ucl.ac.uk/starn.shtml), REGAv2  (http://www.bioafrica.net/rega-genotype/html/ 
subtypinghiv.html) and  REGAv3 (http://bioafrica.mrc.ac.za:8080/rega-genotype-3.0.2/hiv/ typingtool/).  
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2.3.2 STANDARDIZATION OF ASSIGNMENTS AND MANUAL PHYLOGENETIC ANALYSIS 
Comparison between subtyping tools required standardization of the assignments by different subtyping 
tools. Thus, 1) sub-subtypes were not taken into account; 2) “A-ancestral” and “A3 subtype” were 
assigned as A; 3) the assignment “-like” in REGAv3 which is the clustering with a pure subtype outside 
of the reference cluster with bootstrap > 70%, was considered as the subtype or CRF identified by the 
tool; 4) assignments “complex” or “recombinant” in SCUEAL and REGAv3 were considered 
recombinants; 5) different subtypes assigned by Stanford to the RT and PR were considered as 
evidence of recombination.  
 
Each sequence from the clinical and LANL datasets was classified as concordant (all tools agreed on 
the assignment) or discordant (at least one tool had a different assignment than the other tools) based 
on the results of the 8 subtyping tools (see figure 2.1).  The MPhy of concordant sequences was 
performed by using the 2008 Los Alamos curated subtypes and CRFs reference dataset (available at 
http://www.hiv.lanl.gov/content/sequence/NEWALIGN/align.html), the sequences were aligned with 
ClustalW [28] and, if needed, the alignment was minimally edited with BioEdit [29]. Since assignment 
for concordant sequences is less problematic than for discordant sequences, and since the dataset is 
so huge, we opted for a fast NJ method with 1000 bootstrap replicates and a simple substitution model 
(HKY85), which we call fast MPhy. Such method has been proven useful for subtyping [30, 31], and it 
saves computation time. A query sequence was assigned to a particular clade if it clustered 
monophyletically inside that clade with bootstrap support >70% [14, 15, 32]. Otherwise, the query 
sequence was considered discordant.  
 
The discordant sequences were further analyzed with the 2008 Los Alamos curated subtypes and 
CRFs reference dataset complemented with more and curated full-genome sequences available for 
each subtype in the database using a maximum of 15 sequences per subtype (available in 
http://www.hiv.lanl.gov/content/sequence/HIV/COMPENDIUM/compendium.html). To optimize subtype 
classification of the discordant sequences [33, 34], we used as gold standard a slow MPhy using ML 
trees with 1000 bootstrap replicates and the best-fitting nucleotide substitution model (in this case 
GTR+I+ī)  [35, 36]. If the query sequence clustered monophyletically inside a clade with bootstrap 
support >70% it was assigned that clade, otherwise the sequence was further screened for 
recombination using SimPlot with a window size of 300 nts in steps of 20 nts [37]. For the sequences 
with no signal for recombination, the sequence was assigned the clade with the highest similarity in 
 58 |  
 
 The Dynamics of Local HIV-1 Epidemics 
SimPlot, and for all such sequences the majority of windows reached >70% bootstrap support. If there 
was a signal for recombination, the sequence was called URF, and the putative recombinant fragments 
were analyzed separately. A putative recombinant fragment with a phylogenetic signal >0.9 using 
TREEPUZZLE analysis was assigned a pure subtype or CRF if it clustered inside the respective 
subtype or CRF clade with >70% bootstrap support [32, 38], otherwise the fragment was called 
unclassified (U) [2].  
 
The analyzed region for CRF01_AE and CRF14_BG is lacking a recombination breakpoint. We 
considered the pol region in the LANL dataset as correctly assigned to these two CRFs, since that 
assignment is based on the full genome. Such confirmation of breakpoints outside the pol region is not 
available for the clinical dataset, and this can cast doubt on the accurate assignment based on 
concordance between the tools and confirmed only by fast MPhy as described above. Therefore, in 
addition to fast MPhy for concordant sequences, all sequences that were assigned by any of the 
subtyping tools as either these CRFs or the parent pure subtype (even when concordant) were also 
analyzed with slow MPhy [39], which included all complete genomes of the CRF and parent pure 
subtype as reference sequences. In order to be considered CRF, the sequence should cluster inside 
the CRF reference cluster with more than 70% of bootstrap support [32, 38], otherwise it was 
considered the parent pure subtype.  Finally, to verify these assignment, all sequences thus assigned 
subtype G or CRF14_BG were pooled with all full genome CRF14_BG and full genome subtype G 
sequences from LANL, and a single unrooted tree was constructed using RAxML [40](supplementary 
Figure 2.3). We found a big discrepancy between the different analyses for CRF14_BG and subtype G, 
and therefore, for the clinical dataset only, CRF14_BG and subtype G were pooled and analyzed 
together as a single ‘subtype’ called “CRF14_BG or G”. Tools were considered to correctly assign these 
sequences when they scored either CRF14_BG or subtype G. We did not encounter problems with 
CRF01_AE, CRF01_AE was absent in our clinical dataset, and all subtype A sequences were 
confirmed not to be CRF01_AE. 
 2.3.3 SENSITIVITY, SPECIFICITY, REPRODUCIBILITY AND STATISTICAL ANALYSIS 
The reference standard was mPhy of the pol region for the clinical dataset and the full-length genome 
assignment confirmed with mPhy of the pol region for the LANL dataset (the latter two were 100% 
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formula TN/TN+FP [41], where TP =true positives,  FP= false positives, TN= true negatives, FN= false 
negatives. 
To assess the reproducibility, we created a random subset of 100 sequences extracted from the clinical 
and LANL datasets that contained pure subtypes and CRFs and then ran this dataset 10 times with 
each tool (see figure 2.1). The reproducibility was, by definition, the percentage of times the same 
results were obtained when a subtyping tool was used 10 times on the same sequence, then the 
average of these percentages was calculated for the 100 sequences [41]. For G and CRF14_BG, only 
LANL sequences were used. If for a specific tool there were any discordant results between the runs, 
the entire clinical and LANL datasets were evaluated with that tool. The percentage of reproducibility 
was then calculated for this entire dataset, but again excluding G and CRF14_BG from the clinical 
dataset. 
 
We evaluated the performance of the tools in the clinical, LANL, and clinical+ LANL datasets (herein 
named as overall dataset).  Statistical significance of the difference between subtyping tools was 
evaluated with McNemar’s test. The statistical analysis was calculated using R version 2.12.1. 
 
2.4 RESULTS 
2.4.1 SUBTYPE DISTRIBUTION OF THE DATASETS 
Two sequences were excluded from the clinical dataset according to the quality assessment criteria 
[27]. The distribution of subtypes in the datasets is shown in tables 2.1, 2.2 and 2.3 according to the 
MPhy of the pooled clinical and LANL datasets (herein named as overall dataset) (the distribution of 
subtypes according to the clinical or the LANL dataset separately is shown in supplementary material 
2.1 tables 2.2 and 2.3 respectively, phylogenetic trees for the clinical and the LANL datasets are in 
supplementary material figures 2.1 and 2.2).  With regard to the non-B subtypes and the most common 
CRFs, despite the inclusion of two datasets, there was a limited number of H, J, K, CRF06_cpx, 
CRF07_BC, CRF12_BF and CRF14_BG sequences to reliably evaluate the performance of the 
subtyping tools, yet the results are still listed in the tables. The CRF13_cpx, CRF18_cpx, CRF25_cpx 
and CRF27_cpx were also found in the clinical dataset (see supplementary table 2.2), but these CRFs 
had a very low prevalence and not enough full genome sequences were found in LANL at the time of 
the collection of data to reliably assess the performance of the tools for these CRFs, but we included 
the results in supplementary materials (Supplementary table 2.2).  We did not evaluate the performance 
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of the subtyping tools for CRFs that are not contributing substantially to the epidemic or that are poorly 
assigned. That is also why REGAv3 does not score all CRFs reported to date (see information about 
the epidemiological, geographical and recombination information in http://bioafrica.mrc.ac.za/ 
CRFs/CRFs.php). For the clinical dataset, subtype G and CRF14_BG were pooled into a special class 
“G or CRF14_BG”.  
 
 
 
FIGURE 2. 1. METHODOLOGY OF THE STUDY 
Figure 2.1: Methodology of this study: A: analyses performed on both datasets as was explained in 
section 2. B: manual phylogenetic analysis performed on both datasets. Abbreviations: MPhy: Manual 
Phylogenetic analysis, LANL: Los Alamos database, NJ: Neighbor joining, HKY: HKY model 
(Hasegawa, Kishino, Yano), GTR+G+I: General time-reversible model + Gamma + Proportion Invariant, 
bts: bootstrap, %: percentage.   
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 2.4.2 PERFORMANCE OF THE SUBTYPING TOOLS FOR PURE SUBTYPE ASSIGNMENT 
We evaluated the performance on the overall dataset, the clinical separately and the LANL dataset 
separately. Since we did not find many differences between the results of these datasets, we only show 
the performance of the overall dataset (see the performance of the tools for the clinical or the LANL 
dataset separately in supplementary tables 2.2 and 2.3 respectively). However, we found some 
discrepancies in the results for subtype A when we compared the two results of the clinical and the 
LANL datasets. For example, subtype A in the LANL dataset was 100% accurately classified by 
COMET, jpHMM and REGAv2 but the values in the clinical dataset were 76.5%, 86% and 73% 
respectively.  
The sensitivity of each of the subtyping tools was more than 96% for subtype B and 98% for subtype C 
except for NCBI, which had lower values in both datasets (tables 2.1, 2.2, and 2.3, see details in 
supplementary tables 2.2 and 2.3). However the results were variable for other subtypes. For instance, 
COMET, jpHMM, and REGAv3 had a sensitivity of more than 90% for subtype A. jpHMM and REGAv3 
obtained sensitivities of 100% for subtype D and subtype F respectively.  REGAv3, Stanford and STAR 
classified correctly subtypes H, J, K, although the number of sequences available was limited. 
Noteworthy, the specificity for all pure subtypes was more than 98% (Tables 2.1, 2.2 and 2.3).   
 2.4.3 PERFORMANCE OF THE SUBTYPING TOOLS FOR RECOMBINANT FORMS 
COMET, jpHMM, REGAv2, REGAv3, Stanford and STAR had sensitivities and specificities around 99% 
for the classification of CRF01_AE (see tables 2.1, 2.2 and 2.3, supplementary material table 2.3). 
However, the absence of a recombination breakpoint in the pol region makes the classification of this 
CRF challenging by the subtyping tools (see figure 2.2) [42].  Therefore, COMET and REGAv3 used 
other assignments; for example, COMET classified one sequence as “01_AE (check for 15_01B)” and 
REGAv3 identified 99% (168/169) as “HIV Subtype A (CRF01_AE)”. On the other hand, SCUEAL and 
NCBI classified independently CRF15_01B and CRF01_AE, with sensitivity dropping to 84% and 76% 
respectively.  
 
  
 
          
  
Statistical-based  tools             
Subtype 
Total COMET 
   
jpHMM 
   
STAR 
  
  
  Sens 95% CI Spec 95% CI Sens 95% CI Spec 95% CI Sens 95% CI Spec 95% CI 
A 226 91.2 87.4-94.9 100.0 99.9-100 94.7 91.8-97.6 99.8 99.7-99.9 50.4 43.9-57.0 100.0 100-100 
B 3023 99.1 98.8-99.5 99.8 99.6-99.9 99.0 98.7-99.4 99.6 99.4-99.8 97.6 97.0-98.1 99.6 99.4-99.8 
C 628 99.7 99.2-100 100.0 100-100 100.0 100-100 100.0 100-100 99.8 99.5-100 100.0 100-100 
D 69 97.1 93.1-100 100.0 100-100 100.0 100-100 100.0 100-100 89.9 82.7-97.0 100.0 100-100 
F 129 89.1 83.8-94.5 100.0 100-100 92.2 87.6-96.9 100.0 100-100 89.1 83.8-94.5 100.0 100-100 
LANL G* 34 100.0 85.1-100 99.5 99.0-99.7 97.1 84.7-99.9 99.4 98.9-99.7 73.5 55.6-87.1 99.4 98.9-99.7 
H 11 90.9 73.9-100 100.0 100-100 90.9 73.9-100 100.0 100-100 100.0 100-100 100.0 100-100 
J 6 50.0 10.0-90.0 100.0 100-100 100.0 100-100 100.0 100-100 100.0 100-100 100.0 100-100 
K† 2 100.0 100-100 100.0 100-100 100.0 100-100 100.0 100-100 100.0 100-100 100.0 100-100 
CRF01_AE† 169 99.4 98.3-100 100.0 100-100 100.0 100-100 100.0 100-100 98.8 97.2-100 100.0 100-100 
CRF02_AG 272 96.3 94.1-98.6 100.0 99.9-100 NA NA NA NA 96.0 93.6-98.3 99.7 99.5-99.8 
CRF06_cpx 28 50.0 31.5-68.5 100.0 100-100 NA NA NA NA NA NA NA NA 
CRF07_BC† 10 90.0 55-100 100.0 100-100 NA NA NA NA NA NA NA NA 
CRF12_BF† 5 100.0 36.0-100 100.0 100-100 NA NA NA NA NA NA NA NA 
LANL CRF14_BG* 11 81.8 47.8-96.8 99.8 99.6- 99.9 NA NA NA NA NA NA NA NA 
Clinical G+CRF14_BG‡ 1571 98.7 98.2-99.3 99.9 99.8-100 98.3 97.7-99 99.2 98.9-99.5 95.3 94.2-96.3 99.6 99.4-99.8 
 
 
Table 2.1:  Performance of statistical-based subtyping tools. The sensitivity (Sens) and specificity (Spec) are reported for statistical-based tools. The values with 100% of 
performance are highlighted in dark gray; the values with more than 90% of performance are colored in light gray.   * The values for G and CRF14_BG are based on the LANL 
dataset only. †These subtypes of CRFs only were available in the LANL dataset. ‡The 1571 sequences G and CRF14_BG of the clinical dataset were pooled as a single 
category.   Abbreviations: n: sample, cpx: complex, LANL: Los Alamos dataset, NA: Not applicable, URF: Unique recombinant form  
  
 
 
    Similarity-based tools 
Subtype 
Total NCBI       STANFORD     
  Sens 95% CI Spec 95% CI Sens 95% CI Spec 95% CI 
A 226 65.5 59.3-71.7 100.0 99.9-100 63.3 57.0-69.6 100.0 99.9-100 
B 3023 84.7 83.4-85.9 98.8 98.4-99.1 98.3 97.9-98.8 99.0 98.7-99.4 
C 628 92.4 90.3-94.4 100.0 100-100 98.9 98.1-99.7 100.0 99.9-100 
D 69 79.7 70.2-89.2 100.0 100-100 91.3 84.7-98.0 100.0 100-100 
F 129 87.6 81.9-93.3 99.9 99.9-100 71.3 63.5-79.1 100.0 100-100 
LANL G* 34 47.1 29.8-64.9 100.0 99.7-100 97.1 84.7-99.9 99.4 98.9-99.7 
H 11 100.0 100-100 100.0 100-100 100.0 100-100 100.0 100-100 
J 6 66.7 28.9-100 100.0 100-100 100.0 100-100 100.0 100-100 
K† 2 100.0 100-100 100.0 100-100 100.0 100-100 100.0 100-100 
CRF01_AE† 169 76.3 69.9-82.7 99.7 99.4-100 100.0 100-100 99.6 99.3-99.9 
CRF02_AG 272 48.5 42.6-54.5 99.8 99.7-99.9 98.9 97.7-100 98.0 97.6-98.3 
CRF06_cpx 28 82.1 68.0-96.3 99.3 99.1-99.5 NA NA NA NA 
CRF07_BC† 10 100.0 59.0-100 100.0 100-100 NA NA NA NA 
CRF12_BF† 5 100.0 36.0-100 100.0 100-100 NA NA NA NA 
LANL CRF14_BG* 11 100.0 61.5-100 99.5 99.1-99.7 NA NA NA NA 
Clinical G+CRF14_BG‡ 1571 99.7 99.5-100 98.8 98.4-99.2 97.5 96.7-98.3 98.9 98.5-99.2 
 
Table 2.2: Performance of similarity-based subtyping tools. The sensitivity (Sens) and specificity (Spec) are reported for similarity-based tools. The values 
with 100% of performance are highlighted in dark gray; the values with more than 90% of performance are colored in light gray.  * The values for G and 
CRF14_BG are based on the LANL dataset. †These subtypes of CRFs only were available in the LANL dataset. ‡ The  1571 sequences G and CRF14_BG of 
the clinical dataset were included in the total.  Abbreviations: n: sample, cpx: complex, LANL: Los Alamos dataset,NA: Not applicable, URF: Unique recombinant 
form 
 
 
  
 
            Phylogenetic tools             
Subtype 
Total REGAv2 
   
REGAv3 
   
SCUEAL 
 
    
  Sens 95% CI Spec 95% CI Sens 95% CI Spec 95% CI Sens 95% CI Spec 95% CI 
A 226 89.8 85.9-93.8 100.0 99.9-100 95.6 92.9-98.3 100.0 99.9-100 85.8 81.3-90.4 99.9 99.9-100 
B 3023 97.3 96.7-97.8 99.8 99.7-99.9 99.2 98.9-99.5 99.3 99.0-99.5 96.3 95.7-97.0 99.9 99.5-99.9 
C 628 99.8 99.5-100 100.0 100-100 100.0 100-100 100.0 100-100 99.0 98.3-99.8 100.0 100-100 
D 69 84.1 75.4-92.7 100.0 100-100 88.4 80.9-93.0 100.0 100-100 95.7 90.8-100 100.0 100-100 
F 129 93.8 89.6-98.0 100.0 100-100 100.0 100-100 100.0 100-100 89.9 84.7-95.1 100.0 100-100 
LANL G* 34 100.0 85.1-100 99.4 98.9-99.7 100.0 85.1-100 99.4 98.9-99.7 97.1 84.7-99.9 99.9 99.6-100 
H 11 90.9 73.9-100 100.0 100-100 100.0 100-100 100.0 100-100 90.9 73.9-100 100.0 100-100 
J 6 100.0 100-100 100.0 100-100 100.0 100-100 100.0 100-100 100.0 100-100 100.0 100-100 
K† 2 100.0 100-100 100.0 100-100 100.0 100-100 100.0 100-100 100.0 100-100 100.0 100-100 
CRF01_AE† 169 99.4 98.3-100 100.0 100-100 99.4 98.3-100 100.0 100-100 84.0 78.5-89.5 100.0 100-100 
CRF02_AG 272 64.7 59.0-70.4 100.0 99.9-100 98.9 97.7-100 100.0 100-100 33.8 28.2-39.4 100.0 100-100 
CRF06_cpx 28 78.6 63.4-93.8 99.7 99.6-99.9 96.4 89.6-100 99.5 99.3-99.6 46.4 28.0-64.9 100.0 100-100 
CRF07_BC† 10 100.0 59.0-100 100.0 100-100 100.0 59.0-100 100.0 100-100 40.0 9.6-70.4 100.0 100-100 
CRF12_BF† 5 80.0 28.0-100 100.0 100-100 100.0 36.0-100 100.0 100-100 80.0 28.0-100 100.0 100-100 
LANL CRF14_BG* 11 63.6 30.9-88.9 100.0 99.7-100 72.7 39.1-93.7 99.9 99.7-100 81.8 47.8-96.8 99.9 99.6-99.9 
Clinical G+CRF14_BG‡ 1571 98.8 98.3-99.3 99.8 99.6-99.9 99.8 99.6-100 98.9 98.6-99.3 97.6 96.9-98.4 99.7 99.5-99.9 
 
Table 2.3: Performance of phylogeny-based subtyping tools. The sensitivity (Sens) and specificity (Spec) are reported for phylogenetic-based tools. The 
values with 100% of performance are highlighted in dark gray; the values with more than 90% of performance are colored in light gray. .  * The values for G and 
CRF14_BG are based on the LANL dataset. †These subtypes of CRFs only were available in the LANL dataset. ‡ The 1571 sequences G and CRF14_BG of 
the clinical dataset were included in the total.  Abbreviations: n: sample, cpx: complex, LANL: Los Alamos dataset, NA: Not applicable, URF: Unique 
recombinant form, REGAv3: REGA subtyping tool version 3, REGAv2: REGA subtyping tool version 2, URF: Unique recombinant form 
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The sensitivity and specificity was more than 96% using COMET, REGAv3, Stanford and STAR for 
CRF02_AG, while NCBI and SCUEAL had values below 50% for sensitivity. In most of the cases, NCBI 
misclassified some CRF02_AG as CRF30_0206 or CRF36_cpx whereas SCUEAL identified 
CRF02_AG sequences as “complex”. 
Regarding CRF06_cpx, REGAv3 had the highest sensitivity using 17 and 11 sequences in the clinical 
and LANL datasets respectively.  In the clinical dataset low prevalent CRFs were also found, for 
instance, CRF25_cpx was identified 100% by REGAv3 in 9 sequences (see supplementary table 2.2), 
CRF18_cpx was classified with 100% of sensitivity with NCBI, REGAv3 and SCUEAL in 3 sequences. 
Only REGAv2 and REGAv3 correctly identified both sequences of CRF13_cpx and both sequences of 
CRF27_cpx, respectively. On the other hand, the LANL dataset included other prevalent CRFs such as 
CRF07_BC and CRF12_BF. A 100% of 10 sequences of CRF07_BC were identified correctly using 
NCBI, REGAv2 and, REGAv3.  Similarly, a 100% of 5 sequences of CRF12_BF were correctly 
classified by COMET, NCBI and REGAv3.  
 
A CRF was never assigned when the sequence clustered significantly with a CRF but outside of the 
reference clade. In this way, potential CRFs can have been assigned URF; however there is no safe 
way to assign such a sequence to a CRF in absence of the full genome. To overcome this potential 
limitation, the sequences assigned in this way as URF were further analyzed with the slow Mphy and 
the CRFs’ reference dataset complemented with all curated full genome CRF sequences of Los Alamos 
database, and with SimPlot. We found that we had not missed any true CRFs and that all sequences 
that had been assigned URFs were truly URFs with unassigned fragments such as CRF06_cpx/U 
recombinant (23%, 79/336).  
 
to discriminate the parent pure subtypes from the CRFs in geographic areas where the CRFs 
originated. B: An example analysis by SCUEAL. The query sequence of the genomic region pol has no 
evidence of recombination and it clusters with CRF15_01B. However, this pol gene is from a full-length 
genome sequence assigned as CRF01_AE. It is possible that it concerns here a CRF01_AE that was 
very closely related to the founder of CRF15_01B. C: An example analysis by REGAv3. The query 
sequence is the pol region trimmed from a full-length genome sequence assigned as CRF14_BG. In 
the pure subtype analysis it has a high support with subtype G and in the CRF analysis it has a high 
support with CRF14_BG. The algorithm classified it as G. This might be due to the fact that the 
sequence did not cluster reliably within the CRF14_BG clade. D: Example of the assignment “complex” 
by SCUEAL. The assignment of the full genome is CRF02_AG but the tool identified it as a G, 
CRF01_AE, CRF02_AG, A ancestral recombinant. 
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FIGURE 2. 2. FREQUENT PROBLEMS WITH THE CLASSIFICATION OF CRFS 
Figure 2.2: Frequent problems with the classification of CRFs. A: Adapted from the Los Alamos 
database available in http://www.hiv.lanl.gov/content/sequence/HIV/CRFs/CRFs.html. The dashed lines 
delineate the region that is used for resistance testing and for the current performance analysis. The 
CRF01_AE and CRF15_01B are entirely subtype A in the pol gene, similarly CRF14_BG and 
CRF43_02G are entirely subtype G in this region. This complicates the identification since it is difficult  
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Other frequent URFs in the clinical dataset were various B/G recombinants (35%, 118/336), followed by 
other recombinants with unassigned fragments such as G/U recombinant (9%, 31/336) and B/U 
recombinant (5%, 16/336).  The performance of the subtyping tools was not evaluated for URFs 
because of the limited number of sequences available and the complexity to evaluate recombinants 
when tools such as COMET, Stanford and STAR do not show the recombination breakpoints [17, 19, 
20]. 
 2.4.4 PERFORMANCE OF SUBTYPING TOOLS FOR G AND CRF14_BG 
When confronted with the discrepancy in manual phylogenetic assignment for CRF14_BG and subtype 
G in the clinical dataset, as described in methods, we decided to only use the LANL dataset to calculate 
the performance on these two subtypes, because the pol region was trimmed from full genomes which 
is the only way to safely assign CRFs that lack a breakpoint in the here analyzed pol region (see figure 
2.2) [43]. The sensitivity for subtype G was more than 97% for all the tools, except NCBI and STAR in 
the LANL dataset. The first had a sensitivity of 47% because of misclassification of some subtype G 
sequences as CRF14_BG or CRF43_02AG (See figure 2.2). STAR had 73% of sensitivity due to 
“unassigned” sequences. The specificity for subtype G was more than 99% for all the tools. Regarding 
CRF14_BG, COMET and SCUEAL classified 9 out of 11 sequences correctly followed by REGAv2 and 
REGAv3, which classified 8 out of 11 sequences as “Subtype G (CRF14_BG)”.  
 
To evaluate the discordances between the tools, the fast and slow MPhy procedures and the manual 
phylogenetic analysis of subtype G and CRF14_BG sequences in a single tree, as described in 
methods, we retrieved the env sequences from the Portuguese resistance database. We found 44 
sequences (C2-V5 region of the gp120, mean length: 500 nts) from the same patients whose pol 
sequence was included in this study, 28 had their pol sequence classified as G using slow MPhy, and 
16 as CRF14_BG.  4 subtypes B env sequences belonged to patient isolates classified as G in pol, 
similarly 6 subtype G env sequences belonged to patient isolates classified as CRF14_BG in pol. In 
addition, we determined how the Portuguese sequences clustered with respect to all full genome 
G/CRF14_BG sequences available from the Los Alamos database. All Portuguese G or CRF14_BG 
clinical sequences formed a monophyletic cluster within subtype G including all CRF14_BG full 
genomes, but the Portuguese clinical sequences, assigned as CRF14_BG and G by slow MPhy were 
paraphyletic with each other, suggesting that there may be a problem with the assignment of 
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CRF14_BG and this CRF may in fact consist of more than one CRF with very similar breakpoints (see 
supplementary material figure 2.3). 
 
Using slow Mphy, 951 sequences were considered subtype G and in more than 96% of the cases these 
were also classified subtype G by jpHMM, REGAv2, REGAv3 and Stanford (in alphabetical order and 
see supplementary material table 2.2), however, the tools also assigned many of these sequences to 
CRF14_BG; with the exception of COMET and SCUEAL. Using slow Mphy, 620 sequences were 
considered CRF14_BG, and again, COMET and SCUEAL had the highest agreement with slow MPhy, 
but these values were just 62% and 56% respectively. Given that we did no longer consider the slow 
MPhy reliable for subtype G and CRF14_BG, these performance statistics are also not reliable. We 
therefore chose to pool the subtype G and CRF14_BG sequences from the Portuguese clinical 
database, as they were assigned by slow MPhy, and compute the performance of the tools on the 
combined class “G or CRF14_BG”. The sensitivity was above 99% for NCBI and REGAv3, followed by 
COMET, jpHMM, and REGAv2 with more than 98% while specificity was around 99% for all the tools. 
 2.4.5 PERFORMANCE OF SUBTYPING TOOLS FOR PR AND RT SEPARATELY 
The performance of the tools on PR and RT separately was only evaluated on the LANL dataset and 
the results are shown in supplementary data (supplementary table 2.4 and table 2.5). When analyzing 
PR separately, COMET and jpHMM showed similar performance as for pol with regard to pure 
subtypes and the CRF01_AE from the LANL dataset. However, the sensitivities varied for the other 
tools. For instance, Stanford and STAR had a better sensitivity for subtype A, but NCBI a worse 
sensitivity for subtypes A, C, F, and G.  Stanford and STAR had similar sensitivities for CRF02_AG but 
other tools had a lower performance like COMET, NCBI, REGA and SCUEAL. With regard to RT 
sequences, in general, the performance of the subtyping tools was the same as for the pol sequences, 
again using the LANL dataset only. The exceptions included tools with improved sensitivity such as 
NCBI for subtypes B, D and G; REGAv3 for CRF02_AG, Stanford for subtypes A, F and STAR for 
subtype G. However, SCUEAL had decreased sensitivity for subtype CRF02_AG (supplementary table 
2.4).  
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2.4.6 PERFORMANCE OF REGAV3 VERSUS THE PREVIOUS VERSION REGAV2 
The performance of REGAv3 was better than REGAv2 for subtypes B (p=0.01), and CRF02_AG 
(p=0.001) in the genomic region pol in both datasets (see tables 2.1, 2.2 and 2.3 and supplementary 
tables 2.2 and 2.3).  In the case of CRF02_AG, for instance, the changes in the decision tree for 
REGAv3 improved sensitivity by properly assigning CRF02_AG sequences that were classified as 
“check the bootscan” by REGAv2. 
 
We compared the new term “-like” of REGAv3 with MPhy.  “Subtype B-like” corresponded to subtype B 
in 28 sequences analyzed with the MPhy, while 8 were B/U recombinants and 2 were B/G 
recombinants. In the case of “subtype G-like”, the MPhy showed 1 subtype G, 3 recombinants G and 
one CRF06_cpx.  “Subtype A1-like” and “Subtype F1-like” were identified in 2 and 4 sequences 
respectively, but in both cases the MPhy showed these were A and F subtypes.  
 
We also evaluated the performance for PR and RT separately but only using the LANL dataset. In the 
analysis of RT, REGAv3 had higher sensitivity than REGAv2 for subtype B (98.8 versus 91.9). 
However, the performance in PR was variable (see supplementary table 2.5) because the REGA 
subtyping tool algorithm is different for sequences shorter than 800 nts. In short sequences, the criteria 
are based on clustering only and potential recombination is not analyzed. This is because the window 
size for recombination analysis in REGA is chosen as 400 nts to avoid losing too much phylogenetic 
signal [44] and recombination is scanned in steps of 50 nts, such that no meaningful recombination 
signal can be obtained for such short sequences.  REGAv3 correctly identified only 54% of the subtype 
A sequences, which is better than the 45% with REGAv2, but the sensitivity for subtype B decreased 
from 86% to 73% when comparing REGAv2 versus REGAv3. There was no difference between the 
tools for subtype C and G.  The lack of phylogenetic signal in the short fragment of PR significantly 
reduced the sensitivity of the tool, for instance REGAv2 had a sensitivity of 27% and REGAv3 had 24% 
for subtype F; while none of the subtypes D, CRF01_AE and CRF02_AG sequences analyzed were 
properly identified.  2.4.7 REPRODUCIBILITY OF HIV-1 SUBTYPING TOOLS: 
COMET, jpHMM, NCBI, Stanford, and STAR were 100% reproducible. Subtyping tools based on 
phylogenetic methods such as REGAv2, REGAv3 and SCUEAL were reproducible with values of 
99.2% (95% CI: 99.10-99.26), 99.2% (95% CI: 99.15-99.30) and 96.4% (95% CI: 96.27-96.60) 
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respectively. When the clinical and LANL datasets were independently analyzed, the reproducibility did 
not change significantly; for instance, the reproducibility for REGAv2 was 99.1% and 99.5%, for 
REGAv3 98.8% and 99.7 %, and for SCUEAL 95.4% and 98.1%, respectively.  
 
For REGAv2 and REGAv3, most of the non-reproducible results were related to subtype B. For 
example, when the sequence was subtype B, the tool might classify it as subtype B, or as “check the 
report” or “B/D recombinant” (for details see also Supplementary table 2.1). In this paper we considered 
“subtype–like” as belonging to the subtype (or CRF) identified by the tool for REGAv3. If “subtype-like” 
would be considered discordant, then the sensitivity of REGAv3 would go down (from 99.2% to 97.8% 
for subtype B, the assignment with the highest number of –like assignments), and the reproducibility 
would go up (from 98.9% to 99.2%). For SCUEAL, the non-reproducible results were related mainly to 
subtype B and CRF02_AG. For instance, subtype B was sometimes classified as “B/D recombinant” by 
the tool, and CRF02_AG was frequently assigned as “complex”. 
2.5 DISCUSSION 
In the present study, we compared and described the performance of the phylogenetic based 
automated HIV typing and subtyping tool REGAv3, its previous version REGAv2, and six other 
commonly used automated HIV-1 subtyping tools: one other phylogenetic based tool, SCUEAL; three 
statistical-based tools, COMET, jpHMM and STAR; and two similarity based tools, NCBI and Stanford. 
We used only the pol (PR+RT) region that is usually sequenced for drug resistance testing [45, 46], 
since this generates the largest datasets for which these tools are designed. This restriction was also 
made since tools such as SCUEAL and Stanford cannot assign sequences outside this region [17, 24]. 
In addition, we analyzed with phylogenetic analysis two datasets; one dataset was derived from clinical 
samples and another from the Los Alamos database (available in http://www.hiv.lanl.gov/). We used the 
clinical data from Portugal because it is one of the European countries with the highest proportion of 
non B-subtypes [47, 48].  Since phylogenetic analysis of full-length genomes is the gold standard to 
define the current subtypes [2], we also used the assignment of the pol region confirmed with MPhy and 
trimmed from full-length genomes of pure subtypes and the most common CRFs from the Los Alamos 
database, with the aim to better evaluate the performance of automated subtyping tools on all epidemic 
subtypes and CRFs. 
 
Our primary aim was to evaluate the new subtyping tool REGAv3 versus other available tools. REGAv3 
identified subtype B, most of the non-B pure subtypes and the most frequent CRFs with a sensitivity 
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and specificity of more than 96% in the pol region. The classification of REGAv3 for subtype B and 
CRF02_AG has improved compared to REGAv2; additionally, with an updated algorithm and reference 
dataset, REGAv3 is designed to identify most of the epidemic CRFs. Consequently, REGAv3 performs 
equally well as other tools, such as COMET and jpHMM, which also had high sensitivity and specificity 
for classifying most of the pure subtypes and such as COMET, Stanford and STAR for classifying 
CRF01_AE and CRF02_AG. 
 
Concerning some previous reports that suggested a low performance of REGAv2 compared with other 
subtyping tools [26, 49], it is pertinent to add that these discrepancies were almost exclusively due to 
unassigned reports, and not due to wrong assignments [49].  The number of unassigned sequences 
was reduced in REGAv3 compared to REGAv2, by introducing the term “like”. Although 74% of the 
sequences assigned as “like” were classified as a pure subtype by the MPhy in our analysis, 26% of the 
samples showed evidence of recombination; therefore, this terminology “like” is indeed useful, as it 
alerts the user to further verify these sequences.  This helps to reduce the number of inaccurate 
assignments, while also reducing the number of unassigned sequences. Thus, REGAv3 uses the 
“subtype-like” assignment to indicate the most likely subtype for a particular strain, and at the same 
time to caution for potential discrepancies, thereby increasing the usefulness of the tool both for 
epidemiological statistical purposes where it is important to have as few as possible unassigned 
sequences, and for situations where correct assignment is more important.   
One of the aims of the study was to give guidance as to which tool would perform well in a context of 
HIV-1 surveillance activities where the overall prevalence and spread of the epidemic is important to 
estimate [3]. We showed that no subtyping tool is able to classify all HIV-1 clades with a 100% 
accuracy, and we highlighted the difference in performance of the tools according to the subtype (or 
CRF) or the region analyzed such as PR, RT or PR+RT, such that our results can be directly compared 
with other studies [26, 49, 50]. In general, our findings corroborate that phylogenetic-based, statistical-
based tools and the similarity-based tool Stanford perform well for the most frequent subtypes 
worldwide such as B and C [3, 19-21, 24, 51].  However for other important clades such as A, D, F, G, 
CRF01_AE, CRF02_AG, COMET and REGAv3 correctly identified most strains while the remaining 
tools failed much more often.  
 
Since we only had the pol region of the clinical dataset, we cannot exclude that other regions of the 
genome belong to other subtypes or CRFs, as has been reported in other cohorts [52, 53]. However, 
overall, the performance of the tools was similar for the clinical and the LANL dataset, suggesting that 
for most subtypes and CRFs, our performance evaluation is valid. The exception is the assignment of 
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subtype A and CRF06_cpx. For example, COMET correctly identified subtype A in 76% of the 
sequences from the clinical dataset and 100% of the LANL dataset, similarly this tool also identified 
only 18% of the CRF06_cpx in the clinical dataset and 100% in the LANL dataset (see supplementary 
tables 2.2 and 2.3). The reason for this discrepancy has not been further investigated, but we suspect 
that by not taking into account the evolutionary relationship of the sequences, statistical-based tools like 
COMET are prone to overfitting on the training dataset (LANL).  
 
Another reason for variation in the performance of subtyping tools is the analysis of PR and RT 
separately [26, 50]. Most of the tools had similar performance for the RT and the pol region. However, 
with regard to the PR region separately, statistical-based tools such as COMET and jpHMM had a 
higher performance than the other tools. These disagreements, for instance with REGA, occurred 
because short sequences with low phylogenetic signal were frequently reported as “unassigned”[26]. 
The philosophy of REGA is to avoid assigning sequences with low phylogenetic signal, with the aim to 
avoid false conclusions about evolutionary relationships [44, 54]. Consequently, the user must be 
aware that short sequences require further examination to be correctly classified. 
 
Current definitions of some subtypes and CRFs contribute to problems with the performance of 
automated tools. For example, the relationship between CRF02_AG and its parental strain A and G is 
still a matter of debate [24, 55, 56]. For other CRFs, such as CRF02_AG, CRF07_BC, CRF08_BC, 
CRF12_BF, and CRF17_BF, atypical breakpoints were found in the sequences assigned to these 
CRFs in the Los Alamos database [56], suggesting perhaps a wrong assignment in this database. In 
fact, the proper assignment of several CRFs can be disputed, for example when the recombinant region 
is so small that there is not sufficient phylogenetic signal for classification (e.g. around 100 nts for 
CRF12_BF, CRF20_BG, CRF35_A1D, CRF41_CD).  Finally, several CRFs are so closely related to 
each other (e.g. CRF20_BG, CRF23_BG and CRF24_BG) that automated tools have great difficulty to 
discriminate between them. A thorough re-analysis of all CRFs is therefore urgently needed. 
 
The absence of breakpoints in the region of study was another frequent cause of misclassifications; for 
instance CRF01_AE was classified as CRF15_01B [57] (see figure 2.2) and G was classified as 
CRF14_BG. There was no problem with the evaluation of the CRF01_AE pol sequences, but we had to 
question either the value of the manual phylogenetic analysis as gold standard for CRF14_BG, or the 
definition of CRF14_BG itself. The clinical dataset is derived from the country where this CRF 
originated, and the prevalence of the parent subtype G and of CRF14_BG as defined by manual 
phylogenetic analysis was very high. However we had access to env sequences from several patient 
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isolates that were included in the pol dataset, and for several of these, there was discordance with the 
pol assignment, as has been reported before [53]. In a joined phylogenetic analysis of all G and 
CRF14_BG sequences, the CRF14_BG sequences were not monophyletic but were spread among the 
subtype G sequences, and this was also the case for the LANL full genome CRF14_BG sequences. As 
a result, and only for the clinical dataset, we pooled CRF14_BG and subtype G in a single, but 
separate, classification ‘CRF14_BG or G’.  
 
Phylogenetic-based subtyping tools had lower reproducibility than similarity-based tools or statistical-
based tools and the sequences causing this problem were not consistent across tools.  The 
bootstrapping procedure in the tree-based algorithms is responsible for this lower reproducibility. 
Bootstrapping is a random process of resampling [25, 32], and each bootstrap sample is a different 
sample. For a more robust assignment, it would be needed to perform 1000 bootstrap samples, but this 
would cost too much computer time, and the phylogenetic-based tools are already slow.  Other causes 
for the lower reproducibility were the introduction of new thresholds in the bootscan support of REGAv3 
and the term “complex” in SCUEAL. This led sometimes to misidentification especially of subtype B as 
B/D recombinant because of the high similarity between these subtypes in the pol region [2, 58].  
 
Other considerations that influences the widespread use of subtyping tools are the operational 
characteristics (see table 2.4).  For example, the analysis of a bulk of sequences usually takes more 
time with phylogenetic-based tools than statistical-based tools [19, 24, 25], and this is important for any 
application in a context of a large dataset. On the other hand, for the surveillance of the HIV-1 epidemic 
it is sometimes important to have information on recombination breakpoints, which are only shown in 
phylogenetic-based tools and jpHMM [21, 24].  
Although we included prevalent epidemiological non-B subtypes and CRFs, we acknowledge the limited 
number of samples available for subtypes H, J, K, CRF06_cpx, CRF07_BC and CRF12_BF, which 
prevents us from drawing firm conclusions for these subtypes and CRFs. We also did not evaluate all 
available tools, since many are based on similarity, and some have as their main objective the 
evaluation of antiretroviral resistance rather than subtyping [18]. We included the two most commonly 
used similarity-based tools, NCBI and Stanford [16, 27].   
 
Other factors, that influence the performance of subtyping tools, are the high recombination rate of HIV-
1 [4] and human migration as determinants of global HIV dynamics [59]. HIV-1 recombination increases 
the complexity and frequency of recombinant forms [56], while migration has driven the dissemination 
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of subtypes to new regions and established new epidemics [60]. As a consequence the subtyping tools 
should be regularly updated, especially tools which do not consider the intrinsic biologically relevant 
evolutionary relationships like statistical or similarity-based tools.  The analysis of an epidemic where 
many subtypes or new CRFs are prevalent must be identified with COMET or phylogenetic-based tools 
that have an updated reference dataset [19, 22, 24]. 
 
2.6 CONCLUSIONS AND RECOMMENDATIONS 
To our knowledge, this is the first study with an extensive comparison between subtyping tools, and 
manual phylogenetic analysis in PR, RT, PR+RT in two large datasets: a clinical dataset  and a LANL 
dataset in which pol region was trimmed from full-length genomes. The performance of the new 
REGAv3 to identify subtype B and CRF02_AG in the pol region was much better than with REGAv2. 
REGAv3 had a very good performance in classifying pure subtypes, similar to that of COMET, jpHMM 
and SCUEAL, and it was also very good at identifying CRFs in the pol region, comparable to the best 
other tool, COMET. REGAv3 and COMET are currently the best available tools to automatically 
subtype HIV-1 sequences, however recombination breakpoint analysis is not possible with COMET. 
The performance of jpHMM is comparable but this tool has the big disadvantage that it does not classify 
CRFs, except for CRF01_AE [21]. 
 
We could draw some general recommendations from this analysis to use in future surveys of HIV-1 
genetic diversity. First, automated tools might be useful for subtyping large pol datasets that are used in 
clinical and surveillance settings  [24, 51]. Nevertheless, if accuracy is important, for example in 
individual patient follow-up or in detailed epidemiological analyses, it is necessary to use at least two 
subtyping tools whose overall performance is high in the genetic region analyzed such as COMET and 
REGAv3. This methodology has been previously used in different studies that required stringent 
analyses of large datasets [12, 61-63]. This comes at the cost of speed, which is determined by the 
slower of the two tools, the phylogenetic-based tool. The discordant sequences between the two tools 
can then be analyzed using manual phylogenetic analysis, still the gold standard.  Second, for very 
short sequences such as PR, tools like COMET are recommended given that REGAv3 will give a 
considerable number of unassigned sequences, but only if accuracy is not a big issue. Therefore, we 
insist that for short sequences with low phylogenetic signal, such as PR, manual phylogenetic analysis 
is still needed [44].  Third, subtyping is often done in the context of an individual patient follow-up, using 
PR+RT sequences that are available from resistance genotyping. Thus it is often the case that 
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resistance and subtyping are analyzed together in the clinical settings. Stanford does provide this 
information; however, the main goal of Stanford is to provide an accurate algorithm of resistance rather 
than subtyping (http://hivdb.stanford.edu/DR/asi/releaseNotes/index.html#hivdb_subtyping). If this tool 
is used, analysis of subtypes A, F and CRFs should be complemented with other statistical-based or 
phylogenetic-based tools. For example, REGAv3 is also on the same website.  Fourth, the use of at 
least two automated tools to classify subtypes in the patient follow-up could also be useful, for example, 
for clinical collaborators that have little experience with manual analysis. However, if superinfection is 
suspected, phylogenetic analysis should be carried out [64].  
 
 
  
Characteristics 
Tools 
Phylogenetic  Similarity Statistical 
REGAv3 REGAv2 SCUEAL NCBI STANF COMET jpHMM STAR 
Analysis of full genomes + + - + - + + + 
Exact recombination breakpoints + - + * - - + - 
Intra-subtype recombination - - + - - - - - 
Latest CRF that can be analyzed† CRF47_BF CRF14_BG CRF43_02G CRF43_02G CRF02_AG CRF49_cpx CRF01_AE CRF02_AG 
Batch analysis online 1000 1000 500 1 >100‡ 10 Mb§ 5ۤ 500 
Waiting job queue - - + - - - - - 
Average time for 500 sequences ¶ ~5 h ~4 h ~3 h - ~5 min sec ~2 - 7 h ۤ ~15 min 
Average time for 1 sequence ** ~min ~min ~min sec sec sec sec-min sec 
Part of resistance analysis - - - - + - - - 
Phylogenetic signal analysis + + - - - - - - 
Summary table report  + - + - - - - - 
Graphical visualization of results + + + + - - + + 
Position of sequence according to 
HXB2 reference + + - - - - + - 
Download additional files  
(csv, txt, fasta, etc) + + + + + + + + 
Table 2.4: Operational characteristics of subtyping tools. The *NCBI report shows an approximation of the breakpoints,  † Some CRFs are excluded from 
the analysis, such as those with a limited number of strains available in LANL, or where the pol region cannot be discriminated from other CRFs (see 
http://bioafrica.mrc.ac.za/CRFs/CRFs.php)  ‡ Stanford is able to analyze up to 100 sequences at a time (character limit: 600,000). However there are other 
options to analyze more sequences. § COMET accepts files with a maximum size of 10Mb (around 8000 sequences PR+RT). || jpHMM has the option to 
download a command line program without limit of batch analysis. In addition, there is an option to speed up the program. ¶ We ran 500 sequences with pure 
subtypes and CRFs five times in different days. Then we calculated the average time.  ** We ran 5 times a recombinant, the average time for analysis of 1 
sequence is about 1 minute for Phylogenetic-based tools and seconds for the other tools.   Abbreviations: (+) characteristic available in the tool, (-) characteristic 
not available, (h) hours, (min) minutes, (sec) seconds.  
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3.1 SUMMARY 
Objective: To characterize the molecular epidemiology of HIV-1 in Colombia and to elucidate its spatial 
phylodynamics in the context of international and national migration. 
Design: HIV-1 pol nucleotide sequences were compiled from 7 distinct geographic regions of Colombia 
sampled between 2002-2007. 
Methods: 610 HIV-1 sequences were obtained from Bogotá, Cali, Medellin, and the Coffee, Santander, 
Caribbean, Orinoquía and Amazonas regions. Phylogenetic subtyping was performed and a dataset 
was compiled including the closest available sequence data to the Colombian epidemic, and a 
representative set of worldwide subtype B sequences. Phylodynamic and phylogeographic analyses 
revealed the most significant routes of spatial dispersal and viral flow between geographic regions was 
quantified. 
Results: The Colombian epidemic is dominated by subtype B (99.8%) in all analyzed geographic 
regions. One sub-subtype F1 was isolated in Bogotá in 2003. Phylogeographic analyses suggest 
multiple links between the Colombian and the Spanish HIV-1 subtype B epidemic. Subtype B was 
imported multiple times from the late-1970s onwards. Within Colombia, we found strong statistical 
support for viral migration from Bogotá to Medellin, Cali, Santander and the Caribbean and Coffee 
regions.  
Conclusions: This is the first study using a large sample, which shows the predominance of Subtype B 
in Colombia. We find that viral populations in Bogotá play a central role in shaping the HIV-1 epidemic 
also within other regions of Colombia. The Colombian HIV-1 epidemic has most likely been seeded 
multiple times from various countries from the late-1970s onwards, and strong links exist between the 
Spanish and the Colombian epidemic.  
3.2 INTRODUCTION 
According According to UNAIDS Colombia had a HIV-1 prevalence of approximately 0.5%  in  2012 [1]. 
Molecular epidemiological studies up to 2002 have shown that HIV-1 subtype B clade predominates in 
Medellin [2] and Bogotá [3, 4] and, according to a recent study, also in the port city of Barranquilla in 
the northern Caribbean region [5]. Although HIV-1B predominates in the Americas [6], other HIV-1 
clades circulate in Latin America. HIV-1 subtype F has been found in the men who have sex with men 
(MSM) population in Bogotá [3]. Subtype F also circulates in Ecuador and Peru [7] that border southern 
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Colombia. In other countries it was shown that countrywide HIV-1 genetic diversity is not always 
homogeneous. For example, subtype C clade circulates throughout southern Brazil [8, 9], and its 
introduction in the region has attracted considerable attention [10-12]. Subtype C also circulates in 
countries bordering Colombia, such as Venezuela [13], Panama [14] and in Ecuador [7].  
Due to the fast evolutionary rate of HIV, phylodynamic techniques can be used to recover the 
evolutionary and spatial history of viral dispersal in great detail [15-17]. Molecular clock analyses have 
shown that subtype B finds its ultimate origins in the Central African subtype D around the 1960s [18, 
19] from where it was introduced, most probably due to a single founder effect, to Haiti and made its 
way the US as subtype B [20, 21]. Moreover, it was recently shown that the predominance of subtype B 
in most of Central America was the result of a major single introduction occurring in the 1980s, a study 
in which Colombian strains were limited while contemporary country-specific HIV epidemics in this 
region are characterized by early subdivision into discrete sub-epidemics [22, 23]. Recent 
phylogeographic studies suggested that South American subtype B epidemic was also seeded from the 
Caribbean region [23]. However, due to the limited amount of genetic data available from Colombia, 
little is known about the evolutionary history of HIV-1 in this country. 
Here we report the molecular epidemiology of HIV-1 in Colombia based on a large comprehensive 
collection of virus sequence data (n=610) sampled from seven regions between 2002 and 2007, and 
we investigate the most probable routes of subtype B introduction and the pathways of HIV migration 
within Colombia. The identification of the most important foci of HIV transmission in a country with high 
frequency of internal displacement [24], regional conflict and international migration [25] may be useful 
for public health purposes. 
3.3 MATERIAL AND METHODS 
3.3.1 STUDY POPULATION 
Nucleotide data was collected from 619 Colombian patients, as part of genotypic resistance tests 
carried out in the Centro de Análisis Molecular in Colombia between 2002 and 2007; this center 
performed nationwide resistance testing on mainly treated patients during this period. Sequences were 
obtained by population sequencing using TRUGENE® kit (Siemens Healthcare Diagnostics, Germany). 
Only one sequence per patient was included. Quality control (QC) was evaluated with the Los Alamos 
database QC tool (http://www.hiv.lanl.gov/content/sequence/QC/index.html) using previously suggested 
parameters [26]. Nine sequences were excluded from subsequent analyses because of an excessive 
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number of stop codons and frameshifts (n=7) or hypermutations (n=2). No socio-demographic 
information except for city of residence was available. 
 
The final nucleotide dataset consisted of 610 sequences sampled from patients from the following 
regions: 1) the capital Bogotá (n=275), 2) Cali (n=77), 3) Medellin (n=64), 4) Coffee region (n=42) that 
included sequences from Armenia, Pereira and Manizales cities, 5) Santander region (n=26) that 
included sequences from Bucaramanga and Cucuta cities, 6) Caribbean region (n=18) that included 
sequences from Barranquilla, Cartagena, Santa Marta and Sincelejo cities, 7) Orinoquía and Amazonas 
(OAM) region (n=6) that included sequences from Villavicencio and Florencia cities (Figure 3.1A). A 
total of 102 sequences were not assigned to any particular city or region and their most probable 
location was inferred by using an ambiguous trait code in a phylogeographic approach. 
 3.3.2 CLASSIFICATION OF HIV-1 DIVERSITY AND RECOMBINATION TESTING 
To accurately classify the HIV-1 pol sequences, we first used two automated subtyping tools: REGA 
version 3; available at http://regatools.med.kuleuven.be/typing/v3/hiv/typingtool/  [27] and COMET 
version 2; available at http://comet.retrovirology.lu/ [28].  Each sequence was classified as either 
concordant (both tools agreed on the assignment) or discordant (tools had a different assignment). The 
discordant assignments were subsequently classified using a manual phylogenetic analysis approach 
[27]. Sequences were screened for phylogenetic signal with TreePuzzle [29] and recombination using 
SimPlot [30], the Phi-Test [31] implemented in SplitsTree version 4.10 [32] and the genetic algorithm 
single breakpoint (SBP) method [33] available at www.datamonkey.org. 3.3.3 RELATION OF COLOMBIAN SEQUENCES AND GLOBAL SUBTYPE B DIVERSITY  
To investigate the spatial evolutionary dynamics of the HIV-1 subtype B Colombian epidemic in a global 
context, we first downloaded all other available Colombian sequences (n=22), and complemented our 
dataset of Colombian sequences with the 10 closest publicly available sequences for each Colombian 
sequence, identified through a BLASTn search available at http://blast.ncbi.nlm.nih.gov/Blast.cgi. This 
step was done using an in-house PERL script that retrieves the most similar sequences from a fasta file 
(script is available upon request). The respective collection year and country of sampling were compiled 
and all publicly available sequence data were screened for quality control and recombination as 
described above. This compiled dataset was hereafter named BLASTn-COL dataset (supplementary 
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tables 3.1 and 3.2). To evaluate whether the country of origin of the strains changed according to the 
number of closest sequences retrieved by BLASTn, a sensitivity analyses was performed with the 30 
and 50 most similar sequences (supplementary table 3.3).   
 
 
FIGURE 3. 1. SIGNIFICANT EPIDEMIOLOGICAL LINKS OF COLOMBIAN SUBTYPE B WITH OTHER COUNTRIES AND 
WITHIN COLOMBIA 
Figure 3.1: Significant epidemiological links of Colombian Subtype B with other countries and 
within Colombia. (a) The migration pathways are shown according to the BSSVS analysis in an 
international context and within Colombia. (b) This analysis was based on the most similar sequences 
to each Colombian sequence retrieved by BLASTn 
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To have a complete overview of the Colombian subtype B diversity and its relation with the neighboring 
countries and worldwide epidemic, we additionally downloaded available pol subtype B sequences from 
Los Alamos database (http://www.hiv.lanl.gov/). Because of the extensive number of sequences, we 
selected a random dataset of 25 subtype B pol sequences per year for each country worldwide. In 
addition, we included all available sequences from bordering countries such as Brazil, Ecuador, 
Panama, Peru, and Venezuela (http://www.hiv.lanl.gov/, accessed Sept 2013). Clones, duplicates and 
multiple sequences per patient were excluded.This compiled dataset was hereafter named LANL-
Borders dataset (Supplementary table 3.4).  The 2 joined datasets were called BLASTn-COL+ LANL-
Borders dataset. 
 
All sequences were aligned using Muscle [34] and minimally edited using SeaView [35]. Thirty-seven 
codon positions associated with drug resistance mutations were removed from the alignments [36]. A 
Maximum likelihood (ML) phylogenetic tree was constructed with the BLASTn-COL dataset by using 
6HD9LHZXQGHUWKHEHVWILWWLQJQXFOHRWLGHVXEVWLWXWLRQPRGHO*75,Ƚwith the approximate likelihood-
ratio test based on the Shimodaira-Hasegawa-like (SH) procedure as statistical support. ML trees with 
the BLASTn-COL+ LANL-%RUGHUV GDWDVHWV ZHUH FRQVWUXFWHG ZLWK )DVW7UHH XQGHU WKH *75Ƚ
nucleotide substitution model with the SH procedure as statistical support [37, 38].  3.3.4 BAYESIAN PHYLOGENETIC ANALYSES 
To investigate the spatiotemporal dispersal of subtype B, posterior distributions of phylogenetic trees 
and ancestral geographic states were estimated in a joint Bayesian Markov chain Monte Carlo (MCMC) 
framework [39]. First, for the BLASTn-&2/GDWDVHWZHXVHGD*75Ƚ,QXFOHRWLGHVXEVWLWXWLRQPRGHO
[40], an uncorrelated lognormal molecular clock model [41] and a non-parametric skyline tree prior that 
avoids assumptions regarding demographic epidemic growth [42]. MCMC analyses were run in 
triplicate for 250 million steps and trees were sampled every 50,000th state. 10% of the burn-in was 
discarded and the remaining samples were combined using LogCombiner. From the resulting posterior 
tree distribution, 3,500 trees were removed as burn-in and the remaining posterior sample was 
resampled at a frequency of 10% to generate a total of 1,000 posterior empirical trees. BEAGLE library 
was used in all Bayesian computations to improve run-time [43, 44].  
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3.3.5 PHYLOGEOGRAPHIC LINKAGE AND COUNTING NUMBER OF TRANSITIONS BETWEEN LOCATIONS 
To further improve computational time, spatial diffusion analyses were run on the empirical set of 1,000 
trees representative of the posterior distribution. We first identified the most significant non-zero rates of 
viral dispersal using a Bayesian Stochastic Search Variable Selection (BSSVS) procedure [45], under a 
discrete asymmetric diffusion model [46]. The statistical significance of the non-zero rates were 
summarized using a Bayes Factor (BF) test that compares the posterior to the prior odds that a 
particular rate is required to explain the diffusion process [47]. Second, we quantify the number of 
transitions for the set of non-zero rates using a robust counting procedure [48-50]. Maximum clade 
credibility trees (MCC) were summarized using TreeAnnotator and visualized with FigTree v1.4.0 
(available at http://tree.bio.ed.ac.uk ).  3.3.6 STATISTICAL PHYLOGEOGRAPHIC ANALYSES 
To confirm the links obtained by Bayesian phylogenetic analysis at international level, we used a non-
parametric model of geographic spread based on parsimony using the BLASTn-COL dataset and a 
global subtype B dataset as previously described [51] 0/ WUHHV ZHUH LQIHUUHG ZLWK WKH *75Ƚ
nucleotide substitution model with 250 bootstraps as statistical support using RAxML to perform this 
analysis [52]. 3.3.7 SENSITIVITY TO SPATIAL SAMPLING SCHEME 
Three additional datasets comprising a total of 157 Colombian sequences were compiled to investigate 
the potential effect of sampling bias in estimating the geographic dispersal of HIV-1 in Colombia. 
Sequences were randomly selected according to a weighted sampling scheme that took into 
consideration the proportion of HIV-1 in people living in each Colombian region by 2007 [53]. This 
resulted in datasets comprised by 50 sequences from Bogotá, 29 sequences from Cali, 25 sequences 
from Medellin, 18 sequences from the Caribbean, 13 sequences from Santander, 13 sequences from 
the Coffee region, 5 sequences from the OAM region and 4 sequences from unknown regions. Non-
Colombian sequences from the BLASTn search were maintained identical (Supplementary table 3.1), 
resulting in a total of 461 sequences for analysis. Bayesian phylogenetic analyses described above 
were also performed on these datasets.  
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3.4 RESULTS 
3.4.1 MOLECULAR EPIDEMIOLOGY OF HIV-1 IN COLOMBIA 
A total of 610 pol nucleotide sequences were available from individuals who enrolled in the genotypic 
resistance-testing center between 2002 and 2007. All samples were assigned with year of collection 
and 83.2% (508/610) with city of residence of the patient (Supplementary table 3.1). Most pol HIV-1 
sequences (alignment length: 807 nt; positions HXB2: 2262-3290) belonged to subtype B (99.8%, 
609/610), reflecting a regionally uniform predominance of this clade in Colombia. Only one sequence, 
sampled in Bogotá in 2003, was classified as sub-subtype F1 (0.2%, 1/610).  No evidence of 
intersubtype recombination was found; however, eight subtype B sequences had discordant results 
among the three recombination tools because of the presence of unknown fragments with very low 
phylogenetic signal (average length: 335 nt). Therefore, these sequences were excluded for 
phylogeography analyses. The remaining sequences had an adequate phylogenetic signal according to 
TreePuzzle analyses. 
 3.4.2 PHYLOGENETIC CLUSTERING OF COLOMBIAN VS GLOBAL SUBTYPE B SEQUENCES 
The dataset compiled contained the 10 most similar sequences per Colombia strain selected by 
BLASTn search as described in methods. The countries from where those additional sequences were 
originating are mentioned in Supplementary table 3.3. The sensitivity analysis did not show differences 
in the proportion of the countries when the number of similar sequences was increased from 10 to 30 
and 50. However, only the dataset with the 10 closest sequences was analyzed because of the 
additional computational time.  
 
To frame the Colombian subtype B epidemic in a global context, we performed a ML phylogeny using 
BLASTn-COL dataset (non-Colombian sequences: n=304 and Colombian sequences: n=623; See 
Figure 3.1B, and supplementary tables 3.1 and 3.2 for details), and the LANL-Borders dataset that 
included 2968 sequences from neighboring countries and 4963 sequences samples worldwide (Figure 
3.2A, Supplementary table 3.4). The ML tree shows that HIV-1B Colombian sequences were 
intermingled within the global subtype B diversity.  In addition, 17.3% Colombian sequences (108/623) 
fell within 7 clusters with statistical support ranging from 0.846 to 0.992, suggesting only few local 
transmission clusters among the strains analyzed, and supporting a scenario of multiple independent 
introductions to Colombia. 
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FIGURE 3. 2. PHYLOGENETIC RELATION OF COLOMBIAN AND GLOBAL SUBTYPE HIV-1B DIVERSITY 
Figure 3.2:  Phylogenetic relation of Colombian and global subtype HIV-1B diversity. Seven 
clusters consisting of more of 10 Colombian sequences are shown in red. (a) Midpoint-rooted-maximum 
likelihood tree of the Colombian sequences, the most similar sequences retrieved by BLASTn, 
neighboring countries and other worldwide sequences (b) Bayesian maximum clade-credibility tree of 
the Colombian sequences and the most similar sequences retrieved by BLASTn. 
 3.4.3 TIMING OF HIV-1B INTRODUCTIONS IN COLOMBIA 
The Bayesian MCC tree in Figure 3.2B shows six well-supported clusters of HIV-% ZLWK 
Colombian sequences and posterior probability >0.90 [22], using the BLASTn-COL dataset (Table 3.1). 
Cluster IV of 32 Colombian sequences was found in the ML with 0.992 of statistical support (Figure 
3.2A) but with a posterior probability of 0.8 in the MCC tree (Figure 3.2B). All the HIV-1B Colombian 
clusters were mostly composed of Colombian sequences, except clusters III and V that included also 
some sequences from Greece and Spain, respectively. These clusters had an MRCA between 1980 
and 1985, confirming a scenario of multiple introductions prior to those dates as suggested by the ML 
analysis. 
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Clusters n TMRCA 95% HPD Cities, regions or countries involved 
I 12 1983,8 1979,9 1987,3 Bogotá (12) 
II 10 1980,6 1979,9 1986,6 
Amazonas (1), Bogotá (2), Cali (4), Coffee region (1), 
Medellin (2) 
III 17 1982,4 1978,5 1986,8 Bogotá (10), Cali (1), Coffee region (5), Greece (1) 
IV 32 1981,1 1977,0 1985,1 
Amazonas (1), Bogotá (9), Cali (7), Coffee region (11), 
Medellin (3), Santander region (1) 
V 10 1985,1 1981,6 1988,4 Bogotá (9), Spain (1) 
VI 13 1981,1 1977,1 1985,6 Bogotá (6), Cali (1), Coffee region (6) 
VII 22 1980,2 1976,3 1984,8 Bogotá (18), Medellin (2) and Santander region (2) 
 
Table 3.1: The mean of the TMRCA for each cluster and the 95 % HPD intervals. The numbers 
between parentheses are the number of sequences per city, region or country. Abbreviations: TMRCA: 
The most recent common ancestor, HPD: Highest posterior density. 
 
 3.4.4 PHYLOGEOGRAPHIC ANALYSIS OF HIV-1 SUBTYPE B IN COLOMBIA AT INTERNATIONAL LEVEL 
To investigate the geographic origins of HIV-1B in Colombia we used both a BSSVS approach that 
identifies non-zero viral migration rates along with their BF significance and a robust counting 
procedure that quantifies the number of viral migration events between particular sets of locations. In 
this case, we focus on estimating the number of migration events between locations linked by 
significant non-zero rates as estimated by the BSSVS procedure using the BLASTn-COL dataset.  
 
We found a strong BF support for HIV-1B migration between Spain and Bogotá [link “i” in Figure 3.3A, 
BF>1000; number of Markov jumps (MJ): 89.4; 95% Bayesian credible interval (BCI): 74, 105], as well 
as between Spain and Medellin [link “l” in Figure 3.3A, BF=447.6, MJ: 20; 95% BCI: 8-29] (Figure 3.1A, 
3.3A and Supplementary table 3.5). Another link between Bogotá and Spain was found [BF=40.9; 95% 
BCI: 0, 10], but the uncertainty interval did not exclude zero (link “r” in Figure 3.3A). Other significant 
viral pathways obtained using a BSSVS approach for which the uncertainty intervals of the estimated 
number of migrations did not overlap with zero are shown in supplementary Table 3.5. 
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FIGURE 3. 3. BAYESIAN PHYLOGEOGRAPHIC ANALYSES OF HIV-1 SUBTYPE B IN COLOMBIA 
Figure 3.3: Bayesian phylogeographic analyses of HIV-1 subtype B in Colombia. (a) The number 
(No) of migrations are shown according to the Bayes Factor and Markov jump analysis. The links with 
non zero rates are shown between Bogotá, Colombia and Cali (a), Bogotá, Colombia and Santander 
region, Colombia (b), Bogotá, Colombia and Medellín, Colombia (c), Bogotá, Colombia and Coffee 
region, Colombia (d), Spain and North America (e), Spain and West-East-Northern Europe (f), Spain 
and Southern Europe (g), Spain and Central-South America (h), Spain and Bogotá, Colombia (i), West-
East-Northern Europe and Others (j), Spain and Others (k), Spain and Medellín, Colombia (l), Spain 
and Cali, Colombia (m), Spain and Coffee region, Colombia (n), Bogotá, Colombia and Caribbean 
region, Colombia (o),   and Spain and Caribbean region, Colombia (p).  A link between Bogotá, 
Colombia and Spain  (r) was found with a Bayesian credible interval (BCI) overlapping with zero. See 
also Supplementary table 3.4. (b) Number (No) of migrations within Colombia and, between Colombia 
and other countries (outside) using k=8 locations.  
 
To confirm the migration links with Colombia, statistical phylogeographic analysis was performed. A 
significant exporting migration was found between Colombia and Spain, while no other links were found 
for other countries with history of migration like neighboring countries, which gives additional 
robustness to our results with the Bayesian phylogenetic analysis. In an attempt to evaluate the 
directionality of the migration, ML trees were performed by including the Colombian sequences, the 
Spanish sequences retrieved from BLASTn, other Spanish sequences from the global dataset and 3 
reference sequences of subtype A, or C or D as the out-group.  Similar analyses were performed with 
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the LANL-Borders dataset. In this analyses , the directionality of the migration changed with the 
outgroup or the dataset such that the direction of migration remained non-conclusive.  
 3.4.5 PHYLOGEOGRAPHIC ANALYSIS OF HIV-1 SUBTYPE B WITHIN COLOMBIA 
At the national level, since sampling bias towards more heavily sampled locations may interfere with 
spatial root estimation [54], we first used an alternative discretization scheme of the BLASTn-COL 
dataset (n=927). While the first scheme considered k=13 geographic locations (Figure 3.1B and 
Supplementary table 3.1), the second sampling scheme considered k=8 geographic traits and grouped 
all sequences from abroad Colombia into a single geographic trait, named “outside”. The results for the 
different discretization schemes were identical, with overlapping number of migrations along with 
respective uncertainty intervals for viral migration within Colombian locations. In Figure 3.3B, we show 
the estimated number of migrations (Markov jumps) for each well-supported migration pathway within 
Colombian locations. Here, we found statistical evidence for viral flow between Bogotá and several 
other localities. Notably, all Colombian locations were directly linked to the capital Bogotá with 
significant BF support (Supplementary table 3.5), suggesting that Bogotá has had a central role in HIV-
1B Colombian epidemic. Most viral migrations were most likely seeded from Bogotá to Cali [BF>1000, 
MJ: 44.5; 95% BCI: 33, 54], followed by Bogotá to Medellin [BF>1000, MJ: 37.6; 95% BCI: 25, 49]. In 
addition, we found around an average of 19 and 17.6 migrations from Bogotá to Santander and to the 
Coffee region, respectively.  
 3.4.6 EVALUATION OF THE POTENTIAL EFFECT OF SAMPLING BIAS 
To investigate whether the number of sequences per geographic location had any effect on the results, 
we used three additional data sets (n=461, k=13), in which the total number of Colombian sequences 
(n=157) was randomly down-sampled and proportional to the prevalence in each location. Notably, the 
BSSVS approach identifies 81.3% (13/16) of the non-zero migration rates as being not only identical 
between the three down-sampled data sets but also to the larger data BLASTn-COL dataset 
(Supplementary table 3.5), suggesting that our results are robust to sampling 
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3.5 DISCUSSION 
This large study is the first to describe the molecular epidemiology of the HIV-1 epidemic in Colombia at 
a nationwide scale, and to reveal its international connectedness. We report the predominance of 
subtype B in all the seven geographic regions analyzed, despite the migration flow during these years 
[24, 25]. Our approach takes advantage of the full data available for Colombia even though for some 
samples the location was unknown, our approach could estimate that the 102 sequences with unknown 
location sampled in Colombia were most probably from individuals residing mainly in Bogotá (71.6%). 
Our findings are consistent with previous studies developed in Bogotá, Barranquilla and Medellin [2, 4, 
5] and complemented the understanding of the molecular epidemiology in Colombia. These results may 
be explained by the fact that immigration was low in contrast with emigration until 2007 [25],  and the 
main countries of destination such as Andean region, Spain and United States also had a high 
prevalence of subtype B infections [4, 6], whereas countries with high prevalence of non B subtypes or 
BF recombinants such as Brazil and the Southern Cone [6] had limited migration to Colombia [25].  
 
The present study characterized the spatiotemporal spread of subtype B to Colombia.  Seven clusters 
with 17% of Colombian sequences and all other Colombian sequences spread over the tree suggest a 
scenario of multiple introductions that were observed around late 70s and early 80s. This implies that 
the Colombian HIV-1B spread occurred after the introduction of HIV in the United States and Central 
America in the middle 60s and early 70s [20, 22]. The TMRCA estimates agree with the first HIV-1 case 
reported in the Caribbean region in 1983 [53].  
 
Since our methodology was focused to shed light on the spread at the country level rather than to 
elucidate the origin of subtype B in the Americas, we used a BLASTn search to determine the countries 
involved in the Colombian epidemic. Most of the sequences were from Spain, and other European 
countries rather than neighboring countries with available data. Bayesian analyses showed a spatial 
root of Colombian subtype B in Spain, but it was not confirmed with ML and statistical phylogeography 
analyses. Since the main countries involved with migration and tourism to and from Colombia were 
United States and Venezuela [25, 55], and Spain had limited migration to or from Colombia between 
the 70s and 80s [56], our finding was unexpected. A study suggested a Caribbean introduction of 
subtype B to Colombia and Venezuela driven by the booming oil economy in the latter country [23], 
which also received immigrants from Spain at that time [56]. However, we cannot rule out alternative 
scenarios given the lack of demographic data of the sequences. Further research and data is required 
to establish the origins of the subtype B epidemic in Colombia. 
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Although the link between Colombia and Spain could be related with convenience sampling [54], we 
diminished this bias using three random datasets according to the HIV-1 prevalence in Colombia, 
sensitivity analyses and different phylogenetic techniques to evaluate our results in different datasets 
that represented the global diversity of subtype B. As consequence, we consider our data is robust 
enough to confirm the link between the Spanish and the Colombian epidemic, but the directionality 
remains unclear. The intermingling of Colombian and Spanish sequences suggests recent links 
between the countries. The emigration increased substantially in the 90s until Colombians became the 
second most important group of Latin American foreigners in Spain in the 2000s [25, 55] and they still 
remain as an important group of immigrants [57]. Similarly, immigration or tourism to Colombia is mainly 
from Venezuela, United States, Ecuador and Spain [25, 57]. It is important to note, however,  that  
72.7% (72/99) of the Spanish sequences included in the BLASTn-COL dataset were isolated from 
patients originated in Spain from the prospective pan-European SPREAD study [58],  whereas only one 
individual was originated in Colombia and 8 in other Latin American coutries (9.1%) [Vercauteren J. and 
Struck D., personal communication].  Further studies are necessary to unravel the relation between 
these countries.  
 
As expected, we showed Bogotá, Cali, and Medellin were the main cities involved in the viral spread in 
the country because these cities also had the higher number of people living with HIV in 2007 [53]. 
Although Bogotá was the main sink of the epidemic within an international context, it was also the main 
exporter of the epidemic within Colombia, whereas Cali and Medellin had a limited role as exporters. 
These findings differ from the high internal mobility due to violence or socio-economical reasons and 
internal displacement that happened in the years of this study [24, 25], suggesting that tourism from 
Bogotá to other Colombian cities could be an important driver of the epidemic [55]. Interestingly, six 
monophyletic clusters were identified with mainly sequences from Bogotá intermixed with some 
sequences from other cities or regions, that suggests potential transmission networks among those 
regions.  
 
It is important to bear in mind the possible limitations of this study. Colombian sequences retrieved from 
the Center that performs nationwide resistance testing lack epidemiological information that could 
further shed light on the HIV-1 epidemic [16]. It is however known that heterosexual transmission took 
the greatest share of infections in the country (57.8%) followed by men who have sex with men or 
bisexuals (38.4 %) among 33853 cases with known risk transmission until 2007 [53]. Our sample was 
also not fully representative of some Colombian regions but we diminished this bias by doing analyses 
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on three weighted datasets and obtained similar results. Other limitation was the use of pol sequences 
rather than full genome sequences, which limited the detection of recombinants.  
 
In conclusion, the HIV epidemic in Colombia is dominated by subtype B over time. Furthermore, we 
show that multiple introductions happened from the late-1970s onwards, and are still happening today, 
most likely from Spain. Viral populations in Bogotá, Medellin and Cali play a central role in shaping the 
HIV-1 epidemic within Colombia. This study provides a framework for future phylodynamic studies 
targeted at evaluating the dynamics of HIV-1 epidemic at a country-scale, which may provide 
information for prevention policies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 97 | 
 
 Chapter 3: Molecular Epidemiology and Phylodynamics in Colombia 
REFERENCES 
 
 
[1] UNAIDS-WHO. GLOBAL REPORT: UNAIDS report on the global AIDS epidemic. Geneva; 2013. 
[2] Sanchez GI, Bautista CT, Eyzaguirre L, Carrion G, Arias S, Sateren WB, et al. Molecular epidemiology of human 
immunodeficiency virus-infected individuals in Medellin, Colombia. The American journal of tropical medicine and hygiene. 
2006 Apr;74(4):674-7. 
[3] Eyzaguirre L, Bautista CT, Ayala C, Acosta J, Negrete M, Sateren WB, et al. First case of HIV Type 1 subtype F among men 
who have sex with men in Colombia. AIDS research and human retroviruses. 2006 Aug;22(8):808-11. 
[4] Montano SM, Sanchez JL, Laguna-Torres A, Cuchi P, Avila MM, Weissenbacher M, et al. Prevalences, genotypes, and risk 
factors for HIV transmission in South America. Journal of acquired immune deficiency syndromes (1999). 2005 Sep 1;40(1):57-
64. 
[5] Villarreal JL, Gutierrez J, Palacio L, Penuela M, Hernandez R, Lemay G, et al. Characterization of HIV type 1 envelope 
sequence among viral isolates circulating in the northern region of Colombia, South America. AIDS research and human 
retroviruses. 2012 Dec;28(12):1779-83. 
[6] Hemelaar J, Gouws E, Ghys PD, Osmanov S. Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS 
(London, England). 2011 Mar 13;25(5):679-89. 
[7] Hierholzer J, Montano S, Hoelscher M, Negrete M, Hierholzer M, Avila MM, et al. Molecular Epidemiology of HIV Type 1 in 
Ecuador, Peru, Bolivia, Uruguay, and Argentina. AIDS research and human retroviruses. 2002 Dec 10;18(18):1339-50. 
[8] Alencar CS, Sabino EC, Carvalho SM, Leao SC, Carneiro-Proietti AB, Capuani L, et al. HIV genotypes and primary drug 
resistance among HIV-seropositive blood donors in Brazil: role of infected blood donors as sentinel populations for molecular 
surveillance of HIV. J Acquir Immune Defic Syndr. 2013 Jul 1;63(3):387-92. 
[9] Pimentel VF, Morgado MG, Bello Bentancor GJ, Guimaraes MD, Castilho E, Veloso VG, et al. Temporal Trends and Molecular 
Epidemiology of HIV-1 Infection in Rio de Janeiro, Brazil. AIDS research and human retroviruses. 2013 Aug 30. 
[10] Bello G, Zanotto PM, Iamarino A, Graf T, Pinto AR, Couto-Fernandez JC, et al. Phylogeographic analysis of HIV-1 subtype C 
dissemination in Southern Brazil. PloS one. 2012;7(4):e35649. 
[11] de Oliveira T, Pillay, D, Gifford, R. J., for the UK Collaborative Group of HIV Drug Resistance. The HIV-1 Subtype C Epidemic 
in South America Is Linked to the United Kingdom. PloS one. 2010;5(2):e9311. 
[12] Fontella R, Soares, M. A., Schrago, C. G. On the origin of HIV-1 subtype C in South America. Aids. 2008;22:2001-11. 
[13] Castro E, Moreno M, Deibis L, de Perez G, Salmen S, Berrueta L. Trends of HIV-1 molecular epidemiology in Venezuela: 
introduction of subtype C and identification of a novel B/C mosaic genome. Journal of clinical virology : the official publication of 
the Pan American Society for Clinical Virology. 2005 Mar;32(3):257-8. 
[14] Ahumada-Ruiz S, Casado C, Toala-Gonzalez I, Flores-Figueroa D, Rodriguez-French A, Lopez-Galindez C. High divergence 
within the major HIV type 1 subtype B epidemic in Panama. AIDS research and human retroviruses. 2008 Nov;24(11):1461-6. 
[15] Faria NR, Suchard MA, Rambaut A, Lemey P. Toward a quantitative understanding of viral phylogeography. Current opinion in 
virology. 2011 Nov;1(5):423-9. 
[16] Holmes EC. Evolutionary history and phylogeography of human viruses. Annual review of microbiology. 2008;62:307-28. 
[17] Pybus OG, Rambaut A. Evolutionary analysis of the dynamics of viral infectious disease. Nature reviews Genetics. 2009 
Aug;10(8):540-50. 
[18] Korber B, Muldoon M, Theiler J, Gao F, Gupta R, Lapedes A, et al. Timing the ancestor of the HIV-1 pandemic strains. 
Science. 2000 Jun 9;288(5472):1789-96. 
[19] Salemi M, Strimmer K, Hall WW, Duffy M, Delaporte E, Mboup S, et al. Dating the common ancestor of SIVcpz and HIV-1 
group M and the origin of HIV-1 subtypes using a new method to uncover clock-like molecular evolution. Faseb J. 2001 
Feb;15(2):276-8. 
[20] Gilbert MT, Rambaut A, Wlasiuk G, Spira TJ, Pitchenik AE, Worobey M. The emergence of HIV/AIDS in the Americas and 
beyond. Proceedings of the National Academy of Sciences of the United States of America. 2007 Nov 20;104(47):18566-70. 
[21] Robbins KE, Lemey P, Pybus OG, Jaffe HW, Youngpairoj AS, Brown TM, et al. U.S. Human immunodeficiency virus type 1 
epidemic: date of origin, population history, and characterization of early strains. Journal of virology. 2003 Jun;77(11):6359-66. 
[22] Murillo W, Veras N, Prosperi M, de Rivera IL, Paz-Bailey G, Morales-Miranda S, et al. A Single Early Introduction of HIV-1 
Subtype B into Central America Accounts for Most Current Cases. Journal of virology. 2013 Jul;87(13):7463-70. 
[23] Junqueira DM, de Medeiros RM, Matte MC, Araujo LA, Chies JA, Ashton-Prolla P, et al. Reviewing the history of HIV-1: spread 
of subtype B in the Americas. PLoS One. 2011;6(11):e27489. 
[24] IDMC. Colombia: Rate of new displacement highest in two decades. Geneva, Switzerland: IDMC- Internal Displacement 
Monitoring Centre; 2008 17 October. 
[25] OIM. Perfil Migratorio de Colombia. Bogotá, Colombia; 2010. 
[26] Rhee SY, Kantor R, Katzenstein DA, Camacho R, Morris L, Sirivichayakul S, et al. HIV-1 pol mutation frequency by subtype 
and treatment experience: extension of the HIVseq program to seven non-B subtypes. AIDS (London, England). 2006 Mar 
21;20(5):643-51. 
[27] Pineda-Pena AC, Faria NR, Imbrechts S, Libin P, Abecasis AB, Deforche K, et al. Automated subtyping of HIV-1 genetic 
sequences for clinical and surveillance purposes: Performance evaluation of the new REGA version 3 and seven other tools. 
Infect Genet Evol. 2013 May 7. 
[28] Struck D, Perez-Bercoff D, Devaux C, Schmit JC. COMET: A Novel approach to HIV-1 subtype prediction.  8th European HIV 
Drug Resistance Workshop; 2010 17- 19 March; Sorrento, Italy; 2010. 
[29] Schmidt HA, Strimmer K, Vingron M, von Haeseler A. TREE-PUZZLE: maximum likelihood phylogenetic analysis using 
quartets and parallel computing. Bioinformatics (Oxford, England). 2002 Mar;18(3):502-4. 
 98 | 
 
 The Dynamics of Local HIV-1 Epidemics 
[30] Lole KS, Bollinger RC, Paranjape RS, Gadkari D, Kulkarni SS, Novak NG, et al. Full-length human immunodeficiency virus 
type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. Journal of 
virology. 1999 Jan;73(1):152-60. 
[31] Bruen TC, Philippe H, Bryant D. A simple and robust statistical test for detecting the presence of recombination. Genetics. 
2006 Apr;172(4):2665-81. 
[32] Huson DH, Bryant D. Application of phylogenetic networks in evolutionary studies. Molecular biology and evolution. 2006 
Feb;23(2):254-67. 
[33] Kosakovsky Pond SL, Posada D, Gravenor MB, Woelk CH, Frost SD. Automated phylogenetic detection of recombination 
using a genetic algorithm. Molecular biology and evolution. 2006 Oct;23(10):1891-901. 
[34] Edgar RC. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic acids research. 
2004;32(5):1792-7. 
[35] Gouy M, Guindon S, Gascuel O. SeaView version 4: A multiplatform graphical user interface for sequence alignment and 
phylogenetic tree building. Molecular biology and evolution. 2010 Feb;27(2):221-4. 
[36] Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, et al. Drug resistance mutations for surveillance of 
transmitted HIV-1 drug-resistance: 2009 update. PLoS One. 2009;4(3):e4724. 
[37] Price MN, Dehal PS, Arkin AP. FastTree 2--approximately maximum-likelihood trees for large alignments. PLoS One. 
2010;5(3):e9490. 
[38] Anisimova M, Gascuel O. Approximate likelihood-ratio test for branches: A fast, accurate, and powerful alternative. Systematic 
biology. 2006 Aug;55(4):539-52. 
[39] Drummond AJ, Suchard MA, Xie D, Rambaut A. Bayesian phylogenetics with BEAUti and the BEAST 1.7. Molecular biology 
and evolution. 2012 Aug;29(8):1969-73. 
[40] Yang Z. Maximum likelihood phylogenetic estimation from DNA sequences with variable rates over sites: approximate 
methods. Journal of molecular evolution. 1994 Sep;39(3):306-14. 
[41] Drummond AJ, Ho SY, Phillips MJ, Rambaut A. Relaxed phylogenetics and dating with confidence. PLoS biology. 2006 
May;4(5):e88. 
[42] Drummond AJ, Rambaut A, Shapiro B, Pybus OG. Bayesian coalescent inference of past population dynamics from molecular 
sequences. Molecular biology and evolution. 2005 May;22(5):1185-92. 
[43] Suchard MA, Rambaut A. Many-core algorithms for statistical phylogenetics. Bioinformatics (Oxford, England). 2009 Jun 
1;25(11):1370-6. 
[44] Ayres DL, Darling A, Zwickl DJ, Beerli P, Holder MT, Lewis PO, et al. BEAGLE: an application programming interface and high-
performance computing library for statistical phylogenetics. Systematic biology. 2012 Jan;61(1):170-3. 
[45] Lemey P, Rambaut A, Drummond AJ, Suchard MA. Bayesian phylogeography finds its roots. PLoS computational biology. 
2009 Sep;5(9):e1000520. 
[46] Edwards CJ, Suchard MA, Lemey P, Welch JJ, Barnes I, Fulton TL, et al. Ancient hybridization and an Irish origin for the 
modern polar bear matriline. Curr Biol. 2011 Aug 9;21(15):1251-8. 
[47] Bielejec F, Rambaut A, Suchard MA, Lemey P. SPREAD: spatial phylogenetic reconstruction of evolutionary dynamics. 
Bioinformatics (Oxford, England). 2011 Oct 15;27(20):2910-2. 
[48] Minin VN, Bloomquist EW, Suchard MA. Smooth skyride through a rough skyline: Bayesian coalescent-based inference of 
population dynamics. Molecular biology and evolution. 2008 Jul;25(7):1459-71. 
[49] Talbi C, Lemey P, Suchard MA, Abdelatif E, Elharrak M, Nourlil J, et al. Phylodynamics and human-mediated dispersal of a 
zoonotic virus. PLoS pathogens. 2010;6(10):e1001166. 
[50] O'Brien JD, Minin VN, Suchard MA. Learning to count: robust estimates for labeled distances between molecular sequences. 
Molecular biology and evolution. 2009 Apr;26(4):801-14. 
[51] Paraskevis D, Pybus O, Magiorkinis G, Hatzakis A, Wensing AM, van de Vijver DA, et al. Tracing the HIV-1 subtype B mobility 
in Europe: a phylogeographic approach. Retrovirology. 2009;6:49. 
[52] Stamatakis A. RAxML-VI-HPC: maximum likelihood-based phylogenetic analyses with thousands of taxa and mixed models. 
Bioinformatics (Oxford, England). 2006 Nov 1;22(21):2688-90. 
[53] Ministerio de la Protección Social. Informe Nacional sobre los progresos realizados en la aplicación del UNGASS. Bogotá, 
Colombia; 2008. 
[54] Faria NR, Hodges-Mameletzis I, Silva JC, Rodes B, Erasmus S, Paolucci S, et al. The phylogeographic footprint of colonial 
history in the global dispersal of HIV-2 group A. The Journal of general virology. 2012 Jan 4. 
[55] Departamento Administrativo Nacional de Estadistica (DANE). Analisis de los Resultados de la Encuesta Turismo a Hogares. 
Bogota, Colombia: Departamento Administrativo Nacional de Estadistica (DANE) and Ministerio de Comercio Industria y 
Turismo,; 2003. 
[56] Instituto Nacional de Estadística (INe). Anuario Estadístico de España de 1971 a 1980 y de 1981 a 1990. In: Instituto Nacional 
de Estadística (INe), ed. Totales Nacionales: Demografía-Turismo: available at www.ine.es 1970-1990. 
[57] OIM. Perfil Migratorio de Colombia. Bogotá, Colombia; 2012. 
[58] Vercauteren J, Wensing AM, van de Vijver DA, Albert J, Balotta C, Hamouda O, et al. Transmission of drug-resistant HIV-1 is 
stabilizing in Europe. The Journal of infectious diseases. 2009 Nov 15;200(10):1503-8. 
 
  
 99 | 
 
 Chapter 3: Molecular Epidemiology and Phylodynamics in Colombia 
 
C H A P T E R  4  
H I V - 1  T R A N S M I T T E D  D R U G  
R E S I S T A N C E  I N  L A T I N  A M E R I C A  A N D  
C A R I B B E A N :  W H A T  D O  W E  K N O W ?   
 
 
 
 
 
 
 
 
 
 
 
 
Published in: 
Andrea-Clemencia Pineda-Peña, Diana-Carolina Bello, Otto Sussmann, Anne-Mieke Vandamme, 
Jurgen Vercauteren, Kristel Van Laethem,  Arley Gómez-López. HIV-1 Transmitted Drug Resistance in 
Latin America and Caribbean: What do we know? AIDS Reviews. 2012; 14 (4): 256–67
 
 100 | 
 
 The Dynamics of Local HIV-1 Epidemics 
CONTENTS 
4.1 SUMMARY ...................................................................................................................... 101 
4.2 INTRODUCTION ............................................................................................................. 101 
4.3 MATERIAL AND METHODS ........................................................................................... 104 
4.4 RESULTS ........................................................................................................................ 107 
4.5 DISCUSSION .................................................................................................................. 114 
4.6 CONCLUSIONS AND RECOMMENDATIONS ................................................................ 115 
 
Figure 4. 1. HIV and TDR prevalence in Latin America and Caribbean ............................................... 103 
Figure 4. 2. Scaling-up of ART ............................................................................................................ 104 
Figure 4. 3. Selection of studies .......................................................................................................... 106 
Figure 4. 4. Prevalence of TDR and mutations in LAC ........................................................................ 110 
  
 101 | 
 
 Chapter 4: TDR in Colombia, Latin America and Caribbean Countries 
4.1 SUMMARY 
Background: Latin America and the Caribbean countries have increased the scaling-up of antiretroviral 
treatment in the last years. The increase of transmitted drug resistance has been feared due to the 
worrisome indicators associated with the emergence of drug resistance and monitored by the WHO. 
Consequently, our aim was to review all relevant studies on transmitted drug resistance in Latin 
America and the Caribbean countries, to analyze its levels, to identify the frequency of transmitted drug 
resistance mutations, and to put these results in the context of the local Latin American and Caribbean 
countries settings.  
Methodology: A systematic search of Spanish, Portuguese, and English literature was performed in 
databases and international conferences for the period June 1999 to May 2011. In addition, sequences 
were downloaded from the Los Alamos and Stanford databases and the transmitted drug resistance 
was reanalyzed according to the WHO Surveillance Drug Resistance Mutation list 2009. 
Results and Conclusions: In total, 50 articles, 27 abstracts, and 1,922 patients were included. The 
resistance varied geographically, but most of the countries have reached the WHO threshold of 5% of 
resistance. According to the sequences available in public databases, the overall prevalence in Latin 
America and the Caribbean countries for the period 1996-2009 was 7.7% and by region it was 4.3% for 
the Caribbean, 3.9% for Mexico, 9.4% for Brazil, 10.5% for the Andean region and 4.9% for the 
Southern Cone. For the last four investigated years (2006-2009), the information was restricted to 
Brazilian and Venezuelan studies and revealed an overall transmitted drug resistance of 10%. 
Throughout the study period, limited information was available for the Caribbean and Central American 
countries. These findings support the need for developing comprehensive surveys of transmitted drug 
resistance in these regions. 
 
4.2 INTRODUCTION 
The horizontal transmission of HIV-1 strain that already displayed the RT mutation T215F/Y mutation 
was first described in a homosexual man in 1993 [1]. As it was feared that TDR could negatively impact 
the success of first-line ART, TDR was extensively studied in resource-rich countries. Retrospective 
studies provided evidence that infection with drug-resistant HIV-1 could also occur in other risk groups 
and indicated increasing TDR levels and more extensive mutational patterns. As these studies were 
often small and based upon convenience sampling, prospective and representative population-based 
studies were set up in Europe, USA and Canada to monitor the extent and dynamics of TDR [2-5]. The 
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high rates of TDR (overall prevalence 8-9%) resulted into the recommendation of standard genotypic 
drug resistance testing to guide ART selection in therapy-naïve patients [6, 7]. Recently, a large 
European multi-cohort study confirmed the importance of baseline drug resistance testing as patients 
with TDR and resistance to at least one prescribed drug were three times as likely to virologically fail 
within one year [8]. 
 
As access to ART has been implemented and scaled-up in Latin-America and Caribbean (LAC) since 
more than a decade, concerns towards the emergence and spread of TDR strains in LAC exist. In 
general, the prevalence of TDR depends mainly on the time since ART implementation, the scale of 
ART coverage and the overall virological success of the prescribed regimens. As the majority of HIV-1 
patients in LAC started immediately on HAART, the rise in TDR was anticipated to be less extensive 
compared to resource-rich countries where sequential mono- and bitherapies were initially prescribed. 
Nevertheless, other factors unique to the particular setting of LAC could negatively influence TDR rates. 
For instance, the wide-spread use of standard first-line regimens based on low genetic barrier NNRTI in 
the absence of drug resistance testing, together with limited access to second-line therapies, could 
promote emergence of drug resistance and its subsequent spread to new HIV-1 infections.LAC is a 
heterogeneous region that differs extensively in geographical, social and economic characteristics that 
influence the HIV epidemiology and clinical care facilities. The HIV-1 burden varies considerably 
between and within the 27 countries belonging to LAC (Figure 4.1). In 2009, 1.7 million people were 
living with HIV-1 in LAC, of which one third lived in Brazil, and HIV-1 prevalence values ranged between 
0.1% in Cuba and 3.1% in Bahamas [9]. Brazil and Argentina took a leading role in the area by 
providing ART since 1991-1992 and by setting up a national program to provide free access to HAART, 
clinical care and laboratory monitoring (Figure 4.2) [10, 11]. Currently, Cuba, Chile, and Nicaragua 
achieve global access, and Argentina, Brazil, Dominican Republic, Mexico and Uruguay are near to 
universal-coverage levels. However, in other LAC countries ART scale-up has been rather slow and 
only reached ART coverage between 20% in Bolivia and 66% in Paraguay with still limited access to 
laboratory testing and second-line regimens [12]. 
The scope of this review was to collect all relevant studies on TDR in LAC, to analyze TDR levels, to 
identify the frequency of TDR mutations and to put these results in the context of the local LAC settings. 
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FIGURE 4. 1. HIV AND TDR PREVALENCE IN LATIN AMERICA AND CARIBBEAN 
 
Figure 4.1:  HIV and TDR prevalence in Latin America and Caribbean. This region is divided 
geographically in Caribbean (7 countries), Mexico, Central America (7 countries) and South America 
(12 countries). The latter region is subdivided based upon geographical, social and economic 
characteristics: Andean region and Southern Cone. The HIV prevalence according to the UNAIDS 
report is shown in a grayscale [9]. Although, the overall HIV prevalence in Venezuela (hatched) was 
0.75% in 2004, the country was not visualized in a grayscale as the prevalence in 2007 varied between 
1.62 % in metropolitan areas and 0.08% in more rural areas [13].  TDR prevalence values from studies 
that followed the eligibility criteria of WHO surveys are represented in black figures, otherwise they are 
represented in white.  Adapted from UNAIDS report, 2010.  
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FIGURE 4. 2. SCALING-UP OF ART 
Figure 4.2: Scaling-up of ART. The scaling-up of ART in 2003 and after the “3 by 5” strategy launched 
by WHO and UNAIDS. “3 by 5” stands for treatment for three million HIV/AIDS patients in low-middle 
income countries by 2005  (see details in the UNAIDS report  "3 by 5" and beyond) [14]. The regions 
are shown in a grayscale. Progress in access to treatment is shown as a shift to the right for a country, 
comparing 2003 (upper panel) with 2005 (lower panel). Countries are scaled as percentage (%) of 
those diagnosed and eligible for treatment that actually received treatment. The scale is shown in the 
middle panel. Data were not available for Barbados, Chile, Colombia, Costa Rica, Cuba, Ecuador, El 
Salvador and Haiti in 2003. Adapted from UNAIDS[14]. Abbreviations: Trinidad T: Trinidad and Tobago, 
Dominican R: Dominican Republic. 
4.3 MATERIALS AND METHODS 
4.3.1 SYSTEMATIC SEARCHING 
A systematic strategy (Figure 4.3) was used to search for Spanish, Portuguese and English literature 
published in the period between June 1999 and May 2011 and available within the following databases: 
MEDLINE via PubMed, SciELO, BIREME, IBECS, Cochrane, and LILACS. Additionally, abstracts from 
Conference on Retroviruses and Opportunistic Infections (CROI), International AIDS Conference, IAS 
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Conference on HIV Pathogenesis and Treatment, Meetings of the Infectious Diseases Society of 
America, European  AIDS Clinical  Society,  International  Congress  on  Drug  Therapy  in HIV 
Infection,  and the International Drug Resistance Workshop were identified. The combinations of the 
following MeSH (Medline descriptor) or DeCS (Lilacs descriptor) terms were used: "HIV"  or "HIV-1" 
and “Drug Resistance" or "Anti-HIV Agents" or “Anti-Retroviral Agents” and "Latin America", 
"Caribbean", "Central America", "South America", or each individual LAC country (Figure 4.1). For the 
respective international conferences "HIV" and “Resistance" and the name of the LAC country were 
used as search items. The data were independently extracted and reviewed by two researchers 
(Pineda AC, Bello DC). Only studies in which naïve patients were clearly defined as having no 
exposure to any ARV were included. Duplicates or preliminary versions of studies with similar data 
were excluded. Resistance surveys in pregnant women and in children and studies investigating MTCT 
were also excluded due to the high probability of including treated patients. Studies based upon point 
mutation assays (e.g. Line Probe Assay LiPA) were not included as the data collection was restricted to 
specific mutations and sensitivity and specificity characteristics of these assays substantially differ from 
sequencing technology. 
 
The following data were extracted from the articles: region, sample size, data collection period, type of 
infection, mode of transmission, gender, age, CDC classification, CD4 count, subtype, TDR, technique 
and algorithm to determine drug resistance.  
 4.3.2 ANALYSIS OF RESISTANCE 
TDR was reanalyzed according to the SDRM list 2009 [15]. The sequences from the publications that 
were found through the systematic search were downloaded from Los Alamos database 
(www.hiv.lanl.gov accessed in July 2011) and Stanford database (http://hivdb.stanford.edu/index.html 
accessed in August 2011) [13]. The RegaDB sequence alignment tool (available 
http://jose.med.kuleuven.be/) was used to determine amino acid mutations.  If sequences were not 
available, TDR was recalculated based upon the mutations reported in the original figures and tables 
and excluding mutations that were not part of the SDRM list 2009. 
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FIGURE 4. 3. SELECTION OF STUDIES 
Figure 4.3: Selection of studies. Abbreviations: TDR: transmitted drug resistance, MTCT: Mother-to-
child transmission, LiPA: Line Probe Assay. 
 
Both databases were also searched for additional HIV-1 sequences from Latin America and Caribbean. 
The inclusion criteria were therapy naïve patient (according to database and article referenced) and 
availability of RT and PR sequences for each patient. The exclusion criteria were duplicated 
sequences, clones, unknown treatment history, evidence of hypermutation and short sequences 
(minimum requirements: RT positions 41 to 219 positions and PR positions 30 to 90). Dubious data 
were not extracted. The viral subtypes were evaluated by REGA HIV-1 subtyping tool [16]. 
 
The analysis of the data was done with the statistical software R version 2.13.1.  Prevalence values 
were calculated with a 95% Wilson score confidence interval on the basis of a binomial distribution. 
Categorical data were compared with the chi-square test. Logistic regression analysis was used to 
examine TDR time trends in LAC, Brazil and Argentina, likewise the trends of NRTI, NNRTI and PI 
resistance and of 41L and 103N mutations.     
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4.4 RESULTS 
4.4.1 TDR SURVEILLANCE AND EARLY WARNING INDICATORS (EWIs) 
Recently, the fear for TDR in developing countries reappeared due to the worrying reports of EWIs in 
Africa, Caribbean and Central America [17-20]. EWIs were developed by WHO as indicators for the 
prevention of drug resistance. They include ART prescribing practices, lost-to-follow-up, retention of 
first-line therapies, viral suppression and percentage of discontinued drug supplies [17, 20].  These 
indicators alert earlier about the potential of increasing TDR rates than prospective surveys. 
 
Few studies have evaluated EWIs in LAC. Most of the studies were restricted to Brazil or to the seven 
AIDS programs from the CCASAnet Cohort [21, 22]. Lost-to-follow-up was 6% overall, but large 
differences were observed between the different AIDS health care institutions (between 0.6% in 
Honduras to 17% in Argentina) [21]. In El Salvador, Guatemala, Honduras and Nicaragua only 7 of 13 
sites accomplished tKHJRDORIORVW-to-follow-up and 38 of 55 sites in the Caribbean [17, 18]. Low 
numbers of retention in first-line therapy were also observed in LAC, ranging from 16% in Honduras to 
36% in Peru. Adverse events were the main cause in 14% of the cases, predominantly linked to 
zidovudine (hematological toxicity in 7%) and nevirapine (skin rash in 3%) [21, 22]. 
 
To standardize TDR surveillance studies, the WHO has developed minimum recommendations for 
developing countries to enable comparison. Briefly, the criteria are a minimum of 47 samples from small 
geographic areas within countries where ART has been available for more than 3 years to at least 20% 
of the eligible HIV-1 population, HIV-1 infection should have been confirmed by laboratory criteria, 
participants should not have received any antiviral drug, and if female they should have been younger 
than 25 years at their first pregnancy. The inclusion of individuals with less than 3 years of HIV-1 
infection or/and laboratory evidence of seroconversion or recent infection are required. If the 
information is accessible, demographical data like transmission risk group, clinical data like non-AIDS 
stage, or laboratory data like CD4 > 500  cells/ml, no previous positive HIV-1 test are desirable [23, 24]. 
In addition, the analysis of resistance should be done with the SDRM list, which is updated periodically 
and excludes highly polymorphic positions [15]. Nevertheless, some SDRM do occur naturally in 
therapy-naive individuals, which might inflate the estimates of TDR. The working group decided to 
retain these mutations within the list as stricter inclusion criteria would results into the omission of 
important drug resistance mutations and these particular mutations might have been the result of 
unreported therapy-exposure or truly TDR within the therapy-naive dataset [15]. 
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4.4.2 EPIDEMIOLOGY OF TDR IN LATIN AMERICA AND CARIBBEAN 
Due to the low achievement of EWIs in several LAC countries, available publications on TDR were 
reviewed using a systematic search strategy (Figure 4.3). Fifty articles and 27 abstracts were retained 
(Supplementary Tables 4.1, 4.2 and 4.3). Approximately half of the studies originated from Brazil 
(53.2%, 41/77). Ten studies were from Mexico (13%, 10/77), three from Caribbean (3.9%, 3/77), four 
from Central America (5.2%, 4/77), twelve from the Southern Cone (15.6%, 12/77) and seven (9.1%, 
7/77) from the Andean region.  
 
Heterosexual contacts and MSM were the most frequent transmission risk factors. Six studies were 
performed in specific patient populations, such as blood donors [25-27], female sex workers [28], 
intravenous drug users [29] and a combination of the latter two [30]. 
 
Eleven studies used the Serological Testing Algorithm for Recent HIV Seroconversion (STARHS) [31] 
strategy to differentiate between recent or chronic infection [27, 32-39]. In five other studies the 
distinction between recent and chronic infection was based upon previous negative serology test results 
9-18 months before diagnosis date [40-44].  
 
Although plasma was widely used as source material, Peripheral Blood Mononuclear Cells (PBMC) and 
Dried Blood Samples (DBS) were also used in 9 and 2 studies, respectively. In most of the studies in-
house methodologies were used to generate sequences, followed by Trugene® (seven) and ViroSeq® 
(six) (Supplementary Table 4.1). The genotypic resistance interpretation algorithm HIVdb was widely 
used for TDR analysis.  Twenty-one studies used the International AIDS Society list and 19 studies the 
SDRM list.  The version of the respective algorithms and lists were often not mentioned in the original 
publication. 
 
The TDR levels as reported within the original publications are displayed within supplementary tables 
4.2 and 4.3. In summary, the prevalence of TDR ranged from 0 to 7.4% in the Caribbean for 1996-
2003, from 2.8 to 18% in Mexico for 2001-2010, from 0 to 11.6% in Central America for 2002-2007, 
from 0 to 41% in Brazil for 1994-2010, from 3 to 11% in the Andean Region for 1998-2007 and from 2.5 
to 18.8% in the Southern Cone for 1997-2009.  
 
Due to the heterogeneity of mutation lists used within the original studies, TDR was reanalyzed using 
SDRM list 2009  and resulted into TDR prevalence values between 0 and 8.3% (Caribbean), 2.8 and 
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6.8% (Mexico), 0 and 7.5% (Central America), 1.3 and 20.3% (Brazil), 0 and 13% (Andean region), and 
from 1.6 to 12% (Southern Cone). For comparison, values reported in 14 studies that followed the WHO 
surveillance criteria for TDR monitoring were also displayed in supplementary tables 4.1 and 4.2 [25, 
27, 32, 34-36, 38, 39, 41, 42, 44-49]. 
 
For ten studies, the presence of TDR in each sample could be directly linked to the respective 
transmission risk factor [28, 34-36, 40, 44, 47, 50-52] and combining this data did not reveal any 
difference in TDR rate between heterosexuals (37/522, 7.1%) and MSM (39/757, 5.2%). One study that 
solely sampled in blood donors from São Paulo (Brazil) showed a TDR of 5.6% in 1998-2002 (19/341) 
[25], whereas another study sampling in a broader geographical area revealed only a TDR of 1.3% in 
2000-2004 (1/74)[27]. The majority of patients included in studies where differentiation between recent 
and chronic infection was made, were chronically infected and therefore differences in TDR between 
both groups could not be investigated. However, two studies did report a difference [25, 47]. For three 
studies that included at least 50 recent infections, TDR values were 4% (3/74) in Chile [41], 7.7% (4/52) 
in Argentina [44], and 8.1% (17/210) in Brazil [42]. 
 
To obtain a better understanding of the reported TDR rates, public databases were searched and 1922 
relevant HIV-1 sequences were retained for analysis (Figure 4.4A). Based upon automated subtyping 
[16], HIV-1 subtype B was the most frequent subtype (65.7%, 1262/1922), followed by subtype C 
(14.4%, 276/1922), BF recombinants (8.7%, 168/1922) and subtype F1 (4%, 77/1922) The latter two 
mainly originated from Brazil and Argentina (BF: 99.4%, 167/168; F1: 98.7%, 76/77). The remaining 
genetic variants were CRFs such as CRF31_BC and CRF29_BF in Brazil, CRF_18cpx and CRF19_cpx 
in Cuba and BD, BC and CF1 recombinants in Brazil and the Southern Cone. 
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FIGURE 4. 4. PREVALENCE OF TDR AND MUTATIONS IN LAC 
Figure 4.4: Prevalence of TDR and mutations in LAC. A) TDR prevalence in LAC. The number of 
sequences with evidence of TDR (numerator) and the total number of sequences included 
(denominator) from Los Alamos and Stanford database divided according to country and sampling 
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period B) and TDR prevalence (%). B) The prevalence of TDR according to sampling period (black line) 
and the 95% Confidence Intervals (gray dashes) C) The number of sequences with SDRM mutations 
against Nucleoside Reverse Transcriptase Inhibitors (NRTI),  D) against  Non-Nucleoside Reverse 
Transcriptase Inhibitors (NNRTI) and  E) against Protease Inhibitors (PI). Abbreviations: BR: Brazil, AR: 
Argentina, VE: Venezuela, CH: Chile, TT: Trinidad and Tobago, MX: Mexico, CO: Colombia, CU: Cuba, 
BB: Barbados, DO: Dominican Republic, HT: Haiti, Other: Include other Caribbean islands.  
 
In LAC overall TDR prevalence was 7.7% (148/1922, 95% CI: 6.54-8.98) for the period from 1996 to 
2009. The TDR by region was 4.3% in Caribbean for  1996-2005 (8/186, 95% CI: 1.87-8.29), 3.9% in 
Mexico for 2002-2005 (2/51, 95% CI: 1.87-8.29), 9.4% in Brazil for 1998-2009 (99/1056, 95% CI: 7.68-
11.3), 10.5% in the Andean Region for 1999-2007 (15/142, 95% CI: 6.03-16.82) and 4.9% in the 
Southern Cone for 1997-2005 (24/487, 95%CI: 3.2-7.24). NRTI resistance was 4.4% (84/1922, 95% CI: 
3.54-5.38), NNRTI resistance was 2.3% (44/1922, 95% CI: 1.71-3.06] and PI resistance was 2.08% 
(40/1922, 95% CI: 1.53-2.82]. 5.4% (8/148) and 6.8% (10/148) of the TDR cases had dual class 
resistance towards NRTI+NNRTI and NRTI+PI, respectively. Triple class resistance was only detected 
in 0.7% (1/148) of the TDR cases.  The overall TDR time trend was not significant, although two TDR 
peaks above 9% were observed for the periods 1998-1999 and 2006-2007 (Figure 4.4B). The separate 
time trend analysis for the countries that contributed the majority of samples (Argentina and Brazil) 
were also not significant, neither the trends for the individual drug classes (NRTI, NNRTI and PI). 
 
The 103N mutation was the most frequently observed mutation (29/148, 19.6%) followed by 215Y/F/rev 
(27/148, 18.2%) and 41L (26/148, 17.6%) (Figure 4.4C- 4E). Time trends analysis for the individual 
mutations 41L and 103N did not reveal any significant changes. The frequency of the most prevalent 
TDR mutations such as 41L, 184V, 103N, 46I/L, 82A/T and 90M was compared with frequencies in the 
following studies in US, Canada and Europe [2, 3, 5], but no significant differences were observed. 
 
For 447 sequences information was available on whether it concerned a recent or a chronic infection. 
However, the TDR rate did not differ significantly between recent (4/52, 7.7%) and chronic (41/395, 
10.4%) infections. The prevalence of TDR did differ between sequences obtained from PBMC or 
plasma (1712 sequences included). TDR was significantly higher in PBMC than plasma (33/285, 
11.6%, versus 98/1427, 6.8%). However, the exclusion of PBMC samples did not impact significantly 
the overall TDR (7%, 95% CI: 5.83-8.37).  Other factors were not evaluated because of lack of 
information.  
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CARIBBEAN AND CENTRAL AMERICA 
According to the UNAIDS-WHO report, only a minimum ART coverage was installed in the Caribbean 
Region in 2001 [14]. However, coverage increased with extra funding to e.g. 20% in Haiti and 
Dominican Republic in 2005 (Figure 4.2) [14]. As a result, TDR ranged from 0% in several islands in 
2000 to 3.6% in Cuba in 2003 [53-56]. In Cuba, there was already limited access to mono- and 
bitherapy before 2000 which could explain the level of TDR observed in 2003 and its frequency  of the 
NRTI drug class [54]. The overall TDR was estimated to be 4.3% and this was based upon the 
reanalysis using the WHO TDR surveillance list of the collected sequences that were available in public 
databases and that were sampled in the time period 2000-2005 [15]. 
 
From Central America only fragmented data was available for two countries of this region. Indeed, only 
4 publications and no sequences were retained after our search in public databases. A Panamanian 
study showed no TDR mutations in 2005, but NRTI and NNRTI TDR increased in a later report [57, 58]. 
However, in the latter study the exact sampling years were unspecified. Reports that studied the TDR 
rate in Honduras showed a prevalence of 9.2% in 2002-2003 and a prevalence of 7% in 2004-2007 [47, 
59]. In Honduras and Panama, TDR was mainly restricted to NRTI and NNRTI drug classes, explained 
by the first-line therapy options in these countries [47, 58].  
MEXICO 
Reanalysis of Mexican sequences revealed TDR prevalence of 3.9% in the period 2002-2005. This 
result is substantially lower than the 16% reported by Escoto et al [60], which might be partly explained 
by the algorithm used to interpret drug resistance as it also included polymorphisms. However, the TDR 
prevalence of 16% also differed from values obtained in other studies [30, 61], suggesting that the 
heterogeneity in ART availability between the different regions in Mexico might also impact TDR rates 
although further research is warranted [61]. A recent comprehensive WHO-survey determined that 
Mexico has reached 6.8% of TDR for the period 2005-2010 [48]. This overall TDR remained stable at 
the national level. However, increasing trends for NNRTI and PI TDR were observed. The frequency of 
mutations was 4.2% for NRTI (mainly type TAM I pathway), 1.9% for NNRTI (mostly 103N) and 1.8% 
for PI (90M) [48].  
ANDEAN REGION 
In the Andean Region the TDR prevalence was 10.5% according to sequences sampled in the years 
1999, 2001, 2003 and 2007. However, these sequences were mainly collected in Venezuela [49, 62, 
63]. A WHO-survey performed in Venezuela reported at least 7% TDR according to the ANRS 
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algorithm and this value raised to 12.9% when the SDRM list was used for interpretation [49]. In this 
study, drug resistance to all three drug classes was observed. The high TDR rates may be a 
consequence of the early introduction of ART as part of an AIDS National Program that was initiated in 
2000 and was mainly focused in the capital where the surveys were performed. Additionally, one report 
mentioned that patients receiving ART and displaying poor adherence or engagement with the health 
care system were an important source of HIV-1 transmission and TDR in Venezuela [64].  
 
In that era, free access to ART was also guaranteed in other countries belonging to that region (Figure 
4.2). However, scaling-up moved slowly and e.g. in Colombia and Peru scale-up reached only 
respectively 34% and 57%  in 2010 according to UNAIDS [12]. One Colombian survey showed a TDR 
of 5.8% according to HIVdb algorithm. The sequences from this study were not available for reanalysis 
with SDRM 2009, but other Colombian sequences that could be accessed did not reveal significant 
differences in TDR [65]. Two studies in Peru and Ecuador revealed low TDR rates of 3.3% and 4.3% in 
2002-2003 [35, 66]. However, it is worrying that all drug classes were affected in these countries. It is 
unknown whether polymorphisms might have affected these values as data was unavailable for 
reassessment with SDRM 2009. 
BRAZIL  
The overall TDR rate in Brazil was investigated by reanalyzing 1056 sequences that covered the period 
of 1998-2009 and this resulted into a value of 9.4%. Before 1998, only few small-sized studies were 
performed [29, 67]. Barreto et al [25] reported a TDR prevalence of 5.6% in 1998-2002 in a group of 
341 blood donors, using a WHO-survey approach. Noteworthy, this study was able to include 16% 
recent infections and they displayed a TDR rate of 12%, indicating high transmission rates of drug 
resistant strains in São Paulo City at that particular time point [25]. 
 
Several studies performed between 2000 and 2004, one WHO-survey [27] and one large nationwide 
study that sampled in 2001[68], showed that the TDR was below 5% [38, 52, 69-72].  This apparently 
decrease of TDR could be related to the predominant inclusion of chronically infected individuals.  
However, other reports showed that TDR was still above 5% [73-75]. These discordances are 
presumably due to the heterogeneity of the included studies and the geographical variation of TDR. 
 
Since 2005, the TDR rates remained above 5%, with 7% in Curitiba and 8% in Porto Alegre and  Santa 
Catarina [33, 39, 68, 73]. Nationwide studies reported 5.2% TDR in 2007 [76], 8.1% in 2008 [42], and 
12.3% in 2008-2010 [46]. The apparent nationwide increase of TDR in Brazil could not be confirmed in 
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our analysis. This might be explained by the large variations in TDR between and within Brazilian 
regions that were included in our dataset.  
Since 2007, TDR per drug class remained stable with overall values ranging between 5-15%, NNRTI 
between 3-6%, NRTI between 2-6% and PI between 1-3% [32, 42, 50, 51, 76]. The last WHO-survey 
showed resistance against NRTI in 7.6%, followed by 4% against NNRTI and PI [46]. 
SOUTHERN CONE 
As 84% of the Southern Cone sequences originated from Argentina, general conclusions cannot be 
made for this region. Nevertheless, their reanalysis using SDRM 2009 resulted into a TDR prevalence 
of 4.9% for the years in between 1996 and 2005. In Argentina, the number of studies and their 
respective sample size remained limited before the period 2000-2003 [28, 77]. However, since 2003 
several nationwide surveillance studies have been developed that reported TDR rates that ranged from 
3.9% in 2003-2005 to 8.4% in 2006-2008 [34, 36, 44, 78]. The last reported WHO-survey showed a 
substantial level of resistance towards NNRTI (5.6%), NRTI (4.2%) and PI (3%) [36]. Another study that 
was performed in recently infected individuals between 2004 and 2009 also supported the 8% of TDR 
with predominance of  NNRTI resistance [79].  Almost all Argentinean studies documented TDR against 
the three common drug classes. In Chile, TDR was less extensive with an overall TDR of 6.2% in 2000-
2005 that slightly decreased to 4% in 2006-2008 [41, 80]. In this country, TDR mutations were mainly 
restricted to NRTI and NNRTI.  
 
4.5 DISCUSSION 
Our results showed a TDR of 7.7% in 1922 therapy-naive HIV-1 patients. However, the majority of 
sequences were obtained from Brazil, Argentina, Mexico and Chile, countries that correspond to half of 
the people living with HIV-1 in LAC.  This percentage is higher than for other developing countries [81-
83] but similar to the 6.4% reported by the WATCH study that included seven studies since 2000-2006 
[25, 44, 62, 67, 69, 77, 81, 84], and similar to TDR rates in Europe, Canada and USA [2-5]. Although no 
significant trend in TDR was observed in our analysis, two peaks were observed in 1998-1999 and in 
2006-2007. These peaks overlapped with a high inclusion of sequences from Brazil and Venezuela, 
countries characterized with the highest TDR rates in LAC. 
 
Although we tried to standardize the analysis by implementing the SDRM 2009 list for interpretation of 
drug resistance, we acknowledge the limitations of this study. The included studies differed e.g. in the 
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intrinsic characteristics of the analyzed population (age, risk factor of transmission, geographical and 
socioeconomic factors), design of the study (method of sampling, type of study, criteria or exclusion 
criteria), clinical characteristics (recent or chronic infection, immunological status, viral load), drug 
resistance testing (sample type, sequencing method, sequence quality, algorithm used for the analysis 
of mutations),  ART-related factors in the treated population (mono- or bitherapy history, HAART scale-
up,  delay of start therapy, availability of new compounds, pharmacogenetics, toxicity, adherence 
problems, drug failure) and viral factors (subtype, fitness) [85-87]. For example, in one Brazilian study 
20% TDR was reported in PBMC samples [37]. However,  PBMC testing is more apt to detecting drug 
resistance mutations than plasma, and the intrinsic regional characteristics of the population might 
impede the generalization of the obtained results [37, 88]. 
 
Although MSM is one of the main drivers of the LAC epidemic and they are 33.3 times more likely to be 
HIV-1 positive [89], we did not find differences in the TDR rates between heterosexuals and MSM. More 
studies are necessary to understand the trends of TDR, especially in MSM because the risk of 
imprisonment in some countries of the Caribbean and the stigma in LAC could hinder the accurate 
evaluation of this population, especially when TDR prevalence has been reported to range between 
3.3% in Peru for 2002  to 17% in Brazil for 2010 [35, 89, 90].  
 
In regard to distribution of mutations, since NNRTI have been used widely in LAC as the first line 
therapy consequently, the amino acid change in position 103 was the most frequent in the sequences 
analyzed and in the studies included (see figure 4.4C). The amino acid change 215 and 41 were 
frequently found in our study. However, 184V was more frequently detected in our study than in 
European or North-American reports, even though the difference was not statistically significant [2-5]. In 
general, similar patterns have been found in other developing countries but, in the resource-rich 
settings NNRTI resistance seems to be stabilizing, probably due to the changes in therapy prescriptions 
[4, 82]. Overall, we did not find trends in particular drug resistance patterns in the analyzed sequences 
obtained from LAC.  
 
4.6 CONCLUSIONS AND RECOMMENDATIONS 
The overall TDR prevalence in LAC was 7.7% for the period 1996-2009 and reached 10% in the last 4 
investigated years when data was solely restricted to Brazil and Venezuela. Additionally, large 
geographical differences have been found. Although lack of information for Caribbean and Central 
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America prevents us to draw general conclusions, the reported TDR in Cuba and other Caribbean 
islands is still under the 5% WHO threshold. However, Honduras, Mexico and South American 
countries have passed the 5% threshold with the exception of Chile. The limited information available 
for most of the countries should encourage the development of surveys for drug resistance in newly 
infected people.  
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5.1 SUMMARY 
Background: We aimed to study epidemic trends and predictors for transmitted drug resistance (TDR) 
in our region, its clinical impact and its association with transmission clusters.  
Methodology: We included 778 patients from the AIDS Reference Center in Leuven (Belgium) 
diagnosed from 1998 to 2012. Resistance testing was performed using population-based sequencing 
and TDR was estimated using the WHO-2009 surveillance list. Phylogenetic analysis was performed 
using maximum likelihood and Bayesian techniques.  
Results: The cohort was predominantly Belgian (58.4%), MSM (42.8%), and chronically infected 
(86.5%). The overall TDR prevalence was 9.6% (95% confidence interval (CI): 7.7-11.9), 6.5% (CI: 5.0-
8.5) for NRTI, 2.2% (CI: 1.4-3.5) for NNRTI, and 2.2% (CI: 1.4-3.5) for protease inhibitors. A significant 
parabolic trend of NNRTI-TDR was found (p=0.019).  Factors significantly associated with TDR in 
univariate analysis were male gender, Belgian origin, MSM, recent infection, transmission clusters and 
subtype B, while multivariate and Bayesian network analysis singled out subtype B as the most 
predictive factor of TDR. Subtype B was related with transmission clusters with TDR that included 
42.6% of the TDR patients. Thanks to resistance testing, 83% of the patients with TDR who started 
therapy had undetectable viral load whereas half of the patients would likely have received a 
suboptimal therapy without this test.  
Conclusion: TDR remained stable and a NNRTI up-and-down trend was observed. While the presence 
of clusters with TDR is worrying, we could not identify an independent, non-sequence based predictor 
for TDR or transmission clusters with TDR that could help with guidelines or public health measures. 
 
5.2 INTRODUCTION 
In recent years, the number of newly diagnosed HIV-1 patients increased in Belgium [1] with a rate of 
10.7 per 100,000 population in 2011, one of the highest rates in Europe [2]. Studies carried out in 
Europe and America highlighted the important role of transmission networks in the spread of TDR [3-7]. 
TDR is a clinical and public health issue because it can compromise the response to ART at the 
individual and population level [8]. Three nationwide studies were performed previously in Belgium and 
reported a TDR prevalence of 29% (67/231; 95% CI: 23.5– 35.2) between 1995 and 1998 [9], 7.2% 
(6/83; 95% CI: 3.4–14.9) in 2000 [10] and 9.5% (27/285, 95% CI: 6.6–13.4) between 2003 and 2006 
[11]. However, due to differences in methodology and the lack of a recent study, no up-to-date 
information is yet available on TDR trends in Belgium. Nevertheless, recent reports revealed the rapid 
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onward transmission of an HIV-1 strain with K103N mutation [12] and the involvement of transmission 
clusters (TCs) in approximately half of patients with TDR [4] in a local HIV epidemic in Belgium. 
Because other studies consistently showed regional differences between the drivers of the HIV-1 
epidemic [13, 14], this study aimed to characterize the temporal trend in TDR, the factors associated 
with TDR including TCs and the clinical impact of TDR for a period of 15 years in a regional epidemic, 
serviced by the Leuven University Hospitals. The data included socio-demographic, clinical and 
virological variables. 
 
5.3 MATERIAL AND METHODS 
5.3.1 ETHICS STATEMENT 
The research was conducted according to the Declaration of Helsinki. Only patients for whom written 
informed consent was obtained were included in this study, except patients enrolled in care after 2009. 
In 2009, UZ Leuven implemented a generic “opt out” system. Patients, who logged an objection to use 
their medical data for research purposes, were not included in this study. The protocol and this consent 
procedure were approved by the Ethical Committee UZ Leuven (reference ML-8627, approval 
B322201316521 S52637). 
 5.3.2 STUDY POPULATION 
We analysed data from the cohort of the AIDS Reference Centre (ARC) in Leuven, the capital of the 
province of Flemish Brabant (Belgium). The ARC in Leuven has been collecting information since 1997 
on treated HIV-1 patients and since 1999, also for naive HIV-1 patients, including epidemiological, 
clinical and virological data, related with the routine patient healthcare services. The prospective clinical 
use of baseline genotypic drug resistance testing was implemented in 1999 and stored plasma samples 
from before 1999 were available to retrospectively perform drug resistance testing upon clinician’s 
request. Therefore HIV-1 sequences for drug naive patients were either prospectively or retrospectively 
obtained from a sample taken at diagnosis, except for 135 patients for whom a later pre-therapy sample 
was used.  The inclusion criteria for the analysis of TDR in the present study were newly HIV-1 
diagnosed between January 1998 and December 2012, availability of a nucleotide sequence before 
antiviral therapy initiation and age older than 18 years, and this cohort was called the Leuven newly-
diagnosed (ND) cohort for the purpose of this study. The only exclusion criterion used was documented 
vertical transmission. Recent infections were defined using clinical and laboratory information such as 
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p24 ELISA, HIV-specific antibody ELISA, and Inno-Lia profile. Patients with the following criteria were 
classified as recently infected:  Fiebig stages I-V [15] or no more than 6 months difference between the 
last seronegative and first seropositive HIV-1 test [11], CD4 count >200 cells/µ l and absence of AIDS-
defining conditions [16].  5.3.3 DRUG RESISTANCE TESTING 
Drug resistance testing was performed using population-based Sanger sequencing of the pol gene 
fragment encoding PR (amino acids 1 to 99) and 5’-prime end of RT (amino acids 1 to 320). Sequences 
were obtained using the ViroSeq HIV-1 Genotyping System version 2 (Celera Diagnostics, Alameda, 
CA) or with an in-house method upon failure of the commercial test [17].  Sequences with associated 
information are available through Euresist (http://www.euresist.org). 
 
TDR mutations were defined according to the 2009 list of surveillance drug resistance mutations from 
the World Health Organization [18]. Therefore, the nucleotide sequences were submitted to the 
Calibrated Population Resistance tool version 6.0 (http://cpr.stanford.edu/cpr.cgi). The clinical impact of 
genotypic drug resistance on first line therapy was evaluated using Rega algorithm [19] version 9.1.0 
(available at http://rega.kuleuven.be/cev/avd/software/rega-algorithm).  
 5.3.4 HIV-1 SUBTYPING 
HIV-1 subtypes and CRFs were determined using two HIV-1 subtyping tools, namely Rega version 3 
(http://www.bioafrica.net/typing-v3/hiv) and COMET version 0.3 (http://comet.retrovirology.lu/) [20-22]. 
Sequences with discordant results were analyzed using  manual phylogenetic analysis as was 
explained previously [22] %ULHIO\ 0/ SK\ORJHQHWLF WUHHV XQGHU WKH *75ī QXFOHRWLGH VXEVWLWXWLRQ
model were  built with RAxML [23] and recombination was verified using SimPlot [24].  
 5.3.5 TRANSMISSION CLUSTER ANALYSES 
To investigate the factors associated with TDR and onward transmission of TDR, cluster analyses were 
performed on the Leuven ND cohort and four additional datasets as controls: (i) all other pol sequences 
from the ARC in Leuven, including treated HIV-1 patients, HIV-1 patients younger than 18 years old and 
HIV-1 patients with vertical mode of transmission, (ii) HIV-1 pol sequences obtained with the search 
term “Belgium” as sampling country in the Los Alamos HIV sequence database (retrieved from 
http://www.hiv.lanl.gov date in April 2013), (iii) HIV-1 pol sequences from the collaborative study 
SPREAD that enrolled patients with newly diagnosed HIV-1 infection from 22 European countries 
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including Belgium between 2002 and 2008 (see details of the study in [25, 26]), and (iv) the 30 most 
similar sequences to the Leuven ND cohort (retrieved by Basic Local Alignment Search Tool (BLAST) 
from http://blast.ncbi.nlm.nih.gov/Blast.cgi). The quality control of the sequences was performed using 
the tool available at http://www.hiv.lanl.gov/content/sequence/QC/ and the criteria previously described 
[27]. Separate datasets were constructed according to subtype. As an out-group, two or three reference 
sequences of subtype D or B (retrieved from http://www.hiv.lanl.gov) were included for B and non-B 
subtypes, respectively. Sequences were aligned with Muscle as accessory application in the program 
Mega version 5 [28, 29]. Duplicates were removed and the positions encoding surveillance drug 
resistance mutations were excluded [18], which  resulted in an average final length of 950 nucleotides.  
In the resulting dataset,  we had 755 sequences for subtype A, 4225 for subtype B, 1036 for subtype C, 
202 for subtype F, 665 for subtype G, 440 for CRF01_AE and 677 for CFR02_AG to perform 
phylogenetic analyses on. Subtypes with frequencies less than 1% were not included in TCs analyses.  
 
$0/WUHHZDVLQIHUUHGZLWKWKHQXFOHRWLGHVXEVWLWXWLRQ*75īPRGHODQGERRWVWUDSUHSOicates in 
RAxML [23]. TCs, including pairs (two individuals) and larger FOXVWHUVLQGLYLGXDOV were identified 
by using Cluster Picker (retrieved from http://hiv.bio.ed.ac.uk/software.html) [30] with a genetic distance 
OHVVRUHTXDOWKDQVXEVWLWXWLRQVSHUVLWHDQGERRWVWUDSVXSSRUW$VHQVLWLYLW\DQDO\VLVZDV
performed to evaluate the effect of other genetic distances (0.015, 0.030 and 0.045) [31-34].  
 
The robustness of the identified TCs was evaluated using Bayesian phylogenetic analysis.  TCs and the 
closest control sequences together with two reference sequences as an out-group were selected and 
trees were constructed with BEAST v1.7.5 [35] using a lognormal relaxed molecular clock with the 
SRD06 model of nucleotide substitutions [36] and a Bayesian skyline coalescent prior. The analyses 
were run in triplicate for 100 million states and trees were sampled every 10000th states. MCC were 
summarized using TreeAnnotator after 10% of the burn-in was discarded and visualized with FigTree 
v.1.4 (available at http://tree.bio.ed.ac.uk). The TCs with a Bayesian posterior probability of 1 were 
considered robust enough and included in the analysis.  
 
Finally, we defined TCs with TDR as any pair or cluster with more than 3 patients that included at least 
one patient with TDR from the Leuven ND cohort. The TCs with TDR with more than 3 individuals with 
similar TDR mutation profile can be suggestive of onward transmission of TDR, they are specifically 
indicated as TCs with TDR-OT. 
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5.3.6 STATISTICAL ANALYSIS 
Prevalence of TDR and TDR mutations were calculated with a 95% Wilson score confidence interval 
(95% CI) on the basis of a binomial distribution, and their trend was calculated by logistic regression 
analysis. Socio-demographic, virological and clinical variables that were significantly associated with 
TDR or with TCs with TDR were evaluated in the Leuven cohort. Analyses were performed on patients 
involved in TCs from the Leuven ND cohort, and from Leuven ND cohort with the other four control 
datasets. Categorical data were compared using the Chi-square test, the Fisher’s exact test or 
regression techniques as appropriate. The t-test or Mann–Whitney U test was used to compare 
continuous data. The statistical significance was set at p<0.05 two-sided. All data were analysed using 
the statistical R software version 2.13.1.   
Those factors that were found to be significantly associated with TDR or TCs with TDR in univariate 
analysis were included in a Bayesian network analysis. This is a probabilistic model that describes 
statistical conditional dependencies between multiple variables and was performed using the B-course 
software adapted by Deforche et al [37]. In this analysis, the arcs were scored based on the stability of 
the conditional dependency assessed with 100 non-parametric bootstrap replicates. The arcs with 
bootstrap over 75% were considered and depicted in the consensus network. 
 
5.4 RESULTS 
5.4.1 GENERAL CHARACTERISTICS OF THE POPULATION 
778 of the 795 patients who were newly diagnosed with an HIV-1 infection and who received a baseline 
genotypic drug resistance test between January 1998 and December 2012 at University Hospitals 
Leuven were included in the analysis, they are referred to as the Leuven ND cohort. Two patients were 
excluded because their risk group was vertical transmission. For 15 patients, the baseline nucleotide 
sequence did not fulfill the preset quality criteria: 14 sequences did not have the gene fragments 
encoding PR or RT, and one sequence was excluded due to the presence of more than four stop 
codons and indels. The included HIV-1 patients were between 18 and 78 years old and were 
predominantly male (73.7%), of Belgian origin (58.4%), chronically infected (86.5%) with CDC stage 1 
or 2 (67.0%) (Table  5.1). Patients originating from Belgium were more frequently diagnosed with a 
recent infection and displayed higher viral loads and CD4 counts (p<0.001).  Of all included HIV-1 
patients originated from Belgium, 66.7% reported MSM or bisexual contacts as risk factor, whereas 
 128 | 
 
 The Dynamics of Local HIV-1 Epidemics 
22.5% reported heterosexual contacts. In contrast, HIV-1 patients originating from Sub-Saharan 
countries reported infection through heterosexual contacts predominantly (79.3%). HIV-1 patients from 
Sub-Saharan countries were more likely to be co-infected with hepatitis B than patients from Belgium 
(60.9% vs. 34.8%; OR: 4.49, 95% CI 1.75–12.15, p < 0.001). There were 36 HIV-1 therapy-naive 
patients who did not receive a baseline drug resistance test in this period. This group included more 
patients of non-Belgian origin (75.0%) and with CD4 count above 500 cells/mL (42.4%, 14/33).  
 
The demographic characteristics of the Leuven ND cohort were compared to the general HIV-1 
population in Belgium, as reported  by the Belgian Scientific Institute of Public Health (information until 
2011) (available at www.wiv-isp.be) [1]. The Leuven ND cohort contained more men (73.5% vs. 61.0%, 
p <0.0002) and Belgians (58.4% vs. 40.6%, p <0.0002) and more MSM (55.9% vs. 42.5%, p <0.0002). 
National data only covered gender and country of origin from 1998 to 2011, and transmission risk from 
2005 to 2011.  
 
 
 
 
  
Characteristics at time of sampling Total TDR Univariate Multivariate 
  n % n % OR (95% CI) p OR (95% CI) p 
Patients 778  100 75 100  
   
  
Male 573 73.7 67 89.3 3.25 (1.52-7.99) <0.001* 
 
  
Pregnant women 15 1.9 1 1.3 
   
  
Age in years at enrolment, Mean (SD) 37.5 (±10.6) 39.6 (±12.4) 
   
  
<25 69 8.9 6 8.0 
   
  
25-34 287 36.9 23 30.7 
   
  
35-44 241 31.0 23 30.7 
   
  
45-54 121 15.6 12 16.0 
   
  
>55 60 7.7 11 14.7 
   
  
Country or region of origin 
       
  
Belgium 454 58.4 55 73.3 2.09 (1.20-3.77) 0.006* 
 
  
Western Europe (except Belgium) 23 3.0 4 5.3 
   
  
High-prevalent regions† 
    
0.23 (0.08-0.52) <0.001* 
 
  
Sub-Saharan Africa 198 25.4 7 9.3 0.27 (0.10-0.61) <0.001* 
 
  
Other 24 3.1 0 0 
   
  
Other  75 9.6 9 12.0 
   
  
Unknown 4 0.5 0 0 
   
  
Risk of transmission 
       
  
MSM 333 42.8 47 62.7 2.44 (1.46-4.15) <0.001* 
 
  
Heterosexual (high-prevalent country) 179 23.0 5 6.7 
   
  
Heterosexual (non-endemic) 121 15.6 13 17.3 
   
  
Bisexual 32 4.1 5 6.7 
   
  
IVDU 14 1.8 1 1.3 
   
  
Unknown 75 9.6 1 1.3 
   
  
Other 24 3.1 3 4.0 
   
  
Type of infection  
       
  
Chronic  673 86.5 58 77.3 
   
  
  
Characteristics at time of sampling Total TDR Univariate Multivariate 
  n % n % OR (95% CI) p OR (95% CI) p 
Recent 105 13.5 17 22.7 2.04 (1.06-3.75) 0.02* 
 
  
CDC stage§  
       
  
1 and 2  521 67.0 55 73.3 
   
  
3 246 31.6 19 25.3 
   
  
Unknown  11 1.4 1 1.3 
   
  
CD4 cell count, median (IQR) ۅ 335 (163-493) 365 (236-505) 
   
  
<200 cells/mm3 228 29.3 16 21.3 
   
  
200-349 cells/mm3 174 22.4 18 24.0 
   
  
350-499 cells/mm3 181 23.3 21 28.0 
   
  
 182 23.4 19 25.3 
   
  
Unknown 13 1.7 1 1.3 
   
  
  
       
  
HIV-RNA load, median (IQR), log copies/ml ¶ 4.76 (4.12-5.31) 4.76 (4.16-5.25) 
   
  
Co-infection  
       
  
Hepatitis B   23 3.0 4 5.3 
   
  
Negative 412 53.0 36 48.0 
   
  
Unknown  343 44.1 35 46.7 
   
  
Hepatitis C  406 52.2 1 1.3 
   
  
Negative 18 2.3 40 53.3 
   
  
Unknown  354 45.5 34 45.3 
   
  
  
  
      
  Subtype 
B 406 52.2 59 78.7 3.77 (2.09-7.17) <0.001* 3.04 (1.45-6.35) 0.003 
Part of transmission cluster 226 29.0 32 42.6 1.95 (1.15-3.25) 0.010*     
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Table 5.1: Characteristics of the Leuven ND cohort and factors associated with TDR. * Fisher’s 
test or logistic regression techniques were used. †High prevalent countries were defined as HIV-
prevalence over 1% in adult population (UNAIDS 2012), § CDC stage was defined according to 2008 
definitions [38], ۅ CD4 count at diagnosis (median 345, IQR: 158-496) was not statistically different from 
CD4 count at time of sampling. ¶ Viral load at diagnosis (median 4.76 IQR: 4.04-5.31) was not 
statistically different from viral load at time of sampling. Abbreviations: %: percentage, CDC: Center for 
Disease Control and Prevention, CI: Confidence interval, IVDU: Intravenous drug user, IQR: 
interquartile range, MSM: men who have sex with men, n: number, OR: odds ratio, SD: standard 
deviation.  
 5.4.2 SUBTYPES 
52.2% of the HIV-1 patients were infected with subtype B, followed by CRF02_AG (11.2%), subtype C 
(10.3%), subtype A (7.7%), CRF01_AE (6.6%), subtype F (2.8%), subtype G (2.1%) and unique 
recombinant forms (4.8%). Subtypes D, H, J, CRF09_cpx, CRF12_BF, CRF13_cpx, CRF14_BG, 
CRF18_cpx, CRF22_01A1, CRF37_cpx, and CRF45_cpx were each found in less than 1%. Of the 
patients with a subtype B infection, 81.0% were of Belgian origin and 71.9% were MSM. Whereas in 
patients with non-B infections, 33.6% and 51.6% had a Belgian or sub-Saharan origin, respectively, and 
69.9% were infected through heterosexual contacts, followed by bisexual/MSM risk factor (13.2%). 
 5.4.3 LEVEL AND TRENDS OF TDR 
The overall TDR prevalence was 9.6% (75/778; 95% CI 7.7-11.9). The prevalence of TDR against NRTI 
was 6.5% (51/778; 95% CI 5.0-8.5), against NNRTI was 2.2% (17/778; 95% CI 1.4-3.5), and against PI 
2.2% (17/778; 95% CI 1.4-3.5). In recently infected individuals, the prevalence of overall TDR was 
16.2% (17/105; 95% CI 10.4-24.4), significantly higher than in patients with chronic or unknown 
duration of infection (8.6%, 58/673; 95% CI 6.7-11.0). The prevalence of TDR by drug class also varied 
in recently infected individuals. The prevalence of TDR against NRTI was 12.4% (13/105; 95%CI 7.4-
20.0), against NNRTI 1.9% (2/105; 95%CI 0.5-6.7), and against PI 6.7% (7/105; 95%CI 3.3-13.1). Dual 
resistance was detected in 10 patients (1.3%): 3 displayed TDR against NRTI and NNRTI, 6 against 
NRTI and PI and one against NNRTI and PI. The latter patient with NNRTI and PI resistance and 4 out 
of 6 individuals with NRTI and PI resistance were recently infected patients (5/105; 4.8%). No triple 
class resistance was observed. 
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The majority of the 75 TDR patients displayed one single mutation (70.7%), mainly related to NRTI 
(58.5%) and NNRTI resistance (24.5%). The revertants at RT position 215 were the most prevalent 
(44%), followed by M41L (18.7%), K103N (17.3%), L210W (10.7%), K219Q (10.7%), D67N (6.7%), 
K219R (5.3%), G190A (4.0%), M184V (2.7%), L74V (1.3%), Y115F (1.3%) and Y181C (1.3%). Within 
PR, I54VT (10.7%) was the most frequent mutation followed by M46IL (9.3%), N88D (6.7%), V82TS 
(2.7%), L24I (1.3%), I54T (1.3%) and I85V (1.3%). As the inclusion of PR position 46 within the TDR 
mutation list has been debated due to its polymorphic nature [39], TDR was recalculated excluding this 
position. This resulted in an overall TDR of 8.9% (69/778; 95% CI 7.0-11.0) and a PI-TDR of 1.4% 
(11/778; 95% CI 0.8-2.5). 
 
No significant time trends were found in the overall TDR prevalence, nor in transmitted NRTI and PI 
resistance (see Figure 5.1A). A parabolic trend was observed for NNRTI-TDR (p=0.019) with a peak in 
2008. That corresponded with a peak in occurrence of K103N (p=0.026), the only mutation with a 
temporal trend. Surprisingly, the parabolic temporal NNRTI-TDR trend was not observed in the recently 
infected individuals. Instead, a stable temporal trend was observed for overall TDR and individual drug 
classes in this subset of patients. When the analysis was performed according to region of origin, a 
significant parabolic trend of NNRTI resistance was only found in patients originating from Belgium 
(p=0.039). 
 5.4.4 FACTORS ASSOCIATED WITH TDR 
Univariate analysis was performed to identify predictors of TDR (Table 5.1), which were male gender 
(odds ratio (OR) 3.25, 95% CI 1.52-7.99, p<0.001), Belgian origin (OR 2.09, 95% CI 1.20-3.77, 
p=0.006), MSM transmission (OR 2.44, 95% CI 1.46-4.15, p<0.001), recent infection (OR 2.04, 95% CI 
1.06-3.75, p=0.02), being part of  TCs (OR 1.95, 95% CI 1.15-3.25, p=0.010) and infected with subtype 
B virus (OR 3.77, 95% CI 2.09-7.17, p<0.001). Only the latter remained a significant factor (OR 3.04, 
95% CI 1.45-6.35, p=0.003) in multivariate analysis. Since these types of analyses do not display 
possible interdependencies of the variables and subtype B was most frequently found in MSM 
originating in Belgium (p <0.001), we evaluated the interdependencies of the variables with a Bayesian 
network approach. TDR was directly associated only with subtype B, but this subtype was strongly 
associated with MSM (100% bootstrap support) and with Belgian origin (97% bootstrap support), and to 
a lesser extent to being part of TCs (78% bootstrap support) (See Figure 5.1B). To verify whether we 
could find an important predictor of TDR that could be used in guidelines to target a subpopulation of 
newly diagnosed for preferential drug resistance testing, we repeated the analysis excluding any 
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information that results from the genotype itself. When subtype B was thus excluded from the analysis, 
then male gender became directly associated with TDR (64% bootstrap support), and with MSM and 
Belgian origin (100% bootstrap support), whereas the association between the two latter variables with 
TCs had lower bootstrap support (31%). 
 
 
FIGURE 5. 1. TEMPORAL TRENDS AND FACTORS ASSOCIATED WITH TDR 
Figure 5.1: Temporal trends and factors associated with TDR. (A) Trends of prevalence of TDR 
(percentage) and the 95% confidence intervals (light shading) among newly diagnosed HIV-1 patients 
at ARC Leuven (Belgium) from 1998 to 2012 are shown for the overall-TDR, NRTI-TDR, NNRTI-TDR, 
PI-TDR in blue, MSM overall-TDR and Belgian overall-TDR in red.  (B) The significant variables 
associated with TDR in the univariate analysis were included in the Bayesian network, the number next 
to the arcs represents the bootstrap support. Abbreviations: NRTI: nucleoside reverse transcriptase 
inhibitors, NNRTI: non-nucleoside reverse transcriptase inhibitors, MSM: men who have sex with men, 
PI: protease inhibitors. 
 5.4.5 TRANSMISSION CLUSTERS 
We identified 114 TCs, 16 of which harbored 32 of the 75 TDR patients from our Leuven ND cohort. 
Five pairs and eight ODUJHUFOXVWHUVRI LQGLYLGXDOVZHUH IRXQGDPRQJVXEW\SH% LQIHFWHGSDWLHQWV
one cluster of 17 individuals with CRF02_AG, and one pair for each subtypes C and CRF01_AE (see 
Table 5.2). Six of these 16 TCs with TDR included only a single patient with TDR whereas six clusters 
were TCs with TDR-OT and included 20 individuals from the Leuven ND cohort (26.7%, 20/75). 
Singletons were frequently found in patients from the Leuven ND cohort involved in TCs (81.3%, 
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26/32). Likewise, prevalence against NRTI was the most frequent (81.3%, 26/32), followed by PI 
(25.0%) and NNRTI (12.5%). Thymidine analogue mutations (TAMs) were predominantly detected in 
TCs with TDR (81.3%, 26/32), mainly represented by the revertant at position 215 (59.4%, 19/32), 
followed by the mutations K219QR (18.8%), L210W (15.6%) and M41L (6.3%). Mutations for NNRTI 
and PI were I54V, N88D (each 15.6%), K103N (12.5%) and M46IL (9.4%). 
 
The characteristics of the Leuven ND cohort patients involved in TCs were evaluated. Patients carrying 
TDR were significantly more associated with TCs compared to patients without TDR (OR: 1.95, see 
Table 5.1 and supplementary Table 5.1) and the association remained when considering only larger 
clusters by excluding pairs (OR: 2.86, 95% CI 1.59-5.01, p=<0.001). Similarly, when including only TCs 
with TDR-OT, TDR remained significantly associated with TCs (OR: 2.44, 95% CI 1.32-4.36, p=0.002, 
see supplementary Table 5.1). 32 out of 75 TDR patients were involved in TCs (42.6%, 95% CI 32.1-
53.9), while of the 703 patients without TDR, only 194 were found in TCs (27.6%, 95% CI 24.4-31.0). 
As expected, Leuven ND cohort patients with TDR and involved in TCs were significantly more of 
Belgian origin (90.6% versus 65.5%; OR: 4.84, 95% CI 1.41-25.78, p=0.005), infected with subtype B 
(90.6% versus 63.9%; OR: 5.42, 95% CI 1.59-28.85, p=0.001) and characterized with MSM risk factor 
(78.1% versus 52.6%; OR: 2.71, 95% CI 1.07-7.84, p=0.03) than their counterparts without TDR (see 
Supplementary Table 5.1). When we focussed on predictors for TCs with TDR by including the data of 
controls, subtype B remained significantly associated with TCs with TDR (77.4% versus 65.1%, OR: 
1.83 95% CI 1.03-3.35, p=0.036). However, TCs of patients with TDR were larger than TCs without 
TDR (median 3.5 vs. 2 patients per TC, OR: 1.43 95% CI 1.08-1.91, p=0.001). Belgium as sampling 
country or as country of origin and heterosexual contact were then more frequent in the group of TCs 
that included solely patients without evidence of TDR. Multivariate analysis did not show any significant 
factor associated with patients in TCs with TDR versus other TCs. Finally, we also performed separate 
analyses on TCs with TDR-OT (see supplementary Table 5.1). The same variables remained 
significantly associated with TCs in the univariate analysis, with the exception of recent infection that 
became significant. The median of the TCs with TDR-OT was larger than TCs without TDR (5.5 versus 
2 patients per TCs, OR: 2.01 (1.29-3.11).  Likewise, none of the variables were significant in the 
multivariate analysis.   
 
  
 
                 TDR mutations 
Cluster 
Patient 
ID† Subtype Risk of transmission 
Country of 
sampling 
Country of 
origin  
Country of 
infection  Type of infection 
Year  of  
diagnosis NRTI NNRTI PI 
1 
  
  
  
  
AY165241 B 
 
Unknown Sweden Unknown Unknown Naive - Unknown 2000*  -   -   -  
ARCL-1 MSM Belgium Belgium Unknown Naive - Chronic 2002 M41LM  -   -  
 ESAR-1 Heterosexual - Male Spain Pakistan Spain Naive - Recent 2003  -   -   -  
FJ481828 MSM Spain Unknown Unknown Naive - Unknown 2006*  -   -   -  
 ESAR-2 MSM Finland Russia Finland  Naive - Chronic 2007  -   -   -  
2  
  
  
  
  
EU248399 B 
 
Unknown Belgium Unknown Unknown Naive - Unknown 2003*  -  K103N  -  
JN101707 Unknown 
United 
Kingdom Unknown Unknown Unknown 2004*  -  K103N  -  
ARCL-2 Heterosexual - Male Belgium Belgium Belgium Naive - Chronic 2007  -  K103N  -  
ARCL-3 Bisexual - Male Belgium Belgium Unknown Naive - Chronic 2009  -  K103N  -  
JF683797 Unknown Cyprus Unknown Unknown Naive - Unknown 2009*  -  K103N  -  
3 
  
  
  
  
  
ARCL-4 B 
 
MSM Belgium Belgium Belgium Naive -Recent§ 2001 L210W, T215S  - I54V, N88D 
EU248438 Unknown Belgium Unknown Unknown Naive - Unknown 2003* L210W, T215S  - I54V, N88D 
ARCL-5 MSM Belgium Belgium Belgium Naive - Recent 2005 L210W, T215S  - I54V, N88D 
ARCL-6 MSM Belgium Belgium Belgium Naive - Chronic§ 2007 L210W, T215S  - I54V, N88D 
ARCL-7 MSM Belgium Italy Belgium Naive - Recent 2010 L210W, T215S  - I54V, N88D 
ARCL-8 MSM Belgium Belgium Unknown Naive - Recent 2011 L210W, T215S  - I54V, N88D 
4 
  
DQ177230 B Unknown Belgium Unknown Unknown Naive - Unknown 2002* T215E  -  - 
ARCL-9 MSM Belgium Belgium Belgium Naive - Chronic 2005 T215E  -  - 
5 
  
  
  
  
  
  
  
  
ARCL-10 B 
 
MSM Belgium Belgium Belgium Naive - Chronic§ 2007 T215D  -  - 
ARCL-11 MSM Belgium Belgium Unknown Naive - Chronic 2007 T215D  -  - 
ARCL-12 MSM Belgium Belgium Unknown Naive - Chronic 2007 T215D  -  - 
ARCL-13 MSM Belgium Belgium Belgium Naive - Chronic 2007 T215D  -  - 
ARCL-14 MSM Belgium Belgium Unknown Naive - Chronic 2010  -  -  - 
ARCL-15 MSM Belgium Belgium Belgium Naive - Chronic 2010  -  -  - 
ARCL-16 MSM Belgium Belgium Unknown Naive - Recent 2011 T215D  -  - 
ARCL-17 MSM Belgium Belgium Unknown Naive - Recent 2011 T215D  -  - 
ARCL-18 MSM Belgium Belgium Unknown Naive - Chronic 2012 T215D  -  - 
6 
  DQ206665 
B 
Unknown Argentina Unknown Unknown Naive - Unknown 2004*  - 
K103N, 
P225H  - 
  
                 TDR mutations 
Cluster 
Patient 
ID† Subtype Risk of transmission 
Country of 
sampling 
Country of 
origin  
Country of 
infection  Type of infection 
Year  of  
diagnosis NRTI NNRTI PI 
  
  JN670104 
 
Unknown Argentina Unknown Unknown Treated 2005* 
M41L, M184V, 
T215Y  -  D30N, N88D 
ARCL-19 MSM Belgium Belgium Unknown Naive - Chronic 2007 T215S K103N  - 
ARCL-20 MSM Belgium Belgium Belgium Naive - Recent 2007  - K103N  - 
7 
  
  
ARCL-21 B 
 
MSM Belgium Belgium Belgium Naive - Recent 2009  -  - M46L 
ARCL-22 MSM Belgium Belgium Unknown Naive - Chronic 2010 K219Q  -  - 
JQ650683 MSM Netherlands Unknown Unknown Unknown Unknown  -  - M46L 
8 
  
ARCL-23 B 
 
MSM Belgium Belgium Unknown Naive - Recent 2011 T215E  -  - 
JQ650714 MSM Netherlands Unknown Unknown Unknown Unknown T215E  -  - 
9 
  
ARCL-24 B 
 
MSM Belgium Belgium Belgium Naive - Chronic 2006  -  -  - 
ARCL-25 Transfusion - Male Belgium Belgium Unknown Naive - Chronic 2010 K219RK  -  - 
10 
  
ARCL-26 B 
 
MSM Belgium Indonesia Asia Naive - Chronic 2001 T215D  -  - 
ARCL-27 MSM Belgium Belgium Belgium Naive - Chronic 2003 T215D  -  - 
11 
  
ARCL-28 B 
 
MSM Belgium Belgium Unknown Naive - Chronic 1998 T215C  -  - 
ARCL-29 MSM Belgium Belgium Belgium Naive - Chronic 2002 T215S  -  - 
12 
  
  
  
ARCL-30 B 
 
MSM Belgium Belgium Belgium Naive - Recent 2003  -   -   -  
ARCL-31 Bisexual - Male Belgium Belgium Belgium Naive - Recent 2009 K219R  -   -  
ARCL-32 Bisexual - Male Belgium Belgium Unknown Naive - Chronic 2009  -   -   -  
ARCL-33 Unknown Belgium Belgium Belgium Naive - Chronic 2010  -   -   -  
13 
  
  
  
  
  
  
  
  
  
  
  
  
EU817049 
B 
 Unknown 
United 
Kingdom Unknown Unknown Naive - Unknown 1998* K219Q  -   -  
EU817059 Unknown 
United 
Kingdom Unknown Unknown Naive - Unknown 2001* K219Q  -   -  
EU817062 Unknown 
United 
Kingdom Unknown Unknown Naive - Unknown 2001* K219R  -   -  
ARCL-34 MSM Belgium Belgium Belgium Naive - Chronic 2007 K219Q  -   -  
ARCL-35 MSM Belgium Belgium Belgium Naive - Recent 2006 K219Q  -   -  
ESAR-1 MSM/bisexual Italy Italy Unknown Naive - Chronic 2003 K219Q  -   -  
EU817050 Unknown 
United 
Kingdom Unknown Unknown Naive - Unknown 2003* K219Q  -   -  
EU817048 Unknown 
United 
Kingdom Unknown Unknown Naive - Unknown 2004* K219R  -   -  
  
 
                 TDR mutations 
Cluster 
Patient 
ID† Subtype Risk of transmission 
Country of 
sampling 
Country of 
origin  
Country of 
infection  Type of infection 
Year  of  
diagnosis NRTI NNRTI PI 
  
  
  
  
  
  
  
  
  
  
  
  
  
EU817061 Unknown 
United 
Kingdom Unknown Unknown Naive - Unknown 2004* K219Q  -   -  
DQ345509 Unknown Argentina Unknown Unknown Naive - Recent 2005*  -   -   -  
EU817058 Unknown 
United 
Kingdom Unknown Unknown Naive - Unknown 2005* K219Q  -   -  
EU817060 Unknown 
United 
Kingdom Unknown Unknown Naive - Unknown 2005* K219Q  -   -  
EU817065 Unknown 
United 
Kingdom Unknown Unknown Naive - Unknown 2005* K219Q  -   -  
EU817056 Unknown 
United 
Kingdom Unknown Unknown Naive - Unknown 2005* K219Q  -   -  
EU817051 Unknown 
United 
Kingdom Unknown Unknown Naive - Unknown 2005* K219Q  -   -  
EU817068 Unknown 
United 
Kingdom Unknown Unknown Naive - Unknown 2005* K219Q  -   -  
EU817047 Unknown 
United 
Kingdom Unknown Unknown Naive - Unknown 2005* K219Q  -   -  
EU817055 Unknown 
United 
Kingdom Unknown Unknown Naive - Unknown 2005* K219Q  -   -  
EU817063 Unknown 
United 
Kingdom Unknown Unknown Naive - Unknown 2005* K219QR  -   -  
FJ469703 Unknown United States Unknown Unknown Naive - Unknown 2005* K219Q  -   -  
ESAR-2 MSM/bisexual Germany Germany Unknown Naive - Recent 2006 K219Q  -   -  
ESAR-3 MSM/bisexual Cyprus Cyprus Unknown Naive - Chronic 2007  -   -   -  
ESAR-4 MSM/bisexual Germany Germany Germany Naive - Recent 2007  -   -   -  
JF683765 Unknown Cyprus Unknown Unknown Naive - Unknown 2007*  -   -   -  
JF683791 Unknown Cyprus Unknown Unknown Naive - Unknown 2009*  -   -   -  
JF683808 Unknown Cyprus Unknown Unknown Naive - Unknown 2009*  -   -   -  
14 
  
ARCL-36 C 
 
Heterosexual - Female Belgium Belgium Unknown Naive - Chronic 2012  -  - M46LM 
ARCL-37 Heterosexual - Male Belgium Ethiopia Unknown Naive - Chronic 2012  -  -  - 
15 
 
ARCL-38 CRF01_
AE 
Heterosexual - Female Belgium Thailand Thailand Naive - Chronic 2005  -  -  -  
ARCL-39 Heterosexual - Male Belgium Belgium Belgium Naive - Chronic 2005  -  - M46IM 
16 
  JX290261 
CRF02_
AG Unknown Russia Unknown Unknown Unknown 
2001 or 
2002‡  -  -  - 
  
                 TDR mutations 
Cluster 
Patient 
ID† Subtype Risk of transmission 
Country of 
sampling 
Country of 
origin  
Country of 
infection  Type of infection 
Year  of  
diagnosis NRTI NNRTI PI 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
AY829204  IVDU - Male Uzbekistan Unknown Unknown Unknown 2002*  -  -  - 
AY829207 IVDU - Male Uzbekistan Unknown Unknown Unknown 2002*  -  -  - 
AY829214 IVDU - Male Uzbekistan Unknown Unknown Unknown 2002*  -  -  - 
HQ449394 Unknown - Female Russia Unknown Unknown Unknown 2005‡  -  -  - 
DQ465230 MTCT USA Unknown Unknown Unknown 2006*  -  -  - 
GQ290726 Unknown South Korea Unknown Unknown Naive - Unknown 2008*  -  -  - 
GQ290743 Unknown South Korea Unknown Unknown Naive - Unknown 2008*  -  -  - 
HQ412530 Unknown - Male Russia Unknown Unknown Unknown 2008* 
L74I, M184V, 
K219E 
L100I, K101E, 
Y181C, 
G190S  - 
HQ115069 Unknown - Male Ukraine Unknown Unknown Unknown 2009‡  -  -  - 
JX500703 Unknown Russia Unknown Unknown Unknown 2010*  -  -  - 
ARCL-40 Heterosexual - Female Belgium Kazakhstan Unknown Naive - Chronic 2011 K219RK  -  - 
JX500697 Unknown Russia Unknown Unknown Unknown 2011*  -  -  - 
JX500706 Unknown Russia Unknown Unknown Unknown 2011*  -  -  - 
KC509858 Unknown - Female Russia Unknown Unknown Unknown 2012*  -  -  - 
KC120872 Unknown South Korea Unknown Unknown Unknown Unknown  -  -  - 
KC120881 Unknown South Korea Unknown Unknown Unknown Unknown  -  -  - 
 
Table 5.2: Characteristics of transmission clusters containing Leuven patients with TDR.  Abbreviations: ARCL Aids Reference Center Leuven, CRF: circulating 
recombinant form, ESAR: European Society for translational Antiviral Research, IVDU: intravenous drug user, NRTI: nucleoside reverse transcriptase inhibitors, NNRTI: non-
nucleoside reverse transcriptase inhibitors, MSM: men who have sex with men, MTCT: mother to child transmission, PI: protease inhibitors,† Patient ID includes patients of the 
Leuven cohort (bold and italics), ESAR controls and accession numbers of NCBI database  * Control sequences have available year of sampling. ‡ Control sequences with year 
of diagnosis available. § Sequences were also included when the patient was on antiretroviral treatment. 
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The characteristics of the Leuven TDR patients involved in TCs are shown in Table 5.2. Five pairs 
included mainly naive MSM originating from Belgium, infected with a subtype B strain carrying one of 
the 215 revertants, whereas two pairs with subtype C and CRF01_AE strains displaying mutations at 
PR position 46 included heterosexual Belgians with a foreign partner. Two large subtype B TCs with 
TDR included 9 or more patients. Cluster number 5 was composed of nine therapy-naive individuals 
originating from Belgium with MSM as a risk factor and diagnosed between 2007 and 2012.  Seven of 
them displayed a revertant at RT position 215 while two strains had no TDR. Cluster number 13 (Figure 
5.2B) included 26 naive patients mainly from United Kingdom and countries of western and southern 
Europe, western Asia and America. The main mode of transmission was MSM infected with viruses 
carrying mutations at position 219, except for six individuals who mainly originated from Cyprus and did 
not display any mutations. The remaining subtype B TCs were composed of three to six individuals. All 
had at least one individual originating from Belgium and one from another country. For instance, cluster 
number 1 included one patient originating from Belgium and two patients from Russia and Pakistan but 
infected in other countries like Finland and Spain. One peculiar subtype B cluster with extensive NRTI 
and PI resistance (cluster number 3) contained 6 therapy-naive MSM with TDR all with a Belgian 
connection, either infected in Belgium or originating from Belgium. On the other hand, the largest 
cluster of non-B subtypes was composed of 17 individuals infected with CRF02_AG and sampled in 
different countries from Central-eastern Asia and Eastern Europe and characterized by different risks 
factors including heterosexual orientation, IVDU or vertical transmission. The resistance pattern was 
also heterogeneous in this cluster. The majority of patients did not display TDR mutations, whereas one 
naive patient sampled in Belgium and originating from Kazakhstan displayed a mixture of K219RK, and 
one patient who was tested in Russia was probably treated and displayed high-level resistance against 
NRTI and NNRTI. 
 
Since the definition of clustering is still a matter of debate, additional analyses were performed to 
assess the impact of the genetic distance on the identification of TCs with values of 0.015, 0.03 and 
0.045.  As a result, the number of TCs with TDR decreased to 9, 13 and 17, respectively, including 
22.7%, 29.3% and 36.0% of the 75 patients with TDR. The number of TCs that included TDR patients 
was larger with the genetic distance 0.045 because the cluster with 9 individuals identified as number 5 
in Table 5.2 was split in one pair (ARCL-16-TDR and ARCL-18-TDR) and one cluster with the 
remaining patients. With the stringent criteria of 0.015, TDR was still associated with TCs (OR: 2.56 
05% CI 1.32-4.76, p=0.003). Subtype B infection remained as the factor associated with TCs with TDR 
(p=0.002), whereas sociodemographic factors such as Belgian nationality and MSM contact were not 
significantly linked. 
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FIGURE 5. 2.  EXAMPLES OF SUBTYPE B TRANSMISSION CLUSTERS WITH TDR 
Figure 5.2: Examples of subtype B transmission clusters (TCs) with TDR: A maximum likelihood 
(ML) tree per subtype was constructed, and TCs were confirmed by Bayesian Phylogenetic analyses. 
(A) The ML tree for subtype B (Leuven ND cohort and control sequences) with the TCs colored in dark 
red. (B) The largest TC of subtype B: composed of therapy-naive patients, several nationalities and 
mutations at RT position 219; bootstrap values above 98% are shown. Abbreviations: AR: Argentina, 
CY: Cyprus, GE: Germany, IT: Italy, UK: United Kingdom, USA: United States of America, black 
diamond: men who have sex with men, asterisk: posterior distribution equal to 1 in the Bayesian 
phylogenetic analysis.  
 5.4.6 POTENTIAL IMPACT OF TDR ON FIRST-LINE REGIMEN 
For each patient with TDR, we analysed the genotypic susceptibility score (GSS) of the three regimens 
most frequently prescribed during the year the patient was diagnosed, and for each patient who in the 
meantime had started treatment we also estimated the GSS of the first-line therapy received. Rega 
Algorithm 9.1.0 was used for these analyses, which has a recommended GSS for patients with TDR. 
7KLVUHFRPPHQGDWLRQZDVLQWURGXFHGLQ0DUFKDQGVXJJHVWVDUHJLPHQZLWK*66RIZKHQ
TDR is detected, thereby suggesting a triple therapy with a fully active boosted PI which receives a 
score 1.5, but not with an NNRTI which receives a score of 1 when fully active.  
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Amongst the 636 patients who started ART, the GSS of the actual prescribed first-line regimen was 
LQSDWLHQWVLQSDWLHQWVDQGLQSDWLHQWV7KHODWWHUJURXS
included five patients without TDR, of which three patients were treated with bi-therapy in 1998, one 
with bi-therapy including a PI in 2002 and one with a mono PI regimen in 2010. Although the 
GHPRJUDSKLFFKDUDFWHULVWLFVZHUHVLPLODUEHWZHHQWKHSDWLHQWVZLWKD*66DQGWKHODWWHUJURXS
more often started ART before 2002 (8/18, p<0.001).    
 
In the group of patients with viruses carrying TDR, 60 started therapy before the end of 2012. The GSS 
ZDVLQSDWLHQWVHTXDOWRLQSDWLHQWVDQGLQSDWLHQWV7KH
latter group displayed resistance only to NRTIs (6/13), only to PI (2/13) or dual resistance (5/13).  
Sustained undetectable viral load during the first-line therapy was reached in 83.3% (50/60) of the TDR 
patients, whereas 3.3% of the patients (2/60) had sustained low level viremia without evidence of 
virological rebound above 500 copies/ml. Four patients (6.7%) had early changes in ART due to toxicity 
and 1 patient (1.7%) died shortly after therapy initiation. Only 5.1% of the patients (3/60) displayed 
virological failure and the emergence of major NNRTI resistance-related mutations. Two of these 
patients displayed evidence of only NRTI TDR mutations at baseline and received a NRTI+NNRTI 
regimen with a GSS equal to 3. The third patient started a NRTI+NNRTI therapy with a GSS equal to 1 
in 2004, two days after the first contact date and two weeks before the drug resistance results were 
available. In this patient, the therapy was quickly changed after receiving the baseline drug resistance 
report indicating NRTI and NNRTI TDR mutations and observing no virological response. Subsequent 
drug resistance testing on a later sample revealed further accumulation of NNRTI resistance.  
 
To appreciate the value of baseline drug resistance testing, the GSS was calculated for the three most 
frequently prescribed first-line regimens in patients displaying TDR in our cohort per year (see 
supplementary Table 5.2).  Theoretically, 49.3% of TDR patients (37/75) were likely to receive a 
potential suboptimal regimen (GSS <3) if baseline drug resistance testing had not been available to the 
treating physician. However, the frequency of these patients is decreasing over time (p=0.002).  Up 
until 2003, the most common first-line regimens included a thymidine analogue with either a NNRTI- or 
unboosted PI. Thereafter, tenofovir or abacavir were more commonly used as supporting NRTI, but a 
GSS <3 was still mainly observed for NRTI+NNRTI regimens. A low GSS under a boosted PI based 
regimen would only have accounted for approximately 15% of the TDR cases per year between 2005 
and 2011.  
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5.5 DISCUSSION 
The TDR surveillance in the 778 included patients who were newly diagnosed with HIV-1 at our clinic in 
Leuven showed a stable overall prevalence of 9.6% between 1998 and 2012. This result is in line with 
the 9.5% of the latest national survey that included 285 patients who were newly diagnosed in Belgium 
between 2003 and 2006 [11]. It was also consistent with the stable overall TDR levels of 9.7% in Spain 
and of 9.0% in France, results from national surveys with a similar design and time frame as our study  
[34, 40], and with the overall trend of 8.9% in Europe between 2002 and 2007 [26, 41]. However, the 
overall TDR in our local epidemic was higher than the 5.6% between 2003 and 2010 in Sweden [5] and 
the 6.5% between 2001 and 2009 in Ghent (Belgium) [4]. These regional differences highlight the 
importance of studying local epidemics and suggest that TDR prevalence may vary within a single 
country. Indeed, our findings may not be generalizable to the HIV-1 epidemic in Belgium because our 
cohort has a higher prevalence of MSM and of individuals originating from Belgium. It should be pointed 
out, however, that the demographic characteristics data of our study population was more complete 
than the national database for which nationality and mode of transmission were not available in 
approximately 25% of the cases. Although our study could have overestimated the level of TDR, due to 
patients who were unwilling to disclose their ART status, measures were taken to decrease the number 
of misclassifications. Patient records were exhaustively revised by clinicians and virologists, and 
individuals with evidence of drug resistance and viral load profiles suggestive of treatment were not 
considered drug naive.  
 
While subtype B, being MSM, male gender, originating from Belgium, recently infected, and 
involvement in TCs were all significant predictors for TDR, only subtype B remained significantly 
associated in the multivariate analysis. Bayesian analyses however, showed the dependency of this 
factor on being of Belgian origin and MSM. Similarly when subtype B was excluded, male gender 
became directly associated with TDR with low support but significantly dependent on Belgian origin and 
MSM. These findings are in agreement with previous reports from other Belgian, European and 
American studies [4, 5, 11, 40, 42]. In a recent study, the association of subtype with country of 
sampling, risk group and gender has been interpreted as evidence for highly compartmentalized 
epidemics in Europe [43]. Therefore, the early introduction of subtype B in European MSM and their 
broad access to HIV care and ART for decades might explain the single direct association of subtype B 
with TDR in many resource-rich settings. Nevertheless, recent studies revealed an increasing 
prevalence of TDR among Sub-Saharan African migrants residing in Spain and Sweden, potentially 
linked to the increasing drug resistance levels in Africa [5, 44]. However in our cohort, Sub-Saharan 
 143 |  
 
 Chapter 5: Trends and Predictors of TDR and Transmission of TDR in Belgium 
African patients were still associated with less TDR and we did not observe a time trend in those 
patients (data not shown).  
 
Fluctuations in TDR levels were observed over the entire study period, but the only significant trend 
was a parabolic trend detected for transmitted NNRTI resistance. The overall NNRTI TDR prevalence 
was 2.2%, with a maximum of 6.5% in 2008-2009. This parabolic trend, mainly linked to the detection of 
K103N and to a Belgian origin, was not observed among recently infected patients. Although a 
parabolic trend with a peak in 2004 was also described in the SPREAD study that included data up until 
2005 [26], the same surveillance up to 2007 showed a linear increase over time [41] potentially 
associated with the frequent use of NNRTI in first-line regimens as the authors suggested. Similarly, the 
local change of prescribing practices to more potent regimens in later years, use of drug resistance 
testing and the longer time period analyzed in this study could explain the parabolic trend. In the total 
cohort, TDR associated with NRTI and PI resistance fluctuated around 6.5% and 2.2%, respectively. 
Among recently infected patients, NRTI- and PI-TDR levels increased to 12.4% and 6.7% respectively. 
This increase was not observed for NNRTI resistance, presumably due to the lower impact of NNRTI 
mutations on viral fitness with consequently a lower likelihood of reversion to wild-type and of a TDR 
underestimation by population-based Sanger sequencing in chronically infected patients. 
 
Singletons were predominantly detected in our cohort with TAMs as the most commonly observed. 
Although the use of zidovudine has decreased over the last few years, we did not find any time trend for 
TAMs. The peak in NNRTI TDR in 2008 was not related to clustered transmission of TDR or migration 
from other countries as has been suggested in other settings [12, 44].  However, it might have been 
linked with the enhanced use of NNRTI-containing combinations in the years before. From 2009 
onwards, the most commonly prescribed regimen was the potent combination tenofovir + emtricitabine 
+ efavirenz. Up until 2012, no other available NNRTI- or PI/ritonavir-based regimen had proven superior 
to this regimen with respect to virologic responses. 
 
If resistance testing had not been performed and patients with TDR would have received one of the 
preferred first-line regimens at that time, approximately half of them would likely have received a 
regimen in which the virus had lost susceptibility to at least one of the prescribed drugs. Irrespective of 
the detected TDR by population-based Sanger sequencing, all of them would have had a higher risk of 
virological failure, as NNRTI-based regimes were commonly prescribed from 2002 onwards [8]. 
However, 83% of the patients with TDR and who started ART achieved undetectable viral load thanks 
to the prescription of potent regimens enabled by the availability of drug resistance results. Only 3 
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patients with baseline resistance to NRTI had virological failure with development of NNRTI resistance 
after the initiation of a NRTI+NNRTI regimen. 
  
In this cohort, 42.6% of the TDR patients were involved in TCs, which included nine clusters and seven 
pairs. Because we were interested in observing TCs over a period of 15 years, a genetic distance of 
VXEVWLWXWLRQVSHUVLWHDQGDERRWVWUDSVXSSRUWRIZHUHXVHGWRGefine TCs. These TCs were 
also confirmed using Bayesian Phylogenetic techniques, indicating that the obtained results were 
robust [4, 7, 34]. Although, the comparison between studies of transmission networks is difficult due to 
the differences in sampling, phylogenetic techniques and the lack of a standardized TC definition, our 
results were in line with a study carried out in Ghent (Belgium) in which 18 out of 33 (55%) TDR 
patients were involved in pairs or larger clusters [4]. When a more stringent criterion of 0.015 genetic 
distance was used, the percentage of TDR patients involved in TCs decreased to approximately 23%. 
In general, some conclusions can be drawn from the TCs analyses. First, none of the factors were 
significantly associated with TCs with TDR in the multivariate model, although a dependency between 
subtype B and clustering was found in the Bayesian network and TDR was significantly associated with 
TCs in the univariate analysis. Therefore we were unable to identify a non-sequence based predictor of 
being in TCs with TDR, even though the odds were higher for patients who were MSM and originating 
in Belgium. This result is similar to other studies performed in Europe [4, 34]. Second, TAMs were more 
frequently found in TCs and this was also observed in the Ghent cohort and other settings [3, 4, 7]. 
Third, TCs with TDR involved mainly therapy-naive individuals, chronically or recently infected, rather 
than ART-experienced patients, which could suggest that drug naive people, potentially unaware of 
their HIV seropositive status, are the main source of TDR instead of patients failing ART [3, 6, 7]. 
Fourth, 7 out of 16 TCs with TDR involved patients of different nationalities. Although, we were not able 
to retrace the country of infection in many instances, this may imply that migration plays an important 
role in the local spread of subtype B as previously described [45], but also of TDR.  Fifth, spread of non-
B subtypes in the local epidemic was still limited and was related with heterosexuals as has been 
described in other epidemics [6]. They were also not prone to spread TDR. They often involved 
Belgians and other nationalities that could imply a limited intermixing of the HIV-1 epidemic between 
locals and immigrants.  
 
Although we used all the sequences available in public databases and from a collaborative European 
dataset, for 7 TCs with TDR we did not find evidence that patients other than the ones followed at our 
clinic were involved in transmission networks. Similarly, 6 TCs with TDR patients from the Leuven ND 
cohort included only a single patient with TDR, and for these patients, no evidence of onward 
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transmission of TDR is available. When 3 or more patients in a TC had the same TDR mutation profile, 
we indicated the cluster as TDR-OT, since this is suggestive of onward transmission of TDR, although 
we cannot exclude that all these TDR patients received their resistance from a treated patient. The 
association between TDR and TCs remained, also for those TCs with TDR-OT. Since 27% of the 
patients from the Leuven ND cohort were involved in those TCs, this could imply an important role of 
local transmission on the spread of TDR. Nevertheless, we cannot exclude the possibility that the 
networks might include other intermediary individuals who were not sampled or unaware of their 
seropositive status, known limitations of phylogenetic analyses.  
 
Singletons and the TAM 215 were predominant in TCs, but the clinical impact on the current first-line 
therapies remains limited. However, two TCs that involved MSM individuals originating from Belgium 
with viruses carrying the K103N were detected. The latest diagnosis date was 2009 in these TCs, 
suggesting that in our local epidemic this mutation was not involved in a recent spread in contrast to a 
reported outbreak in Namur (Belgium) [12]. Continuous monitoring of the spread of this mutation is 
required to establish the impact on current practices.  On the other hand, two large clusters were 
detected with the TAM 219 and they involved different nationalities from Europe, Asia and America. 
One of these TCs contained one patient living in Belgium but originating from Kazakhstan, and control 
sequences from Uzbekistan that were part of an outbreak of CRF02_AG among IVDU [46]. Our 
analyses revealed the involvement of other countries and risk groups and the absence of K219R in 
many of the clustered sequences. The other large cluster included MSM individuals infected with 
subtype B and control sequences mainly from United Kingdom [47] and other countries in Europe. The 
majority of strains in this cluster displayed K219Q with only a few strains displaying K219R or no TDR.  
 
5.6 CONCLUSION 
In summary, this study showed a stable trend of almost 10% overall TDR between 1998 and 2012 in 
our Leuven (Belgium) cohort. TDR associated with NNRTI resistance displayed a parabolic trend that 
overlapped with an up-and-down NNRTI TDR trend in Belgians and with the trend of K103N. Our cohort 
was mainly composed of chronically infected patients and around 43% of the patients with TDR were 
involved in transmission networks, suggesting public health policies that target early diagnoses of 
recently infected patients are needed. Although the main factor related with TDR was subtype B, this 
variable was dependent on Belgian nationality and MSM mode of transmission. While these variables 
were also associated with being in TCs with TDR, we were unable to significantly identify a population 
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that could be targeted for future TDR prevention policies. More local, national and international 
surveillance studies are needed to confirm the significance and durability of our observations, as 
changes in TDR levels and patterns are not straightforward to predict due to potential changes in 
prevention, testing and treatment strategies and changes in other potentially important drivers, such as 
e.g. behaviour and migration. 
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 Chapter 6: General Discussion 
Different prevention and promotion campaigns are essential to decrease the number of new HIV 
infections. Public policies such as the United Nations Declaration of Commitment on HIV/AIDS in 2001 
and the United Nations Political Declaration on HIV/AIDS in 2006 and 2011 have been setup to tackle 
the pandemic [1]. They include strategies to achieve specific health outcomes, sustainability, goals of 
coverage, resources, and elimination of HIV-related restrictions, inequalities or stigma in all countries.  
A first priority for low-middle-income countries is the scaling up of ART, with universal access to 
antiviral drugs and improvement of the continuum in HIV care [1], whereas the priority for high income 
countries is to decrease HIV transmission by using several additional strategies such as TasP, PrEP 
and PEP, supported by the HPTN 052 study that identified a 96% reduction of HIV transmission in 
serodiscordant couples using TasP [2]. The characterization of local HIV epidemics is needed to 
evaluate the impact, cost-effectiveness and sustainability of these strategies [3].  Therefore, we 
attempted to characterize our local epidemic in Belgium, a high-income country, and in Colombia, an 
upper-middle-income country [4]. In this chapter, we will discuss in more detail the differences in health 
care between both countries that triggered different research questions and objectives for these specific 
settings. Subsequently, we will discuss our main findings and will end with some global and local 
perspectives.  
 
6.1 A TALE OF TWO LOCAL HIV-1 EPIDEMICS 
 
Belgium had an estimated number of PLHIV between 16,000 and 26,000 for 2012 (prevalence ~0.3%) 
[1]. According to the Belgian Scientific Institute for Public Health (ISP-WIV), there were 1,227 new 
diagnosis in 2012 [5], which was one of the highest rates in the European Union, despite ART coverage 
[6]. The most frequently reported mode of transmission was heterosexual contact, accounting for 53.8% 
of new infections, followed by MSM for 44.2% [5]. 
 
Belgium has a privileged response against the HIV epidemic. There are nine AIDS reference centers 
where ART and PEP can be provided [7]. In terms of screening, 64-tests/1000 inhabitants/year are 
performed, however HIV diagnosis still occurred in 42% of the cases at CD4 counts less than 350 
cell/mm3 [7]. In 2011, ART was provided to 81% of the patients engaged in care, and 83% of them 
displayed undetectable viral load. The lost-to-follow-up was 5.5% between 2008 and 2009 and was 
mainly related to newly diagnosed patients or patients originating from Sub-Saharan Africa. There are 
seven AIDS Reference Laboratories where all positive screening tests are confirmed and routine 
 152 | 
 
 The Dynamics of Local HIV-1 Epidemics 
virological and immunological parameters can be evaluated in addition to genotypic drug resistance 
testing for naive and treated patients with virological failure. The strengthening of research programs 
and anti-stigma laws are an important measure in the recently launched national plan [7].  
 
In Colombia, the accumulative number of people living with HIV, AIDS or AIDS-related deaths between 
1983 and 2013 was 92,379 according to country report to UNAIDS from the Ministry of Health [8]. 
There were 8,208 new diagnoses of HIV/AIDS in 2013, mainly men (72%) and between 25 and 35 
years old (35%). Sexual contact was the main risk behavior (98.3%) [9], but this information is only 
available until 2009 and for 44,053 cases, in which 63% were attributed to heterosexual contacts, 
followed by 34% bisexual or MSM contacts [10]. However, UNAIDS estimated that there were 150,000 
PLHIV in 2012 (prevalence ~0.5%), 9,000 new infections and 6,500 AIDS-related deaths, suggesting 
underreporting in the national statistics [1].  
 
The government of Colombia decreed the management of HIV/AIDS and other sexual transmitted 
diseases since 1997 [11], and a structured national plan was released in 2004 [12]. Nowadays, the 
health system guarantees free access to ART, although mainly generic NRTI and NNRTI are provided 
and brand-3,)URPRQZDUGV WKHQDWLRQDOJXLGHOLQHV UHFRPPHQGHG$57ZKHQ&'UHDFKHG
350 cells/mm3 ZLWKDYLUDO ORDGFRSLHVP/ [13]. Recently, the thresholds were redefined in 
accordance to the current WHO guidelines [14, 15]. Frequent clinical follow-up and immunological and 
virological testing every six months are also provided. In contrast, genotypic drug resistance testing was 
initially only recommended at virological failure on second-line regimens [13]. Since 2012, drug 
resistance testing could be performed at any virological failure defined as inability to maintain viral 
suppression <50 copies/mL [14]. Prevention strategies have been implemented, such as free testing,  
free condoms for PLHIV, targeted education to and prevention surveys in vulnerable populations, 
specialized education of health-care professionals and anti-stigma laws [9, 16]. However, the statistics 
seem to show a different scenario due to the apparent underreporting of HIV infections by several 
administrative and health entities or the high internal displacement within the country [17]. For instance, 
HIV screening is guaranteed by the health system but only HIV screening in pregnant women is 
reported with the aim to follow-up MTCT. This revealed that the coverage of screening in pregnant 
women was only 60% in 2010 [9]. Additionally, the CD4 count at diagnosis was in more than 40% of the 
patients <200 cells/mm3 [18]. The decentralization of the health system makes it difficult to evaluate 
how many centers are treating PLHIV or how many laboratories are providing viral load and CD4. 
Regardless of the ART scale up that started in 2000, it was estimated that still 51% of the population 
was in need of therapy in 2012 according to the WHO report [1], although the Ministry of Health 
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reported a coverage of 80% for the same year [9]. With the new recommendations for ART initiation in 
the WHO 2013 guidelines, the proportion of PLHIV in need of ART increased to 90% in 2012 [1]. The 
lost-of-follow-up during the first year was 14.2% between 2009- 2011 [18], but the retention in ART was 
only 53% in 2012, well below the goal of >85% set by the WHO [18, 19].  
 
Consequently, the challenges in these two countries are currently different. Belgium, as other high-
income countries, is looking forward to decrease the number of new infections based on several 
prevention strategies such as the guarantee of free condoms and water-and/or silicon-based lubricants 
for commercial gay venues or high migrant population areas, education about prevention and 
reinforcement of the community stakeholders that work with migrants or other vulnerable populations, 
improvement of the access to syringes to reduce HIV transmission in IVDU, the availability of non-
occupational PEP, among other measures. Belgium has been working on a national plan against 
HIV/AIDS since 2012, in which one of the priorities is to support research to improve and extent existing 
data and to monitor if prevention strategies and care are improving the quality of life of PLHIV or the 
people who are at risk of HIV transmission. Other priorities include research on the feasibility of PrEP 
and TasP  [7].  
 
In contrast, low and middle-income countries still face the scaling-up of ART [1], where 28.6 million of 
people are in need of ART [15]. Therefore, the challenges are somehow different such as the 
elimination of MTCT, the decrease of Tuberculosis-related deaths among PLHIV, mobilization of 
financial resources for AIDS response, reinforcement of HIV health integration, elimination of gender 
inequality or stigma, and abolition of punitive laws [1]. Although one of the aims is to reduce HIV 
transmission by 50% by 2015, prevention strategies are generally associated with effective measures 
such as male circumcision, decrease of STD or condom use. TasP or PrEP are not yet recommended 
due to the lack of information about cost-effectiveness and the necessity to prioritize access to ART for 
the ones in need [20, 21]. Currently, research mainly focuses on monitoring heath care and prevention 
strategies. However, there is still limited information about the main drivers of the epidemic in Colombia. 
This information could guide the decision makers in defining the next steps in the national plan and in 
the research agenda.  
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6.2 MOLECULAR EPIDEMIOLOGY RESEARCH IN COLOMBIA AND 
BELGIUM 
6.2.1 PERFORMANCE OF SUBTYPING TOOLS 
In chapter 2, subtyping tools were evaluated for their performance in the classification of viral strains, 
an important step in molecular epidemiology research and a necessary pre-processing step in the study 
of viral transmission networks or viral spread. The REGA subtyping tool was designed based on the 
phylogenetic definition of subtypes [22] by including NJ methods and bootscanning methods [23-25]. 
However, REGAv2 presented several limitations such as the high number of unassigned sequences 
and the inclusion of CRFs only up to CRF14_BG, when more than 58 CRFs had been identified until 
2013. Therefore, REGAv3 was developed with the aim to decrease the number of unassigned 
sequences by including reference sequences for the more recently identified CRFs and by introducing 
some tags to alert the user for possible recombinants, such as the assignments “-like or potential 
recombinant”.  In addition, other co-authors designed a more fashionable interface to show the 
summary of a given dataset in terms of frequency of subtypes, characteristics of any sequence (length, 
support, position in the genome), the phylogenetic statistics (average bootstrap support of the NJ trees, 
the average bootscan support) and the exact recombination breakpoints according to the bootscan 
analysis (available at http://dbpartners.stanford.edu:8080/RegaSubtyping/stanford-hiv/typingtool/).  
 
We compared REGAv3 with the most commonly used subtyping tools that are based on similarity, 
statistical or phylogenetic methods. We took two large datasets from a public database with full-length 
genomes and a clinical database from a country with high subtype variability with the aim to retrieve the 
highest number of non-B subtypes, which is a frequent caveat of this type of studies [26, 27]. Even 
though we used those datasets, we only obtained representative number of sequences for pure 
subtypes such as A, B, C, D, F, G and CRFs such as CRF01_AE and CRF02_AG. These subtypes are 
responsible for 89% of the infections in the global HIV-1 epidemic [28]. Subtype C and subtype B were 
identified with a sensitivity of more than 96% by Stanford, phylogenetic and statistical-based tools. 
These subtypes are commonly found in Oceania, India, East-Southern Africa and the Western world, 
respectively [28]. This suggests that subtype classifications would give similar results, independent from 
the subtyping tool used in the study of an epidemic. Although these two subtypes together do represent 
approximately 60% of the HIV-1 pandemic, several local epidemics are often characterized with 
completely different genetic forms. Indeed, several reports have shown the increase in non-B subtypes 
and recombinants because of migration and mixing of the local strains [29-34]. Since global traveling is 
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increasing, it is not surprising that some HIV subtypes may disappear or new subtypes may arise in a 
local epidemic [35]. In this respect, the subtyping tools performed differently in the identification of non-
B subtypes. In general, subtyping tools like COMET, jpHMM, REGAv3 and SCUEAL (in alphabetical 
order) had sensitivity higher than 90% for other pure subtypes, whereas only COMET and REGAv3 had 
comparable sensitivity values for some CRFs such as CRF01_AE that is prevalent in South and East 
Asia and CRF02_AG that is prevalent in West Africa [28].  
 
The election of a subtyping tool depends on its performance, the technical facilities at the lab and the 
goal of the specific analysis e.g. evaluation of recombination, surveillance purposes and clinical follow-
up. In chapter 2, the performance and operational characteristics of automated subtyping tools were 
studied and summarized. We also provided some recommendations to guide people who need to 
classify HIV strains but are not familiar with the specific technicalities, such as the use of at least two 
subtyping tools for surveillance purposes due to the variable performance of subtyping tools for non-B 
and non-C subtypes. It is important to note this scheme has not been validated, but our results suggest 
this would be a more correct approach for the evaluation of viral diversity than to only rely on the 
assignment of one subtyping tool. For instance, we found 98% of concordance between COMET, 
REGAv3 and the MPhy in the LANL dataset (data no shown), these tools being the ones with a high 
sensitivity for most subtypes. In addition, we used this strategy in subsequent chapters of this thesis. In 
Chapter 5, 719 out of 778 (92.4%) sequences analyzed were concordant between COMET and 
REGAv3 (data no shown) in a cohort characterized by a high number of non-B subtypes [36]. The 
discordant sequences were mainly URFs that accounted for 4.8% of the total population.  
 6.2.2 VIRAL DIVERSITY AND MOBILITY OF SUBTYPE B 
In chapter 3, we studied the viral diversity and spread of subtypes in Colombia because nationwide 
studies were not yet available and it was unknown if other non-B subtypes had become predominant in 
recent years given the increase of recombinants BF or other non-B in neighboring countries such as 
Brazil or Venezuela (see chapter4) [37-40]. Two previous studies included 115 patients from Medellin 
using pol sequences and 237 patients from Bogotá using Heteroduplex mobility assay, both performed 
between 2001 and 2002 [41, 42]. A later report included 35 patients from Barranquilla using env 
C2V3C3 region sequences (Figure 1.7) [43]. All studies revealed the predominance of subtype B. Also 
in our study, 99.8% of the sequences were subtype B despite the high migration and internal 
displacement in Colombia [44, 45]. Possible explanations are that infections are mainly transmitted 
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locally and migration occurs between countries where subtype B has been frequent such as United 
States, Spain and Venezuela [28, 45]. 
 
In this respect, Belgium, as well Austria and Luxembourg, were the main sinks for subtype B in Europe 
[46]. On the other hand, little was yet known about the dispersal of subtype B in Colombia. Therefore, 
we tried to investigate this in chapter 3 and we showed that the dispersal of subtype B occurred by 
multiple introductions in the early 1980’s. This is later than the estimates for neighboring countries such 
as Central America or Brazil [47, 48], but it is consistent with the first AIDS case in Colombia [49]. 
Multiple introductions were observed between Spain and Bogotá, the capital of Colombia, which also 
acted as the main hub of the epidemic. Despite the high displacement in the country, Bogotá exported 
most of the infections to other regions. This suggests that tourism did play a role in the spread of HIV 
within the country. However, we lacked the transmission group and other important demographic 
information that could have informed us about the dynamics of the epidemic. Another possible bias in 
our sample was the inclusion of mainly treated patients who were in follow-up, whereas internally 
displaced people could have been underestimated in this analysis due to their irregular follow-up.  
Further research should be done to investigate to what extent the role of internal displacement or 
tourism is. 
 
In chapter 5, the viral diversity within Belgium was also evaluated to a limited extent. Previous studies 
found 52% subtype B infections, followed by approximately 11% subtype A and C infections among 281 
patients at the AIDS Reference Centers from Brussels and Leuven, and an increase of non-B subtypes 
from zero to 57% from 1983 to 2001 [36]. From 2003 to 2006, all the eight Belgian AIDS Reference 
Centers collaborated in the Pan-European SPREAD study, that detected the following proportions of 
subtypes: B (58%), CRF02_AG (11%), A (10%), C or URFs (8%), G (3%) and others (2%) (Figure 1.7). 
This study also suggested based upon the survey questionnaire that half of the non-B subtypes 
originated from Sub-Saharan Africa; however trends and more detailed phylogenetic analyses were not 
done [50]. In our study, we also found that half of the infections were caused by subtype B, followed by 
CRF02_AG and subtype C with approximately 10%. We also checked for trends of the most frequent 
subtypes, and this revealed that the number of subtype B infections was stable over time, in contrast to 
other countries in Europe such as France, Sweden, and UK [29, 30, 34]. These countries displayed an 
increase in non-B subtypes mainly related to immigrants originating from high-prevalent countries. This 
pattern seems to be expanding to other countries like Germany and UK, where MSM seem to play a 
role in the spread of non-B subtypes [32, 51]. In our Leuven cohort, 81% of the patients infected with 
subtype B originated from Belgium, and the remaining originated from Northern, Southern and Western 
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Europe (9.6%) whereas 2% subtype B infections originated from high prevalence countries (data no 
shown). Likewise, 51.6% of the individuals infected with non-B subtypes originated from sub-Saharan 
Africa, followed by 33.6% individuals originated from Belgium and 6.2% from Southeast Asia. Although, 
these findings could suggest the intermixing of the epidemic as is occurring in other settings [33, 52, 
53], more detailed analyses will be required to address this matter.  
 
We also observed an association of subtype B with TDR that could be related with the predominance of 
subtype B in Western Europe, a region with a history of suboptimal ART exposure [50]. It is important to 
bear in mind that there is no evidence that subtypes could influence the frequency of TDR, nor that the 
methodology used could impact the measurement as the SDRM list has already excluded the different 
polymorphisms present in non-B subtypes [54]. Therefore, to better understand the identification of 
subtype B as the main factor associated with TDR, our analysis was complemented with Bayesian 
network analysis to evaluate dependencies. We found that male gender was the main factor associated 
with TDR with low support, and gender was related to MSM and Belgian origin with 100 bootstrap 
support. The association of subtype and gender was also described in a pan-European study, where 
gender was associated with subtype via risk factor [31]. 
 6.2.3 TRANSMITTED DRUG RESISTANCE 
In chapter 4, we aimed to find any available data on the level and patterns of TDR in Colombia for the 
evaluation of the efficacy of standard first-line regimens used in the country, as patients do not receive 
baseline drug resistance testing [14]. One survey showed 5.8% of resistance in 2006 based upon the 
Stanford algorithm [55], and we found similar values in our systematic review where we interpreted all 
available sequences in databases at that time using the WHO SDRM 2009 list [56]. Recently, another 
survey in Cali showed 6.6% of resistance between 2008 and 2010 using the same list [57]. According to 
these results, a strict monitoring of TDR should be performed soon in this city. However, baseline drug 
resistance testing cannot yet be recommended because the sampling in all surveys performed up until 
now is not representative for the entire country. Further work is required to establish if this measure 
would be cost-effective and feasible given the actual statistics about monitoring and people in need of 
ART [1, 9, 18]. 
 
In low-middle-income countries the scaling-up of ART is still a priority, but the surveillance of TDR 
should be done if ART has been available for more than 3 years and TDR testing should be considered 
according to the detected TDR prevalence [58]. In general, routine resistance testing is not available for 
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naive patients, and most of the national guidelines in LAC only recommend it when virological failure 
occurs [59]. However, the key questions are still how well PLHIV are monitored and how the TDR 
results of surveillance studies reflect the actual TDR prevalence and trends in the last years. The EWIs 
were developed to answer the first question but unfortunately, the results were not encouraging. The 
low follow-up and retention in care indicators suggested a potential risk for increased drug resistance in 
sub-Saharan Africa, Caribbean and Central America [60-62]. In Latin America, there were conflicting 
results due to differences in the design of the studies, such as the use of different lists for the 
evaluation of TDR and inclusion criteria’s. In addition, limited information on EWIs was available in 
South America as Colombia was the only country for which all relevant data was available [63]. In our 
systematic review, we found overall 7.7% TDR in Latin America and  a stable trend [54]. It should be 
pointed out that this trend was in agreement two other systematic reviews that were released in the 
same time period [64, 65]. The strength of our analysis was the exclusive focus on all countries in Latin 
America and Caribbean, the stringent recalculation of the prevalence values based on sequences and 
tables, and the highlight of studies that were performed according to WHO criteria [58]. Using the 5% 
threshold recommended by WHO, more extensive TDR surveillance should be performed in Mexico, 
Brazil, and Venezuela [37, 66-68]. In some regions within Brazil and Venezuela, there was even an  
increase in TDR above 10%, suggesting the need for routine baseline resistance testing. New 
publications confirmed the increase of TDR in Brazil, but for Venezuela no recent data is available that 
could confirm the increase [69, 70]. Nevertheless, the new Brazilian guidelines interpreted the surveys 
with caution due to the heterogeneity in the methodology used in the past studies and therefore need to 
perform more representative studies for the entire country [71]. Meanwhile, the indications for baseline 
resistance testing are pregnancy and newly infected individuals with a partner under ART. Contrary to 
expectations, the strategy “test and treat” or TasP has been implemented, which is a big step for an 
upper-middle income country [71]. 
 
In chapter 5, we studied the Leuven cohort, where baseline drug resistance testing for naive patients 
was already a routine procedure at the end of the 90’s, and where the retrospective evaluation of left-
over plasma samples for viral load were used to guide clinicians who wanted to start therapy at a later 
date. We found a stable TDR trend in the overall, NRTI and PI resistance. This was in agreement to 
previous reports on Europe and Belgium [50, 72, 73]. This could be related to the prescribing practices 
of more potent ART regimens, individualization of treatment using resistance testing, and the strict 
follow-up of viral load and adherence. However, an up-and-down trend of NNRTI was observed with a 
peak in 2008. This down trend was not observed in the SPREAD study that included newly diagnosed 
patients from 22 European countries until 2010, and in which a peak in NNRTI TDR was observed in 
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similar period for which the cause has not been investigated [72, 74]. Our analyses excluded that 
immigrants were responsible of this peak. It coincided with a similar peak in the prevalence of K103N in 
MSM originating from Belgium and not any TDR trend in Sub-Saharan immigrants was observed. Our 
analysis also excluded the contribution of possible local transmission clusters to the NRTI trend. In this 
analysis, we used sequences of the entire HIV population followed at the ARC in Leuven and several 
controls from Belgium and other European countries. However, it is important to note that individuals 
unaware of their serostatus or sampled in other regions could have been part of an unidentified cluster, 
which is a common limitation in cluster analyses [75, 76]. Nevertheless, the ongoing transmission of the 
K103N mutation was observed in some patients in Gent [77] and the region of Namur, the capital of the 
province Namur and Wallonia, where a cluster of 29 individuals mainly naive, MSM and originated from 
Belgium was observed. 22 cases of them had viruses carrying the K103N mutation, but none of our 
sequences was part of this cluster and none of our clusters had that size [78]. These findings highlight 
the different dynamics within the HIV epidemic, even within countries.  
  
The search for target populations, in which focused routine resistance testing or target prevention 
strategies could be performed, has drawn the attention in recent reports [79-87]. Given the complete 
data of the AIDS Reference Center, we performed an exhaustive analysis of transmission clusters and 
associated factors. We found that 42% of the TDR patients were involved in transmission clusters and 
mainly associated with subtype B (13 clusters), 7 of them with at least one individual originated from or 
sampled in other countries. The spread of TDR among non-B subtypes was limited and mainly 
circumscribed to pairs (3 pairs), all of them included at least one individual originating from or sampled 
in other country. As expected, subtype B was the factor associated with transmission clusters, but 
Bayesian analyses showed the dependency of this variable with MSM risk factor and Belgian origin. 
Therefore, the Belgian MSM population seems to play a central role in the spread of TDR, but the non-
significance of these variables in the multivariate and Bayesian analyses limit our conclusions. 
Moreover, these results cannot be extrapolated to the entire Belgian epidemic due to the higher 
proportion of MSM and Belgian people in our cohort compared to the national cohort. Ultimately, our 
study showed the importance of baseline drug resistance testing and the retrospective evaluation of the 
impact on health care. For instance, 83% of the patients with TDR achieved nevertheless undetectable 
viral load, and none of the treated patients were involved in the local spread of TDR as indicated by the 
phylogenetic analysis. In addition, if baseline resistance testing had not been performed, half of the 
TDR patients would have received a suboptimal regimen. These findings support the impact of 
genotyping and the proposal of some researches to use it in low-middle-income countries [88]. 
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6.3 PERSPECTIVES 
6.3.1 PERSPECTIVES IN THE TWO LOCAL EPIDEMICS 
This thesis constitutes the first step in the analysis of the two HIV epidemics here described, with the 
aim to formulate recommendations for public health policies, with TasP being one of the promising 
strategies thanks to the availability of better and tolerable regimens, the effect of HIV on chronic 
endothelial inflammation and the impact on the prevention of new infections according to the HPTN 052 
trial [2]. We already achieved a complete view on TDR and the contribution of transmission clusters in 
Leuven, Belgium. However, several questions remain. For instance, how transmission clusters, 
irrespective of the presence of TDR, contribute to the spread of HIV in Leuven and Belgium: does the 
epidemic have super-transmitters or is transmission mainly related to small and local clusters, are 
mainly recently infected or chronically infected individuals involved, are these patients already 
diagnosed or engaged in care at the time of transmission, are migrants participating in the viral spread, 
are the infections mainly acquired in Belgium or are they imported, is the migrant epidemic intermixed 
with the local Belgian epidemic, and what are the demographic and clinical characteristics of these 
patients. These questions are currently being analyzed in the Leuven cohort using phylogenetic 
analyses, but this analysis should be enlarged to the country level. For this, the participation of all ARC 
and ARL are needed and plans are made to hopefully perform this in the near future within the 
framework of the Belgium Research on AIDS and HIV Consortium (BREACH) (available at 
http://www.breach-hiv.be/). To complete these studies, the next steps should ideally  include behavioral 
data such as condom use, substance use, serosorting, concurrency, sexual mixing [89]; as well as the 
engagement in care and the possible barriers to access health care. Following this, mathematical 
models could be developed based on these parameters to predict how the epidemic is going to evolve 
and what the impact of each prevention strategy could be [90].  Finally, cost-effectiveness analyses will 
be needed to evaluate if particular prevention strategies should be implemented at country level [91].  
 
Regarding the Colombian epidemic, some other priorities should be first addressed before similar 
research can be carried out. The first step is to improve the quantity and quality of the HIV database 
with the inclusion of as much demographic, clinical and laboratory data and to complete it with tools that 
help the management of sequences in clinical practice, such as is possible with Rega DB [92]. Then the 
focus should be on the basic characterization of the epidemic in terms of the health care cascade, such 
as possible barriers to HIV diagnosis and the characterization of the population with late diagnosis, 
retention in care, therapy adherence and suppression of viral load. The surveillance of TDR should be 
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also in the list of priorities according to the WHO recommendations [93] and the result of our systematic 
review. However, the surveillance of secondary resistance may be useful to evaluate if multiple 
resistance is disappearing as in high-income countries and might be more readily achievable as 
resistance testing is more commonly performed in failing patients [94-96]. Finally, behavioral studies 
can complement the description of the epidemic and evaluate how other strategies such as condom 
use can be increased to tackle the HIV epidemic.  
 6.3.2 GENERAL CHALLENGES IN THE DYNAMICS OF THE HIV EPIDEMIC 
Although in Europe resistance remains stable and several therapeutic alternatives are available [72, 73, 
94-96], resistance still constitutes a threat in low-middle-income countries where around 10 million of 
people are currently receiving ART [88]. Several reports have shown a concomitant rise in resistance in 
low income countries [65, 97, 98]. The inability to perform viral load in most of the centers, the 
difficulties in the integration of monitoring services, the lack of trained health-care personal and limited 
access and options for first-line therapies among other factors have contributed to the incredible profile 
of resistance in some African settings. On-going administration of virological failing therapies have 
impaired options for second line therapies as no other alternatives are yet available in these settings 
[99]. This problem in low-middle income countries will probably be transferred to high-income countries 
due to tourism and migration [88]. Several stakeholders have called the attention to public health 
entities to tackle this situation, but up to now the first measure was the compulsory implementation of 
viral load in these settings, the continuous surveillance of EWIs and the periodic performance of drug 
resistance surveys [15, 19, 93]. Therefore, a global challenge is the set-up of complete health-care 
facilities to monitor therapy and response in low-middle-income countries and not only to prioritize the 
scaling-up of ART.  
 
The monitoring of the health care cascade in LAC countries constitutes a priority. For instance, 
diagnosis and linkage to care should be improved given the frequency of late presenters ranging from 
56% in Argentina to 91% in Haiti ZKHQWKHGHILQLWLRQRI&'FRXQW 200 cell/mm at baseline or AIDS-
defining illnesses prior to or at ART initiation is used [100-102]. Moreover, the low retention in care and 
other EWIs suggest that the surveillance of resistance should be prioritized [61, 63]. According to our 
studies, the prevalence of TDR was still stable in LAC and the pattern of mutations was relatively 
similar to other high-income countries. However, some limited data suggest an increase and therefore, 
surveillance of TDR should be more profoundly monitored to enable the implementation of adequate 
 162 | 
 
 The Dynamics of Local HIV-1 Epidemics 
measures if needed. Notorious improvements in TDR surveys have been observed in African and 
Caribbean countries [20], albeit this improvement was not observed in some Central American and 
Andean region countries. Finally, studies in vulnerable populations or populations characterized with a 
high HIV prevalence should be encouraged. For instance, MSM have a  33.3 times higher risk of being 
infected with HIV [103, 104], vulnerable population such as females [105, 106], seasonal immigrants 
like the bateyes in Dominican Republic (Haitian descendents working in sugar canes); ethnic groups 
such as the Mayans in Guatemala, other several indigenous or rural communities in the Andean Region 
and, the Garifunas (Nigerian descendents) in Honduras or other countries in Central America are at 
socio-economical risk [107]. It is worth mentioning that the latter group may have a higher level of TDR 
than the general population in Honduras, as indicated by  a small study [108]. 
 
A lot of resources are devoted to study resistance but there are still some improvements to make. In 
terms of TDR, the SDRM list will be updated soon [109]. In this new version, some controversial 
mutations like the 46IL (also discussed in our studies) and 85V (was present in 1.3% of the cases in the 
Leuven cohort and none of the sequences in the LAC analysis) will be excluded because they occur  as 
a polymorphisms, whereas other RT or PI mutations should be included [109]. On the long-term, a 
similar effort for the assessment of INI TDR should be done as more and more patients in high-income 
countries will be treated with this new drug class. These drugs have excellent tolerance and with the 
new data on dolutegravir, this latter drug will be part of many first-line regimens. Additionally, some 
authors are very optimistic about its use in prevention and ART simplification strategies [110, 111]. In 
general, the surveillance of TDR and acquired resistance should be continued and collaborative 
research is still needed to better understand the resistance profile of new drugs. In addition, NGS 
technologies are also opening a door to evaluate resistance against all drug classes in one test, and to 
understand viral evolution and drug resistance development in the context of viral protein interactions 
and to investigate the impact of minority variants on response [112-114].  
 
There are also methodological challenges for the near future. One of them is the rapid and accurate 
classification of subtypes of large datasets, IN, full-genome and NGS sequences. Automatic subtyping 
tools require continuous updates given the increasing number of recombinants in high-income 
countries, the intermixing of variants plus the scaling-up of facilities to perform resistance testing in low 
and middle-income countries. Special attention should go to their improvement in the correct 
assignment of non-B and non-C subtypes. Some subtyping tools would require the expansion of the 
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coverage up to full-length genome, given the increasing performance of drug resistance testing against 
INI in clinical practice and of next generation sequencing (NGS). Although NGS is not yet an alternative 
as Sanger sequencing in clinical practice, it is broadly used in studies investigating host-virus 
interactions, minority variants with drug resistance mutations and vaccines [115]. Another 
methodological challenge is the clear definition of transmission clusters as disagreements could 
influence the results and conclusions in prevention studies or clinical trials [116, 117]. In our research, 
we used several definitions to assess the impact of the thresholds in genetic distance on our results. 
However, it will be important to reach a consensus in this research field to enable the comparisons of 
different studies. Two groups have designed software to evaluate transmission clusters and our group 
is currently working on a similar script [118, 119]. This will facilitate us a flexible framework to compare 
different definitions of clusters and link the results with clinical data. Additionally, the directionality of 
transmission is still difficult to assess and is important information. At this moment, at least longitudinal 
testing or time-scaled phylogenies need to be performed to make some conclusions [117, 120]. Other 
needs for standardization in definitions to enable the comparison of  studies in different settings, are 
situated at the level of sequencing technology (Sanger sequencing or NGS), the region investigated 
(full-length genome, env or pol), the measurement of acute or early infection, sampling density, dealing 
with missing data [117].  
 
6.4 CONCLUSION 
In conclusion, we have described the viral diversity and TDR in the cohorts of Leuven, Belgium and 
Colombia. The study of viral diversity should preferentially be performed with COMET or REGAv3 
automated subtyping tools because their good performance and operational characteristics. However, 
the analysis of short sequences like PR requires a more extensive phylogenetic analysis. The TDR 
prevalence and viral diversity between 1998 and 2012 was stable in Leuven, although a parabolic trend 
for NNRTI resistance was observed. No specific population was significantly associated with TDR or 
the local spread of TDR, although MSM originating from Belgium do play a central role. The number of 
clusters with TDR patients and the number of chronically infected individuals involved suggest the need 
of a national survey to formulate public health policies in prevention of HIV transmission and promoting 
early diagnosis. On the other hand, LAC displayed also a stable TDR trend but the lack of data for 
Central America and Andean region emphasizes the need for TDR surveillance in these regions. 
Although the available data of Colombia showed a TDR prevalence around 6%, a national survey 
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according to the WHO guidelines should be considered as an imperative step in the research agenda. 
The viral diversity remained dominated by subtype B until 2007. Additional phylogenetic analyses 
suggested that Bogotá was the main hub of the epidemic, whereas other large cities such as Medellin 
and Cali were mainly sinks. These findings suggest that tourism plays a role in the spread of HIV, but 
further research will be needed to understand what are the populations involved in the spread of HIV at 
the country level.  This thesis shaded some light on the Leuven and Colombian epidemic, and some 
results could help to formulate effective prevention policies in the future.   
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dataset and used to perform Bayesian Phylogenetic analyses. The 10 most similar sequences 
to the Colombian sequences were retrieved from BLASTn.  The countries were grouped in regions 
to analyze the data. The location of sequences with unknown origin was estimated with Bayesian 
analyses and the results are in italics. *Additional Colombian sequences that were retrieved from 
BLASTn. Abbreviations: n: Number of sequences, USA: United States of America, OAM: Orinoquía 
and Amazonas 
 
Region Country n (%) 
Se
qu
en
ce
s r
et
rie
ve
d 
by
 B
LA
ST
n 
Spain Spain 99 10.7 
North America Canada 21 2.3 
USA 19 2.0 
Southern Europe Croatia 1 0.1 
Greece 25 2.7 
Italy 3 0.3 
Portugal 3 0.3 
Serbia 8 0.9 
Slovenia 12 1.3 
Rest of Europe Belgium 2 0.2 
Denmark 1 0.1 
France 5 0.5 
Germany 3 0.3 
Ireland 13 1.4 
Luxembourg 4 0.4 
Norway 1 0.1 
Poland 18 1.9 
Romania 1 0.1 
Russia 2 0.2 
Switzerland 5 0.5 
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Region Country n (%) 
Ukraine 1 0.1 
United Kingdom 4 0.4 
Central and South 
America 
Costa Rica 2 0.2 
Honduras 2 0.2 
Mexico 29 3.1 
Venezuela 3 0.3 
Others Australia 2 0.2 
China 2 0.2 
Georgia 7 0.8 
Israel 4 0.4 
Japan 1 0.1 
South Africa 1 0.1 
Fi
na
l C
ol
om
bi
an
 d
at
as
et
 
Colombia Bogotá 269+18*   
Cali 76   
Caribbean 18+1*   
Coffee 42   
Medellin 63   
OAM 6   
Santander 25+3*   
Unknown 102   
Bogotá 73   
Cali 11   
Caribbean 1   
Coffee 6   
Medellin 8   
Santander 3   
Total 623 67.2 
 Total 927 100.0 
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Supplementary material Table 3.2. GenBank accession numbers, sampling locations and year for the 
dataset retrieved from BLASTn.  
GenBank Country Year 
 
GenBank Country Year 
AB078708 China 2002 
 
GQ399577 Poland 2003 
AB485638 USA 2009 
 
GQ399578 Spain 2004 
AB485640 USA 2009 
 
GQ399586 Slovenia 2004 
AB640503 Japan 2011 
 
GQ399587 Slovenia 2004 
AF301289 USA 2000 
 
GQ399588 Spain 2004 
AF395350 USA 2001 
 
GQ399595 Spain 2003 
AF514275 USA 2002 
 
GQ399609 Greece 2004 
AJ401737 Luxembourg 2000 
 
GQ399627 Denmark 2004 
AJ401788 Luxembourg 2000 
 
GQ399656 Slovenia 2004 
AJ401794 Luxembourg 2000 
 
GQ399658 Spain 2003 
AJ401800 Luxembourg 2000 
 
GQ399680 Greece 2004 
AJ971093 Slovenia 2005 
 
GQ399683 Ireland 2004 
AY013837 USA 2000 
 
GQ399704 Spain 2003 
AY016968 Venezuela 2000 
 
GQ399730 Spain 2003 
AY016973 Venezuela 2000 
 
GQ399745 Spain 2004 
AY030760 USA 2001 
 
GQ399747 Spain 2004 
AY064298 Australia 2001 
 
GQ399748 Spain 2003 
AY260915 CostaRica 2003 
 
GQ399753 Spain 2003 
AY260931 CostaRica 2003 
 
GQ399767 Spain 2004 
AY800676 USA 2004 
 
GQ399772 Ireland 2005 
AY801082 USA 2004 
 
GQ399773 Greece 2004 
AY801206 USA 2004 
 
GQ399782 Israel 2003 
DQ177224 Belgium 1989 
 
GQ399848 Spain 2004 
DQ177233 Belgium 1989 
 
GQ399860 Spain 2004 
DQ369203 Italy 2006 
 
GQ399871 Spain 2003 
DQ537049 USA 2006 
 
GQ399880 Spain 2004 
DQ823364 Ukraine 2006 
 
GQ399887 Spain 2004 
EF368737 Canada 2007 
 
GQ399892 Poland 2003 
EF368889 Canada 2007 
 
GQ399893 Spain 2004 
EF369020 Canada 2007 
 
GQ399899 Ireland 2003 
EF369068 Canada 2007 
 
GQ399900 Greece 2004 
EF549344 USA 2007 
 
GQ399909 Poland 2003 
EU091157 Canada 2007 
 
GQ399926 Poland 2003 
EU091158 Canada 2007 
 
GQ399936 Spain 2003 
EU091164 Canada 2007 
 
GQ399939 Spain 2003 
EU091165 Canada 2007 
 
GQ399963 Spain 2003 
EU091167 Canada 2007 
 
GQ399968 Greece 2004 
EU091171 Canada 2007 
 
GQ400005 Spain 2003 
EU091173 Canada 2007 
 
GQ400024 Spain 2003 
EU091174 Canada 2007 
 
GQ400029 Slovenia 2004 
EU091175 Canada 2007 
 
GQ400041 Spain 2003 
EU091176 Canada 2007 
 
GQ400058 Portugal 2003 
EU091178 Canada 2007 
 
GQ400088 Spain 2004 
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GenBank Country Year 
 
GenBank Country Year 
EU091179 Canada 2007 
 
GQ400098 Spain 2004 
EU091180 Canada 2007 
 
GQ400110 Spain 2004 
EU091181 Canada 2007 
 
GQ400116 Spain 2003 
EU345857 Russia 2007 
 
GQ400122 Spain 2004 
EU345913 Russia 2007 
 
GQ400123 Poland 2003 
EU346342 USA 2007 
 
GQ400140 Spain 2004 
EU375798 Canada 2008 
 
GQ400152 Poland 2003 
EU375799 Canada 2008 
 
GQ400153 Spain 2003 
EU375801 Canada 2008 
 
GQ400173 Greece 2004 
FJ030791 United Kingdom 2000 
 
GQ400176 Spain 2003 
FJ030794 United Kingdom 1998 
 
GQ400178 Spain 2003 
FJ376432 Georgia 2006 
 
GQ400182 Greece 2004 
FJ426617 Georgia 2006 
 
GQ400183 Spain 2003 
FJ426619 Georgia 2006 
 
GQ400197 Spain 2004 
FJ426620 Georgia 2007 
 
GQ400198 Poland 2003 
FJ426621 Georgia 2007 
 
GQ400199 Greece 2005 
FJ426624 Georgia 2007 
 
GQ400228 Poland 2003 
FJ426625 Georgia 2007 
 
GQ400246 Poland 2003 
FJ469749 USA 2002 
 
GQ400247 Spain 2003 
FJ659544 Venezuela 2005 
 
GQ400251 Spain 2003 
FJ983533 USA 2005 
 
GQ400256 Ireland 2004 
FN424301 Croatia 2009 
 
GQ400271 Spain 2004 
GQ207662 USA 2003 
 
GQ400274 Spain 2004 
GQ209719 USA 2002 
 
GQ400276 Ireland 2004 
GQ210679 USA 2005 
 
GQ400289 Spain 2004 
GQ251249 Italy 2009 
 
GQ400291 Spain 2003 
GQ251256 Italy 2009 
 
GQ400293 Spain 2004 
GQ398832 Spain 2004 
 
GQ400301 Spain 2003 
GQ398847 Spain 2004 
 
GQ400302 Spain 2003 
GQ398871 Spain 2004 
 
GQ400306 Greece 2004 
GQ398875 Spain 2004 
 
GQ400311 Greece 2004 
GQ398887 Greece 2004 
 
GQ400314 Greece 2004 
GQ398913 Spain 2003 
 
GQ400317 Ireland 2004 
GQ398929 Spain 2003 
 
GQ400358 Spain 2003 
GQ398930 Spain 2003 
 
GQ400416 Israel 2003 
GQ398951 Spain 2004 
 
GQ400417 Spain 2003 
GQ398963 Spain 2004 
 
GQ400435 Israel 2003 
GQ398974 Spain 2004 
 
GQ400440 Greece 2004 
GQ398980 Ireland 2004 
 
GQ400443 Poland 2003 
GQ398985 Spain 2003 
 
GQ400447 Spain 2003 
GQ398986 Spain 2003 
 
GQ400474 Slovenia 2004 
GQ398987 Greece 2004 
 
GQ400481 Spain 2004 
GQ398996 Spain 2004 
 
GQ400509 Spain 2004 
GQ398997 Poland 2003 
 
GQ400512 Poland 2003 
GQ399000 Greece 2005 
 
GQ400516 Spain 2003 
GQ399013 Spain 2003 
 
GQ400518 Spain 2003 
GQ399017 Spain 2004 
 
GQ400524 Slovenia 2005 
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GenBank Country Year 
 
GenBank Country Year 
GQ399021 Portugal 2003 
 
GQ400532 Slovenia 2004 
GQ399024 Ireland 2003 
 
GQ400568 Serbia 2004 
GQ399025 Spain 2004 
 
GQ400572 Germany 2004 
GQ399034 Spain 2004 
 
GQ400634 Serbia 2004 
GQ399045 Spain 2004 
 
GQ400712 Germany 2004 
GQ399049 Poland 2003 
 
GQ400727 Serbia 2004 
GQ399060 Spain 2004 
 
GQ400745 Germany 2004 
GQ399094 Poland 2003 
 
GQ400860 Serbia 2004 
GQ399096 Spain 2004 
 
GQ400943 Serbia 2004 
GQ399113 Slovenia 2004 
 
GQ400971 Serbia 2004 
GQ399119 Spain 2004 
 
GQ401005 Serbia 2004 
GQ399132 Ireland 2003 
 
GU264223 Spain 2006 
GQ399136 Greece 2004 
 
GU326139 Spain 2008 
GQ399139 Spain 2003 
 
GU344279 Switzerland 1997 
GQ399162 Greece 2004 
 
GU344280 Switzerland 1998 
GQ399173 Spain 2003 
 
GU344281 Switzerland 1998 
GQ399177 Spain 2003 
 
GU344283 Switzerland 1997 
GQ399193 Greece 2004 
 
GU344284 Switzerland 1998 
GQ399195 Poland 2003 
 
GU345179 China 2006 
GQ399198 Poland 2003 
 
GU382759 Mexico 2003 
GQ399201 Spain 2003 
 
GU382761 Mexico 2003 
GQ399212 Greece 2005 
 
GU382766 Mexico 2003 
GQ399215 Greece 2004 
 
GU382767 Mexico 2003 
GQ399216 Greece 2004 
 
GU382769 Mexico 2003 
GQ399218 Spain 2004 
 
GU382772 Mexico 2003 
GQ399220 Ireland 2003 
 
GU382776 Mexico 2003 
GQ399244 Slovenia 2004 
 
GU382778 Mexico 2003 
GQ399245 Slovenia 2004 
 
GU382781 Mexico 2003 
GQ399247 Poland 2003 
 
GU382783 Mexico 2003 
GQ399278 Spain 2004 
 
GU382785 Mexico 2003 
GQ399288 Greece 2005 
 
GU382786 Mexico 2003 
GQ399293 Serbia 2004 
 
GU382787 Mexico 2003 
GQ399299 Israel 2003 
 
GU382799 Mexico 2003 
GQ399300 Spain 2003 
 
GU382811 Mexico 2003 
GQ399313 Spain 2004 
 
GU382812 Mexico 2003 
GQ399339 Ireland 2003 
 
GU382813 Mexico 2003 
GQ399342 Spain 2004 
 
GU382814 Mexico 2003 
GQ399350 Poland 2003 
 
GU382819 Mexico 2003 
GQ399360 Greece 2005 
 
GU382823 Mexico 2003 
GQ399376 Spain 2004 
 
GU382824 Mexico 2003 
GQ399383 Spain 2004 
 
GU382827 Mexico 2003 
GQ399395 Slovenia 2004 
 
GU382830 Mexico 2002 
GQ399407 Greece 2004 
 
GU382831 Mexico 2003 
GQ399412 Spain 2004 
 
GU382832 Mexico 2003 
GQ399420 Spain 2004 
 
GU382833 Mexico 2002 
GQ399422 Ireland 2003 
 
GU382835 Mexico 2003 
GQ399424 Spain 2004 
 
GU382836 Mexico 2003 
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GenBank Country Year 
 
GenBank Country Year 
GQ399447 Spain 2004 
 
GU382847 Mexico 2002 
GQ399450 Spain 2004 
 
HM460461 Spain 2001 
GQ399453 Spain 2004 
 
JF895261 Australia 2011 
GQ399454 Norway 2004 
 
JN100967 United Kingdom 2007 
GQ399466 Spain 2004 
 
JN101340 United Kingdom 2006 
GQ399469 Spain 2003 
 
JN214965 USA 2008 
GQ399484 Spain 2004 
 
JN215231 Honduras 2005 
GQ399495 Spain 2004 
 
JN215307 Honduras 2005 
GQ399516 Ireland 2003 
 
JN638211 South Africa 2007 
GQ399531 Portugal 2003 
 
JN982147 Romania 2010 
GQ399539 Spain 2004 
 
JQ292205 France 2010 
GQ399541 Spain 2004 
 
JQ292207 France 2010 
GQ399548 Spain 2004 
 
JQ292208 France 2010 
GQ399564 Greece 2004 
 
JQ292209 France 2010 
GQ399568 Spain 2004 
 
JQ292677 France 2010 
 
 
Supplementary Material Table 3.3: Proportion of sequences per country or region according to 
the number of the closest sequences used in the BLASTn search. 
BLASTn Search 
10 sequences 30 sequences 50 sequences 
Country/Region n % Country/Region n % Country/ Region n % 
Spain 99 32.6 Spain 148 26.8 Spain 180 23.3 
North America 40 13.2 North America 92 16.6 North America 138 17.9 
Southern Europe 52 17.1 Southern Europe 85 15.4 Southern Europe 113 14.6 
Rest of Europe 60 19.7 Rest of Europe 84 15.2 Rest of Europe 141 18.2 
Central and South 
America 36 11.8 
Central and South 
America 82 14.8 
Central and South 
America 118 15.3 
Others 17 5.6 Others 62 11.2 Others 83 10.7 
 Total 304 100  Total 553 100  Total 773 100 
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Supplementary material Table 3.4: Sampling locations of the dataset retrieved from Los Alamos 
database (n=7931) named the LANL-Borders dataset. We took the available pol subtype B 
sequences up to 25 for each year and each country, except for the neighboring countries such as 
Brazil, Ecuador, Panama, Peru, and Venezuela. 
 
 
Country N Country N Country N 
Argentina 230 Gabon 2 Norway 46 
Austria 55 United Kingdom 275 Panama 134 
Australia 107 Georgia 3 Peru 248 
Belgium 52 Ghana 1 Philippines 10 
Burkina Faso 1 Greenland 72 Poland 52 
Bolivia 1 Greece 37 Portugal 70 
Brazil 2193 Guyana 6 Paraguay 3 
Bahamas 11 Hong Kong 3 Romania 69 
Belarus 7 Honduras 166 Russian Federation 86 
Belize 9 Haiti 16 Sudan 1 
Canada 186 Ireland 6 Sweden 131 
Central African Republic 1 India 1 Singapore 26 
Switzerland 284 Iran (Islamic Republic of) 13 Slovenia 65 
Chile 25 Italy 246 Slovakia 8 
China 187 Jamaica 30 Senegal 24 
Costa Rica 1 Japan 108 Suriname 5 
Cuba 109 Korea, Republic of (South) 305 El Salvador 17 
Cyprus 69 Luxembourg 20 Thailand 36 
Czech Republic 63 Latvia 18 Trinidad And Tobago 30 
Germany 182 Mali 1 Taiwan 272 
Denmark 107 Myanmar 1 Ukraine 5 
Dominican Republic 75 Mongolia 10 United States 426 
Ecuador 46 Mexico 48 Uruguay 6 
Spain 248 Malaysia 11 Venezuela 347 
Finland 31 Nigeria 2 Yemen 2 
France 77 Netherlands 30 South Africa 24 
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Supplementary material Table 3.5: Results of the Bayesian analyses on the BLASTn-Col 
dataset. The table shows the migration links within Colombia and with other regions or countries.  
Abbreviations: a The migration rate was identical in the three additional weighted datasets, BCI: 
Bayesian credible intervals 
 
 
Link Bayes 
Factor 
Markov Jumps 
Mean 95% BCI 
a. Bogotá, Colombia and Cali, Colombia >1000 a 44,5 33 - 54 
b. Bogotá, Colombia and Santander region, Colombia >1000 19,1 12 - 24 
c. Bogotá, Colombia and Medellín, Colombia >1000 a 37,6 25 - 49 
d. Bogotá, Colombia and Coffee region, Colombia >1000 17,6 9 - 27 
e. Spain and North America >1000 a 31,9 26 - 38 
f. Spain and West-East-Northern Europe >1000 a 40,6 35 - 46 
g. Spain and Southern Europe >1000 a 45,4 39 - 51 
h. Spain and Central-South America >1000 a 27,2 21 - 32 
i. Spain and Bogotá, Colombia >1000 a 89,4 74 - 105 
j. West-East-Northern Europe and Others >1000 a 1,4 1 - 3 
k. Spain and Others 605,1 a 6,9 4 - 10 
l. Spain and Medellín, Colombia 447,6 a 20,1 8 - 29 
m. Spain and Cali, Colombia 395,5 a 21,3 12 - 28 
n. Spain and Coffee region, Colombia 220,3 a 13,9 6 - 20 
o. Bogotá, Colombia and Caribbean region, Colombia 175,8 8,9 3 - 14 
p. Spain and Caribbean region, Colombia 80,3 a 10,0 4 - 15 
q. Bogotá, Colombia and Amazonas region, Colombia 45,4 2,6 0 - 5 
r. Bogotá, Colombia and Spain 40,9 5,1 0 - 10 
s. Others and West-East-Northern Europe 15,1 1,1 0 - 2 
t. Spain and Santander region, Colombia 10,5 4,7 0 - 9 
u. North America and West-East-Northern Europe 5,9 1,0 0 - 3 
v. Medellín, Colombia and Cali, Colombia 4,5 1,8 0 - 4 
w. Cali, Colombia and Santander region, Colombia 3,6 1,6 0 - 4 
x. Cali, Colombia and Bogotá, Colombia 3,5 0,7 0 - 3 
y. Others and Spain 3,2 0,2 0 - 1 
z. Medellín, Colombia and Bogotá, Colombia 3,1 1,5 0 - 5 
aa. Cali, Colombia and Amazonas region, Colombia 3,1 0,3 0 - 1 
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CHAPTER 4:  HIV-1 TRANSMITTED DRUG RESISTANCE IN LATIN 
AMERICA AND CARIBBEAN: WHAT DO WE KNOW? 
 
Supplementary material is available at  
http://www.aidsreviews.com/files/2012_14_4_256-267_SUPL.pdf 
x Supplementary material table 4.1: Characteristics of published studies on transmitted drug 
resistance in Latin America and Caribbean 
x Supplementary material table 4.2: Levels of transmitted drug resistance in Latin America and 
Caribbean (articles) 
x Supplementary material table 4.3: Levels of transmitted drug resistance in Latin America and 
Caribbean (abstracts) 
 
 
CHAPTER 5:  TRENDS AND PREDICTORS OF TDR AND CLUSTERS 
WITH TDR IN A LOCAL BELGIAN HIV-1 EPIDEMIC 
Supplementary material is available at  
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0101738#s5 
 
x Supplementary material Table 5.1: Characteristics of patients from the Leuven ND cohort 
and from patients involved in transmission clusters.  
x Supplementary Table 2: Impact of transmitted drug resistance (TDR) on clinical care. 
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Abstract
Latin America and the Caribbean countries have increased the scaling-up of antiretroviral treatment 
in the last years. The increase of transmitted drug resistance has been feared due to the worrisome 
indicators associated with the emergence of drug resistance and monitored by the World Health 
Organization (WHO). Consequently, our aim was to review all relevant studies on transmitted drug 
resistance in Latin America and the Caribbean countries, to analyze its levels, to identify the frequency 
of transmitted drug resistance mutations, and to put these results in the context of the local Latin 
American and Caribbean countries settings.
A systematic search of Spanish, Portuguese, and English literature was performed in databases and 
international conferences for the period June 1999 to May 2011. In addition, sequences were downloaded 
from the Los Alamos and Stanford databases and the transmitted drug resistance was reanalyzed 
according to the WHO Surveillance Drug Resistance Mutation list 2009. 
In total, 50 articles, 27 abstracts, and 1,922 patients were included. The resistance varied geographically, 
but most of the countries have reached the WHO threshold of 5% of resistance. According to the se-
quences available in public databases, the overall prevalence in Latin America and the Caribbean coun-
tries for the period 1996-2009 was 7.7% and by region it was 4.3% for the Caribbean, 3.9% for Mexico, 
9.4% for Brazil, 10.5% for the Andean region and 4.9% for the Southern Cone. For the last four investi-
gated years (2006-2009), the information was restricted to Brazilian and Venezuelan studies and revealed 
an overall transmitted drug resistance of 10%. Throughout the study period, limited information was 
available for the Caribbean and Central American countries. These findings support the need for develop-
ing comprehensive surveys of transmitted drug resistance in these regions. (AIDS Rev. 2012;14:256-67)
Corresponding author: Arley Gómez-López, arley.gomez@urosario.edu.co
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Introduction
The horizontal transmission of an HIV-1 strain that al-
ready displayed the reverse transcriptase (RT) mutation 
T215F/Y was first described in a homosexual man in 
19931. As it was feared that transmitted drug resis-
tance (TDR) could negatively impact the success of 
first-line antiretroviral therapy (ART), TDR was exten-
sively studied in resource-rich countries. Retrospective 
studies provided evidence that infection with drug-re-
sistant HIV-1 could also occur in other risk groups, and 
indicated increasing TDR levels and more extensive 
mutational patterns. As these studies were often small 
and based upon convenience sampling, prospective 
and representative population-based studies were set 
up in Europe, the USA and Canada to monitor the 
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extent and dynamics of TDR2-5. The high rates of TDR 
(overall prevalence 8-9%) resulted in the recommenda-
tion of standard genotypic drug resistance testing to 
guide ART selection in therapy naive patients6,7. Re-
cently, a large European multi-cohort study confirmed 
the importance of baseline drug resistance testing as 
patients with TDR and resistance to at least one pre-
scribed drug were three times as likely to virologically 
fail within one year8.
As access to ART has been implemented and scaled-
up in Latin-America and the Caribbean (LAC) since 
more than a decade, concerns about the emergence 
and spread of TDR strains in LAC exist. In general, the 
prevalence of TDR depends mainly on the time since 
ART implementation, the scale of ART coverage, and 
the overall virologic success of the prescribed regi-
mens. As the majority of HIV-1 patients in LAC started 
immediately on HAART, the rise in TDR was antici-
pated to be less extensive compared to resource-rich 
countries where sequential mono- and bitherapies 
were initially prescribed. Nevertheless, other factors 
unique to the particular setting of LAC could nega-
tively influence TDR rates. For instance, the wide-
spread use of standard first-line regimens based on 
8
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3. Cuba
4. Dominican Republic
5. Haiti
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7. Trinidad and Tobago
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 19. Bolivia
 20. Colombia
 21. Ecuador
 22. Peru
 23. Venezuela
 rSouthern Cone
 24. Argentina
 25. Chile
 26. Paraguay
 27. Uruguay
9. Belize
10. Costa Rica
11. El Salvador
12. Guatemala
13. Honduras
14. Nicaragua
15. Panama
Figure 1. HIV and transmitted drug resistance (TDR) prevalence in Latin America and the Caribbean. This region is divided geographi-
cally in Caribbean (seven countries), Mexico, Central America (seven countries) and South America (12 countries). The latter region is 
subdivided based upon geographical, social and economic characteristics: the Andean region and Southern Cone. The HIV prevalence 
according to the UNAIDS report is shown in a grayscale9. Although the overall HIV prevalence in Venezuela (hatched) was 0.75% in 2004, 
the country was not visualized in a grayscale as the prevalence in 2007 varied between 1.62 % in metropolitan areas and 0.08% in more 
rural areas90. The TDR prevalence values from studies that followed the eligibility criteria of WHO surveys are represented in black figures, 
otherwise they are represented in white. Adapted from UNAIDS report, 2010. 
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low genetic barrier non-nucleoside RT inhibitors (NNRTI) 
in the absence of drug resistance testing, together with 
limited access to second-line therapies, could promote 
emergence of drug resistance and its subsequent 
spread to new HIV-1 infections. The LAC is a hetero-
geneous region that differs extensively in geographi-
cal, social and economic characteristics that influence 
the HIV epidemiology and clinical care facilities. The 
HIV-1 burden varies considerably between and within 
the 27 countries belonging to LAC (Fig. 1). In 2009, 1.7 
million people were living with HIV-1 in LAC, of which 
one-third lived in Brazil, and HIV-1 prevalence values 
ranged between 0.1% in Cuba and 3.1% in Bahamas9. 
Brazil and Argentina took a leading role in the area by 
providing ART since 1991-1992 and by setting up na-
tional programs to provide free access to HAART, 
clinical care and laboratory monitoring (Fig. 2)10,11. 
Currently, Cuba, Chile and Nicaragua achieve global 
access, and Argentina, Brazil, Dominican Republic, 
Mexico and Uruguay are near to universal-coverage 
levels. However, in other LAC countries ART scale-up 
has been rather slow and only reached ART coverage 
between 20% in Bolivia and 66% in Paraguay with still 
limited access to laboratory testing and second-line 
regimens12.
The scope of this review was to collect all relevant 
studies on TDR in LAC, to analyze TDR levels, to iden-
tify the frequency of TDR mutations, and to put these 
results in the context of the local LAC settings.
Transmitted drug resistance surveillance 
and early warning indicators
Recently, the fear of TDR in developing countries 
reappeared due to the worrying reports of early warn-
ing indicators in Africa, the Caribbean and Central 
America13-16. Early warning indicators were developed 
by the WHO as indicators for the prevention of drug 
Venezuela
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Panama
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Dominican R.
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Dominican R.
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Chile
Uruguay
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Panama
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Uruguay
Paraguay
Guatemala
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Argentina
MexicoPeru
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0-19% 20-39% 40-59% 60-79% >80%
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Figure 2. Scaling-up of antiretroviral therapy (ART). The scaling-up of ART in 2003 and after the “3 by 5” strategy launched by WHO and 
UNAIDS. The “3 by 5” stands for treatment for three million HIV/AIDS patients in low-middle income countries by 2005 (see details in the 
UNAIDS report “3 by 5” and beyond)51. The regions are shown in a grayscale. Progress in access to treatment is shown as a shift to the 
right for a country, comparing 2003 (upper panel) with 2005 (lower panel). Countries are scaled as percentage (%) of those diagnosed 
and eligible for treatment that actually received treatment. The scale is shown in the middle panel. Data were not available for Barbados, 
Chile, Colombia, Costa Rica, Cuba, Ecuador, El Salvador and Haiti in 2003. Adapted from UNAIDS51. Trinidad T: Trinidad and Tobago; 
Dominican R: Dominican Republic.
N
o 
pa
rt
 o
f 
th
is
 p
ub
lic
at
io
n 
m
ay
 b
e 
re
pr
od
uc
ed
 o
r 
ph
ot
oc
op
yi
ng
 w
it
ho
ut
 t
he
 p
ri
or
 w
ri
tt
en
 p
er
m
is
si
on
 o
f 
th
e 
pu
bl
is
he
r. 
 
©
 P
er
m
an
ye
r 
Pu
bl
ic
at
io
ns
 2
01
2
Andrea-Clemencia Pineda-Peña, et al.: Transmitted Resistance in Latin America
259
resistance. They include ART prescribing practices, 
lost-to-follow-up, retention of first-line therapies, viral 
suppression and percentage of discontinued drug 
supplies13,16. These indicators alert earlier than pro-
spective surveys about the potential of increasing TDR 
rates.
Few studies have evaluated early warning indicators 
in LAC. Most of the studies were restricted to Brazil or 
to the seven AIDS programs from the CCASAnet Co-
hort17,18. Lost-to-follow-up was 6% overall, but large 
differences were observed between the different AIDS 
healthcare institutions (between 0.6% in Honduras to 
17% in Argentina)17. In El Salvador, Guatemala, Hon-
duras and Nicaragua, only seven of 13 sites accom-
plished the goal of ≤ 20% lost-to-follow-up, and 38 of 
55 sites in the Caribbean13,14. Low numbers of retention 
in first-line therapy were also observed in LAC, ranging 
from 16% in Honduras to 36% in Peru. Adverse events 
were the main cause in 14% of cases, predominantly 
linked to zidovudine (hematological toxicity in 7%) and 
nevirapine (skin rash in 3%)17,18.
To standardize TDR surveillance studies, the WHO 
has developed minimum recommendations for devel-
oping countries to enable comparison. Briefly, the 
criteria are: a minimum of 47 samples from small 
geographic areas within countries where ART has 
been available for more than three years to at least 
20% of the eligible HIV-1 population; HIV-1 infection 
should have been confirmed by laboratory criteria; 
participants should not have received any antiviral 
drug; and if female they should have been younger 
than 25 years at their first pregnancy. The inclusion 
of individuals with less than three years of HIV-1 infec-
tion or/and laboratory evidence of seroconversion or 
recent infection are required. If the information is ac-
cessible, demographic data like transmission risk 
group, clinical data like non-AIDS stage, or labora-
tory data like CD4 > 500 cells/ml, and no previous 
positive HIV-1 test are desirable19,20. In addition, the 
analysis of resistance should be done with the WHO 
Surveillance Drug Resistance Mutation (SDRM) list, 
which is updated periodically and excludes highly 
polymorphic positions21. Nevertheless, some SDRM 
do occur naturally in therapy naive individuals, which 
might inflate the estimates of TDR. The working group 
decided to retain these mutations within the list as 
stricter inclusion criteria would result in the omission 
of important drug resistance mutations and these par-
ticular mutations might have been the result of unre-
ported therapy exposure or truly TDR within the ther-
apy naive dataset21.
Epidemiology of transmitted drug resistance 
in Latin America and the Caribbean
Due to the low achievement of early warning indica-
tors in several LAC countries, available publications on 
TDR were reviewed using a systematic search strategy 
(Fig. 3; see Supplementary methods). Fifty articles and 
27 abstracts were retained (Tables 1, 2, 3). Approxi-
mately half of the studies originated from Brazil (53.2%, 
41/77). Ten studies were from Mexico (13%, 10/77), 
three from the Caribbean (3.9%, 3/77), four from Central 
America (5.2%, 4/77), 12 from the Southern Cone (15.6%, 
12/77) and seven (9.1%, 7/77) from the Andean region. 
Heterosexual contacts and men who have sex with 
men (MSM) were the most frequent transmission risk 
factors. Six studies were performed in specific patient 
populations such as blood donors22-24, female sex 
workers25, intravenous drug users26 and a combination 
of the latter two27.
Eleven studies used the Serological Testing Algo-
rithm for Recent HIV Seroconversion (STARHS)28 strat-
egy to differentiate between recent or chronic infec-
tion24,29-36. In five other studies, the distinction between 
recent and chronic infection was based upon previous 
negative serology test results 9-18 months before di-
agnosis date37-41. 
Although plasma was widely used as source mate-
rial, peripheral blood mononuclear cells (PBMC) and 
dried blood samples (DBS) were also used in nine and 
two studies, respectively. In most of the studies, in-
house methodologies were used to generate sequenc-
es, followed by Trugene® (seven) and ViroSeq® (six) 
(Table 1). The genotypic resistance interpretation algo-
rithm HIVdb was widely used for TDR analysis. Twenty-
one studies used the International AIDS Society list and 
19 studies the SDRM list. The version of the respective 
algorithms and lists were often not mentioned in the 
original publication.
The TDR levels as reported within the original publi-
cations are shown in tables 2 and 3. In summary, the 
prevalence of TDR ranged from 0 to 7.4% in the Carib-
bean for 1996-2003, from 2.8 to 18% in Mexico for 
2001-2010, from 0 to 11.6% in Central America for 
2002-2007, from 0 to 41% in Brazil for 1994-2010, from 
3 to 11% in the Andean Region for 1998-2007 and from 
2.5 to 18.8% in the Southern Cone for 1997-2009. 
Due to the heterogeneity of mutation lists used with-
in the original studies, TDR was reanalyzed using the 
SDRM list 2009 and resulted in TDR prevalence values 
between 0 and 8.3% in the Caribbean, 2.8 and 6.8% 
in Mexico, 0 and 7.5% in Central America, 1.3 and 
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20.3% in Brazil, 0 and 13% in the Andean region and 
from 1.6 to 12% in the Southern Cone. For comparison, 
values reported in 14 studies that followed the WHO 
surveillance criteria for TDR monitoring are also dis-
played in tables 1 and 222,24,29,31-33,35,36,38,39,41-46.
For 10 studies, the presence of TDR in each sample 
could be directly linked to the respective transmission 
risk factor25,31-33,37,41,44,47-49 and combining this data did 
not reveal any difference in TDR rate between hetero-
sexuals (37/522, 7.1%) and MSM (39/757, 5.2%). One 
study that solely sampled blood donors from São Paulo 
(Brazil) showed a TDR of 5.6% in 1998-2002 (19/341)22, 
whereas another study sampling in a broader geograph-
ical area revealed only a TDR of 1.3% in 2000-2004 
(1/74)24. The majority of patients included in studies 
where differentiation between recent and chronic infec-
tion was made were chronically infected and therefore 
differences in TDR between both groups could not be 
investigated. However, two studies did report a differen-
ce22,44. For three studies that included at least 50 recent 
infections, TDR values were 4% (3/74) in Chile38, 7.7% 
(4/52) in Argentina41, and 8.1% (17/210) in Brazil39.
To obtain a better understanding of the reported TDR 
rates, public databases were searched and 1,922 relevant 
HIV-1 sequences were retained for analysis (Fig. 4 A). 
Based upon automated subtyping50, HIV-1 subtype B 
was the most frequent subtype (65.7%, 1,262/1,922), 
followed by subtype C (14.4%, 276/1,922), BF recombi-
nants (8.7%, 168/1,922) and subtype F1 (4%, 77/1,922); 
the latter two mainly originated from Brazil and Argentina 
(BF: 99.4%, 167/168; F1: 98.7%, 76/77). The remaining 
genetic variants were circulating recombinant forms 
(CRF) such as CRF31_BC and CRF29_BF in Brazil, 
CRF_18cpx and CRF19_cpx in Cuba, and BD, BC and 
CF1 recombinants in Brazil and the Southern Cone.
In LAC, overall TDR prevalence was 7.7% (148/1,922; 
95% CI: 6.54-8.98) for the period from 1996 to 2009. 
The TDR by region was 4.3% in Caribbean for 1996-
2005 (8/186; 95% CI: 1.87-8.29), 3.9% in Mexico for 
2002-2005 (2/51; 95% CI: 1.87-8.29), 9.4% in Brazil for 
1998-2009 (99/1,056; 95% CI: 7.68-11.3), 10.5% in the 
Andean Region for 1999-2007 (15/142; 95% CI: 6.03-
16.82), and 4.9% in the Southern Cone for 1997-2005 
(24/487; 95% CI: 3.2-7.24). The NRTI resistance was 
13,664 citations
526 for further review
202 for full text revision and
extraction of data
34 duplicates or extended 
versions
125 excluded: MTCT or pediatric
studies, treated surveys, results
without differentiation between
treated and naive patients, use of LiPA
290 reviews, editorials, opinions, perspectives,
methods, experimental studies with animals,
cell lines or in vitro experiments, case reports,
modeling studies, developing clinical trials,
subtype-epidemiology studies without
analysis of TDR
50 articles and
27 abstracts included
13,138 excluded after
screening by title
Figure 3. Selection of studies on transmitted drug resistance (TDR). MTCT: Mother-to-child transmission; LiPA: Line Probe Assay.
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Country
Year
Total
96-97 98-99 00-01 02-03 04-05 06-07 08-09
BR – 10/66 23/244 6/68 14/213 33/337 13/128 99/1,056
AR 1/28 – 1/47 13/274 4/59 – – 19/408
VE – 2/31 – 0/12 – 8/62 – 10/105
CH – – 5/79 – – – – 5/79
TT – – 1/61 0/2 – – – 1/63
MX – – – 2/40 0/11 – – 2/51
CO – – 5/37 – – – – 5/37
CU – 3/25 – – – – – 3/25
BB 2/24 – – – – – – 2/24
DO – – – 1/12 0/5 – – 1/17
HT – – – – 0/16 – – 0/16
Other – – 1/40 – 0/1 – – 1/41
Total 3/52 15/122 36/508 22/408 18/305 41/399 13/128 148/1,922
20
15
10
5
25
B TDR in LAC
0
96-97 98-99 00-01 02-03 04-05 06-07 08-09
Prevalence
A
Figure 4. Prevalence of transmitted drug resistance (TDR) and mutations in Latin America and the Caribbean (LAC). See Supplementary 
methods. A: TDR prevalence in LAC. The number of sequences with evidence of TDR (numerator) and the total number of sequences 
included (denominator) divided according to country and sampling period. B: The prevalence of TDR (%) according to sampling period 
(black line) and the 95% confidence intervals (gray dashes). BR: Brazil; AR: Argentina; VE: Venezuela; CH: Chile; TT: Trinidad and Tobago; 
MX: Mexico; CO: Colombia; CU: Cuba; BB: Barbados; DO: Dominican Republic; HT: Haiti; Other: include other Caribbean islands.
4.4% (84/1,922; 95% CI: 3.54-5.38), NNRTI resistance 
was 2.3% (44/1,922; 95% CI: 1.71-3.06), and protease 
inhibitor (PI) resistance was 2.08% (40/1,922; 95% CI: 
1.53-2.82). Of the TDR cases, 5.4% (8/148) and 6.8% 
(10/148) had dual class resistance towards NRTI + NNRTI 
and NRTI + PI, respectively. Triple-class resistance 
was only detected in 0.7% (1/148) of the TDR cases. 
The overall TDR time trend was not significant, although 
two TDR peaks above 9% were observed for the periods 
1998-1999 and 2006-2007 (Fig. 4 B). The separate time 
trend analysis for the countries that contributed the 
majority of samples (Argentina and Brazil) were also 
not significant, neither were the trends for the individ-
ual drug classes (NRTI, NNRTI and PI).
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The 103N mutation was the most frequently observed 
mutation (29/148, 19.6%), followed by 215Y/F/rev 
(27/148, 18.2%) and 41L (26/148, 17.6%) (Fig. 4 C). 
Time trends analysis for the individual mutations 41L 
and 103N did not reveal any significant changes. The 
frequency of the most prevalent TDR mutations, such as 
41L, 184V, 103N, 46I/L, 82A/T and 90M, was compared 
with frequencies in the following studies in the USA, 
Canada and Europe2,3,5, but no significant differences 
were observed.
For 447 sequences, information was available on 
whether it concerned a recent or a chronic infection. 
However, the TDR rate did not differ significantly between 
recent (4/52, 7.7%) and chronic (41/395, 10.4%) infections. 
The prevalence of TDR did differ between sequences 
obtained from PBMC or plasma (1,712 sequences in-
cluded). The TDR was significantly higher in PBMC than 
plasma (33/285, 11.6%, vs. 98/1,427, 6.8%). However, 
the exclusion of PBMC samples did not significantly im-
pact the overall TDR (7%; 95% CI: 5.83-8.37). Other 
factors were not evaluated because of lack of information. 
Caribbean and Central America
According to the UNAIDS-WHO report, only a min-
imum ART coverage was implemented in the Carib-
bean region in 200151. However, coverage increased 
with extra funding to, for example, 20% in Haiti and 
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Figure 4. Prevalence of transmitted drug resistance (TDR) and mutations in Latin America and the Caribbean (LAC). See Supplementary 
methods. C: The number of sequences with SDRM mutations against nucleoside reverse transcriptase inhibitors (NRTI), non-nucleoside 
reverse transcriptase inhibitors (NNRTI) and protease inhibitors (PI).
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Dominican Republic in 2005 (Fig. 2)51. As a result, 
TDR ranged from 0% in several islands in 2000 to 
3.6% in Cuba in 200352-55. In Cuba there was already 
limited access to mono- and bitherapy before 2000, 
which could explain the level of TDR observed in 
2003 and its frequency of the NRTI drug class53. The 
overall TDR was estimated to be 4.3% and this was 
based upon reanalysis using the WHO TDR surveillance 
list of the collected sequences that were available in 
public databases and that were sampled in the time 
period 2000-200521.
From Central America, only fragmented data was 
available for two countries of this region. Indeed, only 
four publications and no sequences were retained after 
our search in public databases. A Panamanian study 
showed no TDR mutations in 2005, but NRTI and 
NNRTI TDR increased in a later report56,57. However, in 
the later study the exact sampling years were unspec-
ified. Reports that studied the TDR rate in Honduras 
showed a prevalence of 9.2% in 2002-2003 and a 
prevalence of 7% in 2004-200744,58. In Honduras and 
Panama, TDR was mainly restricted to NRTI and NNRTI 
drug classes, explained by the first-line therapy options 
in these countries44,57. 
Mexico
Reanalysis of Mexican sequences revealed TDR 
prevalence of 3.9% in the period 2002-2005. This result 
is substantially lower than the 16% reported by Escoto, 
et al.59, which might be partly explained by the algo-
rithm used to interpret drug resistance as it also in-
cluded polymorphisms. However, the TDR prevalence 
of 16% also differed from values obtained in other 
studies27,60, suggesting that the heterogeneity in ART 
availability between the different regions in Mexico 
might also impact TDR rates, although further research 
is warranted60. A recent comprehensive WHO-survey 
determined that Mexico has reached 6.8% of TDR for 
the period 2005-201045. This overall rate of TDR remained 
stable at the national level. However, decreasing trends 
for NNRTI and increasing trends for PI TDR were ob-
served. The frequency of mutations was 4.2% for NRTI 
(mainly type TAM I pathway), 1.9% for NNRTI (mostly 
103N), and 1.8% for PI (90M)45. 
Andean Region
In the Andean Region, the TDR prevalence was 
10.5% according to sequences sampled in the years 
1999, 2001, 2003, and 2007. However, these sequences 
were mainly collected in Venezuela46,61,62. A WHO 
survey performed in Venezuela reported at least 7% 
TDR according to the French ANRS algorithm, and this 
value rose to 12.9% when the SDRM list was used for 
interpretation46. In this study, drug resistance to all 
three drug classes was observed. The high TDR rates 
may be a consequence of the early introduction of ART 
as part of an AIDS National Program that was initiated 
in 2000 and mainly focused in the capital where the 
surveys were performed. Additionally, one report men-
tioned that patients receiving ART and displaying poor 
adherence or engagement with the healthcare system 
were an important source of HIV-1 transmission and 
TDR in Venezuela63. 
In that era, free access to ART was also guaranteed 
in other countries belonging to that region (Fig. 2). 
However, scaling-up moved slowly and, for example, in 
Colombia and Peru scale-up reached only 34 and 57%, 
respectively, in 2010 according to UNAIDS12. One Co-
lombian survey showed a TDR of 5.8% according to the 
HIVdb algorithm. The sequences from this study were 
not available for reanalysis with SDRM 2009, but other 
Colombian sequences that could be accessed did not 
reveal significant differences in TDR64. Two studies in 
Peru and Ecuador revealed low TDR rates of 3.3 and 
4.3%, respectively, in 2002-200332,65. However, it is 
worrying that all drug classes were affected in these 
countries. It is unknown whether polymorphisms might 
have affected these values as data was unavailable for 
reassessment with SDRM 2009.
Brazil 
The overall TDR rate in Brazil was investigated by 
reanalyzing 1,056 sequences that covered the period 
1998-2009 and this resulted in a value of 9.4%.
Before 1998, only a few small-sized studies were 
performed26,66. Barreto, et al.22 reported a TDR preva-
lence of 5.6% in 1998-2002 in a group of 341 blood 
donors, using a WHO survey approach. Noteworthy, 
this study was able to include 16% recent infections 
and they displayed a TDR rate of 12%, indicating high 
transmission rates of drug-resistant strains in São 
Paulo City at that particular time point22.
Several studies performed between 2000 and 2004, 
one WHO survey24, and one large nationwide study 
that sampled in 200167, showed that the TDR was be-
low 5%35,49,68-71. This apparent decrease of TDR could 
be related to the predominant inclusion of chronically 
infected individuals. However, other reports showed 
that TDR was still above 5%72-74. These discordances 
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are presumably due to the heterogeneity of the in-
cluded studies and the geographical variation of TDR.
Since 2005, the TDR rates remained above 5%, with 
7% in Curitiba and 8% in Porto Alegre and Santa Ca-
tarina30,36,67,72. Nationwide studies reported 5.2% TDR 
in 200775, 8.1% in 200839 and 12.3% in 2008-201043. 
The apparent nationwide increase of TDR in Brazil 
could not be confirmed in our analysis. This might be 
explained by the large variations in TDR between and 
within Brazilian regions that were included in our dataset. 
Since 2007, TDR per drug class remained stable, 
with overall values ranging between 5-15%, NNRTI 
3-6%, NRTI 2-6%, and PI 1-3%29,39,47,48,75. The last 
WHO survey showed resistance against NRTI in 7.6%, 
followed by 4% against NNRTI and PI43.
Southern Cone
As 84% of the Southern Cone sequences originated 
from Argentina, general conclusions cannot be made 
for this region. Nevertheless, their reanalysis using 
SDRM 2009 resulted in a TDR prevalence of 4.9% for 
the years 1996-2005. In Argentina, the number of stud-
ies and their respective sample size remained limited 
before 2000-200325,76. However, since 2003 several 
nationwide surveillance studies have been developed 
that reported TDR rates that ranged from 3.9% in 
2003-2005 to 8.4% in 2006-200831,33,41,77. The last re-
ported WHO survey showed a substantial level of 
resistance towards NNRTI (5.6%), NRTI (4.2%), and PI 
(3%)33. Another study that was performed in recently 
infected individuals between 2004 and 2009 also sup-
ported the 8% of TDR with predominance of NNRTI 
resistance78. Almost all Argentinean studies document-
ed TDR against the three common drug classes. In 
Chile, TDR was less extensive, with an overall TDR of 
6.2% in 2000-2005 that slightly decreased to 4% in 
2006-200838,79. In this country, TDR mutations were 
mainly restricted to NRTI and NNRTI. 
Transmitted drug resistance in Latin America 
and the Caribbean: What do we know?
This review showed a TDR of 7.7% in 1,922 therapy 
naive HIV-1 patients. However, the majority of sequenc-
es were obtained from Brazil, Argentina, Mexico, and 
Chile, countries that correspond to half of the people 
living with HIV-1 in LAC. This percentage is higher than 
for other developing countries80-82, but similar to the 
6.4% reported by the WATCH study that included seven 
studies since 2000-200622,41,61,66,68,76,80,83, and similar to 
TDR rates in Europe, Canada, and the USA2-5. Although 
no significant trend in TDR was observed in this ana-
lysis, two peaks were observed in 1998-1999 and 2006-
2007. These peaks overlapped, with a high inclusion 
of sequences from Brazil and Venezuela, countries 
characterized with the highest TDR rates in LAC.
Although the analysis has been standardized, imple-
menting the SDRM 2009 list for interpretation of drug 
resistance, we acknowledge the limitations of this 
study. The included studies differed, for example, in 
the intrinsic characteristics of the analyzed population 
(age, risk factor of transmission, geographical and so-
cioeconomic factors), design of the study (method of 
sampling, type of study, criteria or exclusion criteria), 
clinical characteristics (recent or chronic infection, im-
munological status, viral load), drug resistance testing 
(sample type, sequencing method, sequence quality, 
algorithm used for the analysis of mutations), ART-re-
lated factors in the treated population (mono- or bi-
therapy history, HAART scale-up, delay of start therapy, 
availability of new compounds, pharmacogenetics, 
toxicity, adherence problems, drug failure) and viral 
factors (subtype, fitness)84-86. For example, in one Bra-
zilian study 20% TDR was reported in PBMC samples34. 
However, PBMC testing is more apt to detect drug 
resistance mutations than plasma, and the intrinsic 
regional characteristics of the population might impede 
the generalization of these results34,87.
Although the MSM group is one of the main drivers 
of the LAC epidemic and they are 33.3 times more 
likely to be HIV-1 positive88, we did not find differences 
in the TDR rates between heterosexuals and MSM. 
More studies are necessary to understand the trends 
of TDR, especially in MSM because the risk of impris-
onment in some countries of the Caribbean and the 
stigma in LAC could hinder the accurate evaluation of 
this population, especially when TDR prevalence has 
been reported to range between 3.3% in Peru for 2002 
to 17% in Brazil for 201032,88,89. 
In regard to distribution of mutations, since NNRTI 
have been used widely in LAC as first-line therapy con-
sequently, the amino acid change in position 103 was 
the most frequent in the sequences analyzed and in 
the studies included (Fig. 4 C). The amino acid change 
215 and 41 were frequently found in this review. How-
ever, 184V was more frequently detected in this study 
than in European or North American reports, even 
though the difference was not statistically significant2-5. 
In general, similar patterns have been found in other 
developing countries but, in the resource-rich settings, 
NNRTI resistance seems to be stabilizing, probably 
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due to the changes in therapy prescriptions4,81. Over-
all, this review did not observe trends in particular drug 
resistance patterns in the analyzed sequences ob-
tained from LAC. 
Conclusions
The overall TDR prevalence in LAC was 7.7% for the 
period 1996-2009 and reached 10% in the last four 
investigated years when data was solely restricted to 
Brazil and Venezuela. Additionally, large geographical 
differences have been found. Although lack of informa-
tion for the Caribbean and Central America prevents 
us from drawing general conclusions, the reported 
TDR in Cuba and other Caribbean islands is still under 
the 5% WHO threshold. However, Honduras, Mexico 
and South American countries have passed the 5% 
threshold, with the exception of Chile. The limited in-
formation available for most of the countries should 
encourage the development of surveys for drug resis-
tance in newly infected people. 
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Trends and Predictors of Transmitted Drug Resistance
(TDR) and Clusters with TDR in a Local Belgian HIV-1
Epidemic
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Abstract
We aimed to study epidemic trends and predictors for transmitted drug resistance (TDR) in our region, its clinical impact
and its association with transmission clusters. We included 778 patients from the AIDS Reference Center in Leuven (Belgium)
diagnosed from 1998 to 2012. Resistance testing was performed using population-based sequencing and TDR was
estimated using the WHO-2009 surveillance list. Phylogenetic analysis was performed using maximum likelihood and
Bayesian techniques. The cohort was predominantly Belgian (58.4%), men who have sex with men (MSM) (42.8%), and
chronically infected (86.5%). The overall TDR prevalence was 9.6% (95% confidence interval (CI): 7.7–11.9), 6.5% (CI: 5.0–8.5)
for nucleoside reverse transcriptase inhibitors (NRTI), 2.2% (CI: 1.4–3.5) for non-NRTI (NNRTI), and 2.2% (CI: 1.4–3.5) for
protease inhibitors. A significant parabolic trend of NNRTI-TDR was found (p = 0.019). Factors significantly associated with
TDR in univariate analysis were male gender, Belgian origin, MSM, recent infection, transmission clusters and subtype B,
while multivariate and Bayesian network analysis singled out subtype B as the most predictive factor of TDR. Subtype B was
related with transmission clusters with TDR that included 42.6% of the TDR patients. Thanks to resistance testing, 83% of the
patients with TDR who started therapy had undetectable viral load whereas half of the patients would likely have received a
suboptimal therapy without this test. In conclusion, TDR remained stable and a NNRTI up-and-down trend was observed.
While the presence of clusters with TDR is worrying, we could not identify an independent, non-sequence based predictor
for TDR or transmission clusters with TDR that could help with guidelines or public health measures.
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Introduction
In recent years, the number of newly diagnosed HIV-1 patients
increased in Belgium [1] with a rate of 10.7 per 100,000
population in 2011, one of the highest rates in Europe [2].
Studies carried out in Europe and America highlighted the
important role of transmission networks in the spread of
transmitted drug resistance (TDR) [3–7]. TDR is a clinical and
public health issue because it can compromise the response to
antiretroviral therapy (ART) at the individual and population level
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[8]. Three nationwide studies were performed previously in
Belgium and reported a TDR prevalence of 29% (67/231; 95%
CI: 23.5–35.2) between 1995 and 1998 [9], 7.2% (6/83; 95% CI:
3.4–14.9) in 2000 [10] and 9.5% (27/285, 95% CI: 6.6–13.4)
between 2003 and 2006 [11]. However, due to differences in
methodology and the lack of a recent study, no up-to-date
information is yet available on TDR trends in Belgium.
Nevertheless, recent reports revealed the rapid onward transmis-
sion of an HIV-1 strain with K103N mutation [12] and the
involvement of transmission clusters (TCs) in approximately half of
patients with TDR [4] in a local HIV epidemic in Belgium.
Because other studies consistently showed regional differences
between the drivers of the HIV-1 epidemic [13,14], this study
aimed to characterize the temporal trend in TDR, the factors
associated with TDR including TCs and the clinical impact of
TDR for a period of 15 years in a regional epidemic, serviced by
the Leuven University Hospitals. The data included socio-
demographic, clinical and virological variables.
Materials and Methods
Ethics Statement
The research was conducted according to the Declaration of
Helsinki. Only patients for whom written informed consent was
obtained were included in this study, except patients enrolled in
care after 2009. In 2009, UZ Leuven implemented a generic ‘‘opt
out’’ system. Patients, who logged an objection to use their medical
data for research purposes, were not included in this study. The
protocol and this consent procedure were approved by the Ethical
Committee UZ Leuven (reference ML-8627, approval
B322201316521 S52637).
Study Population
We analysed data from the cohort of the AIDS Reference
Centre (ARC) in Leuven, the capital of the province of Flemish
Brabant (Belgium). The ARC in Leuven has been collecting
information since 1997 on treated HIV-1 patients and since 1999,
also for naive HIV-1 patients, including epidemiological, clinical
and virological data, related with the routine patient healthcare
services. The prospective clinical use of baseline genotypic drug
resistance testing was implemented in 1999 and stored plasma
samples from before 1999 were available to retrospectively
perform drug resistance testing upon clinician’s request. Therefore
HIV-1 sequences for drug naive patients were either prospectively
or retrospectively obtained from a sample taken at diagnosis,
except for 135 patients for whom a later pre-therapy sample was
used. The inclusion criteria for the analysis of TDR in the present
study were newly HIV-1 diagnosed between January 1998 and
December 2012, availability of a nucleotide sequence before
antiviral therapy initiation and age older than 18 years, and this
cohort was called the Leuven newly-diagnosed (ND) cohort for the
purpose of this study. The only exclusion criterion used was
documented vertical transmission. Recent infections were defined
using clinical and laboratory information such as p24 ELISA,
HIV-specific antibody ELISA, and Inno-Lia profile. Patients with
the following criteria were classified as recently infected: Fiebig
stages I-V [15] or no more than 6 months difference between the
last seronegative and first seropositive HIV-1 test [11], CD4 count
.200 cells/ml and absence of AIDS-defining conditions [16].
Drug Resistance Testing
Drug resistance testing was performed using population-based
Sanger sequencing of the pol gene fragment encoding protease
(PR) (amino acids 1 to 99) and 59-prime end of reverse
transcriptase (RT) (amino acids 1 to 320). Sequences were
obtained using the ViroSeq HIV-1 Genotyping System version 2
(Celera Diagnostics, Alameda, CA) or with an in-house method
upon failure of the commercial test [17]. Sequences with
associated information are available through Euresist (http://
www.euresist.org).
TDR mutations were defined according to the 2009 list of
surveillance drug resistance mutations from the World Health
Organization [18]. Therefore, the nucleotide sequences were
submitted to the Calibrated Population Resistance tool version 6.0
(http://cpr.stanford.edu/cpr.cgi). The clinical impact of genotypic
drug resistance on first line therapy was evaluated using Rega
algorithm [19] version 9.1.0 (available at http://rega.kuleuven.
be/cev/avd/software/rega-algorithm).
HIV-1 Subtyping
HIV-1 subtypes and circulating recombinant forms (CRF) were
determined using two HIV-1 subtyping tools, namely Rega version
3 (http://www.bioafrica.net/typing-v3/hiv) and COMET version
0.3 (http://comet.retrovirology.lu/) [20–22]. Sequences with
discordant results were analyzed using manual phylogenetic
analysis as was explained previously [22]. Briefly, maximum
likelihood (ML) phylogenetic trees under the GTR+C nucleotide
substitution model were built with RAxML [23] and recombina-
tion was verified using SimPlot [24].
Transmission Cluster Analysis
To investigate the factors associated with TDR and onward
transmission of TDR, cluster analyses were performed on the
Leuven ND cohort and four additional datasets as controls: (i) all
other pol sequences from the ARC in Leuven, including treated
HIV-1 patients, HIV-1 patients younger than 18 years old and
HIV-1 patients with vertical mode of transmission, (ii) HIV-1 pol
sequences obtained with the search term ‘‘Belgium’’ as sampling
country in the Los Alamos HIV sequence database (retrieved from
http://www.hiv.lanl.gov date in April 2013), (iii) HIV-1 pol
sequences from the collaborative study SPREAD that enrolled
patients with newly diagnosed HIV-1 infection from 22 European
countries including Belgium between 2002 and 2008 (see details of
the study in [25,26]), and (iv) the 30 most similar sequences to the
Leuven ND cohort (retrieved by Basic Local Alignment Search
Tool (BLAST) from http://blast.ncbi.nlm.nih.gov/Blast.cgi). The
quality control of the sequences was performed using the tool
available at http://www.hiv.lanl.gov/content/sequence/QC/ and
the criteria previously described [27]. Separate datasets were
constructed according to subtype. As an out-group, two or three
reference sequences of subtype D or B (retrieved from http://
www.hiv.lanl.gov) were included for B and non-B subtypes,
respectively. Sequences were aligned with Muscle as accessory
application in the program Mega version 5 [28,29]. Duplicates
were removed and the positions encoding surveillance drug
resistance mutations were excluded [18], which resulted in an
average final length of 950 nucleotides. In the resulting dataset, we
had 755 sequences for subtype A, 4225 for subtype B, 1036 for
subtype C, 202 for subtype F, 665 for subtype G, 440 for
CRF01_AE and 677 for CFR02_AG to perform phylogenetic
analyses on. Subtypes with frequencies less than 1% were not
included in TCs analyses.
A ML tree was inferred with the nucleotide substitution GTR+
C model and 1000 bootstrap replicates in RAxML [23]. TCs,
including pairs (two individuals) and larger clusters ($3 individ-
uals), were identified by using Cluster Picker (retrieved from
http://hiv.bio.ed.ac.uk/software.html) [30] with a genetic distance
less or equal than 0.06 substitutions per site and bootstrap support
Transmitted Drug Resistance in a Belgian Regional Epidemic
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$98%. A sensitivity analysis was performed to evaluate the effect
of other genetic distances (0.015, 0.030 and 0.045) [31–34].
The robustness of the identified TCs was evaluated using
Bayesian phylogenetic analysis. TCs and the closest control
sequences together with two reference sequences as an out-group
were selected and trees were constructed with BEAST v1.7.5 [35]
using a lognormal relaxed molecular clock with the SRD06 model
of nucleotide substitutions [36] and a Bayesian skyline coalescent
prior. The analyses were run in triplicate for 100 million states and
trees were sampled every 10000th states. Maximum clade
credibility trees (MCC) were summarized using TreeAnnotator
after 10% of the burn-in was discarded and visualized with
FigTree v.1.4 (available at http://tree.bio.ed.ac.uk). The TCs with
a Bayesian posterior probability of 1 were considered robust
enough and included in the analysis.
Finally, we defined TCs with TDR as any pair or cluster with
more than 3 patients that included at least one patient with TDR
from the Leuven ND cohort. The TCs with TDR with more than
3 individuals with similar TDR mutation profile can be suggestive
of onward transmission of TDR, they are specifically indicated as
TCs with TDR-OT.
Statistical Analysis
Prevalence of TDR and TDR mutations were calculated with a
95% Wilson score confidence interval (95% CI) on the basis of a
binomial distribution, and their trend was calculated by logistic
regression analysis. Socio-demographic, virological and clinical
variables that were significantly associated with TDR or with TCs
with TDR were evaluated in the Leuven cohort. Analyses were
performed on patients involved in TCs from the Leuven ND
cohort, and from Leuven ND cohort with the other four control
datasets. Categorical data were compared using the Chi-square
test, the Fisher’s exact test or regression techniques as appropriate.
The t-test or Mann–Whitney U test was used to compare
continuous data. The statistical significance was set at p,0.05
two-sided. All data were analysed using the statistical R software
version 2.13.1.
Bayesian Network Learning
Those factors that were found to be significantly associated with
TDR or TCs with TDR in univariate analysis were included in a
Bayesian network analysis. This is a probabilistic model that
describes statistical conditional dependencies between multiple
variables and was performed using the B-course software adapted
by Deforche et al [37]. In this analysis, the arcs were scored based
on the stability of the conditional dependency assessed with 100
non-parametric bootstrap replicates. The arcs with bootstrap over
75% were considered and depicted in the consensus network.
Results
General Characteristics Of The Study Population
778 of the 795 patients who were newly diagnosed with an HIV-
1 infection and who received a baseline genotypic drug resistance
test between January 1998 and December 2012 at University
Hospitals Leuven were included in the analysis, they are referred
to as the Leuven ND cohort. Two patients were excluded because
their risk group was vertical transmission. For 15 patients, the
baseline nucleotide sequence did not fulfill the preset quality
criteria: 14 sequences did not have the gene fragments encoding
PR or RT, and one sequence was excluded due to the presence of
more than four stop codons and indels. The included HIV-1
patients were between 18 and 78 years old and were predomi-
nantly male (73.7%), of Belgian origin (58.4%), chronically
infected (86.5%) with CDC stage 1 or 2 (67.0%) (Table 1).
Patients originating from Belgium were more frequently diagnosed
with a recent infection and displayed higher viral loads and CD4
counts (p,0.001). Of all included HIV-1 patients originated from
Belgium, 66.7% reported men who have sex with men (MSM) or
bisexual contacts as risk factor, whereas 22.5% reported hetero-
sexual contacts. In contrast, HIV-1 patients originating from Sub-
Saharan countries reported infection through heterosexual con-
tacts predominantly (79.3%). HIV-1 patients from Sub-Saharan
countries were more likely to be co-infected with hepatitis B than
patients from Belgium (60.9% vs. 34.8%; OR: 4.49, 95% CI 1.75–
12.15, p,0.001). There were 36 HIV-1 therapy-naive patients
who did not receive a baseline drug resistance test in this period.
This group included more patients of non-Belgian origin (75.0%)
and with CD4 count above 500 cells/mL (42.4%, 14/33).
The demographic characteristics of the Leuven ND cohort were
compared to the general HIV-1 population in Belgium, as
reported by the Belgian Scientific Institute of Public Health
(information until 2011) (available at www.wiv-isp.be) [1]. The
Leuven ND cohort contained more men (73.5% vs. 61.0%, p,
0.0002) and Belgians (58.4% vs. 40.6%, p,0.0002) and more
MSM (55.9% vs. 42.5%, p,0.0002). National data only covered
gender and country of origin from 1998 to 2011, and transmission
risk from 2005 to 2011.
Subtypes
52.2% of the HIV-1 patients were infected with subtype B,
followed by CRF02_AG (11.2%), subtype C (10.3%), subtype A
(7.7%), CRF01_AE (6.6%), subtype F (2.8%), subtype G (2.1%)
and unique recombinant forms (4.8%). Subtypes D, H, J,
CRF09_cpx, CRF12_BF, CRF13_cpx, CRF14_BG, CRF18_cpx,
CRF22_01A1, CRF37_cpx, and CRF45_cpx were each found in
less than 1%. Of the patients with a subtype B infection, 81.0%
were of Belgian origin and 71.9% were MSM. Whereas in patients
with non-B infections, 33.6% and 51.6% had a Belgian or sub-
Saharan origin, respectively, and 69.9% were infected through
heterosexual contacts, followed by bisexual/MSM risk factor
(13.2%).
Levels And Trends Of Transmitted Drug Resistance
The overall TDR prevalence was 9.6% (75/778; 95% CI 7.7–
11.9). The prevalence of TDR against nucleoside RT inhibitors
(NRTI) was 6.5% (51/778; 95% CI 5.0–8.5), against non-NRTI
(NNRTI) was 2.2% (17/778; 95% CI 1.4–3.5), and against
protease inhibitors (PI) 2.2% (17/778; 95% CI 1.4–3.5). In
recently infected individuals, the prevalence of overall TDR was
16.2% (17/105; 95% CI 10.4–24.4), significantly higher than in
patients with chronic or unknown duration of infection (8.6%, 58/
673; 95% CI 6.7–11.0). The prevalence of TDR by drug class also
varied in recently infected individuals. The prevalence of TDR
against NRTI was 12.4% (13/105; 95%CI 7.4–20.0), against
NNRTI 1.9% (2/105; 95%CI 0.5–6.7), and against PI 6.7% (7/
105; 95%CI 3.3–13.1). Dual resistance was detected in 10 patients
(1.3%): 3 displayed TDR against NRTI and NNRTI, 6 against
NRTI and PI and one against NNRTI and PI. The latter patient
with NNRTI and PI resistance and 4 out of 6 individuals with
NRTI and PI resistance were recently infected patients (5/105;
4.8%). No triple class resistance was observed.
The majority of the 75 TDR patients displayed one single
mutation (70.7%), mainly related to NRTI (58.5%) and NNRTI
resistance (24.5%). The revertants at RT position 215 were the
most prevalent (44%), followed by M41L (18.7%), K103N
(17.3%), L210W (10.7%), K219Q (10.7%), D67N (6.7%),
K219R (5.3%), G190A (4.0%), M184V (2.7%), L74V (1.3%),
Transmitted Drug Resistance in a Belgian Regional Epidemic
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Y115F (1.3%) and Y181C (1.3%). Within PR, I54VT (10.7%) was
the most frequent mutation followed by M46IL (9.3%), N88D
(6.7%), V82TS (2.7%), L24I (1.3%), I54T (1.3%) and I85V
(1.3%). As the inclusion of PR position 46 within the TDR
mutation list has been debated due to its polymorphic nature [38],
TDR was recalculated excluding this position. This resulted in an
overall TDR of 8.9% (69/778; 95% CI 7.0–11.0) and a PI-TDR
of 1.4% (11/778; 95% CI 0.8–2.5).
No significant time trends were found in the overall TDR
prevalence, nor in transmitted NRTI and PI resistance (see
Figure 1A). A parabolic trend was observed for NNRTI-TDR
(p= 0.019) with a peak in 2008. That corresponded with a peak in
occurrence of K103N (p= 0.026), the only mutation with a
temporal trend. Surprisingly, the parabolic temporal NNRTI-
TDR trend was not observed in the recently infected individuals.
Instead, a stable temporal trend was observed for overall TDR and
individual drug classes in this subset of patients. When the analysis
was performed according to region of origin, a significant
parabolic trend of NNRTI resistance was only found in patients
originating from Belgium (p= 0.039).
Factors Associated With Transmitted Drug Resistance
Univariate analysis was performed to identify predictors of
TDR (Table 1), which were male gender (odds ratio (OR) 3.25,
95% CI 1.52–7.99, p,0.001), Belgian origin (OR 2.09, 95% CI
1.20–3.77, p= 0.006), MSM transmission (OR 2.44, 95% CI
1.46–4.15, p,0.001), recent infection (OR 2.04, 95% CI 1.06–
3.75, p= 0.02), being part of TCs (OR 1.95, 95% CI 1.15–3.25,
p = 0.010) and infected with subtype B virus (OR 3.77, 95% CI
2.09–7.17, p,0.001). Only the latter remained a significant factor
(OR 3.04, 95% CI 1.45–6.35, p = 0.003) in multivariate analysis.
Since these types of analyses do not display possible interdepen-
dencies of the variables and subtype B was most frequently found
in MSM originating in Belgium (p,0.001), we evaluated the
interdependencies of the variables with a Bayesian network
approach. TDR was directly associated only with subtype B, but
this subtype was strongly associated with MSM (100% bootstrap
support) and with Belgian origin (97% bootstrap support), and to a
lesser extent to being part of TCs (78% bootstrap support) (See
Figure 1B). To verify whether we could find an important
predictor of TDR that could be used in guidelines to target a
subpopulation of newly diagnosed for preferential drug resistance
testing, we repeated the analysis excluding any information that
results from the genotype itself. When subtype B was thus excluded
from the analysis, then male gender became directly associated
with TDR (64% bootstrap support), and with MSM and Belgian
origin (100% bootstrap support), whereas the association between
the two latter variables with TCs had lower bootstrap support
(31%).
Transmission Clusters
We identified 114 TCs, 16 of which harbored 32 of the 75 TDR
patients from our Leuven ND cohort. Five pairs and eight larger
clusters of $3 individuals were found among subtype B infected
patients, one cluster of 17 individuals with CRF02_AG, and one
pair for each subtypes C and CRF01_AE (see Table 2). Six of
these 16 TCs with TDR included only a single patient with TDR
whereas six clusters were TCs with TDR-OT and included 20
individuals from the Leuven ND cohort (26.7%, 20/75).
Singletons were frequently found in patients from the Leuven
ND cohort involved in TCs (81.3%, 26/32). Likewise, prevalence
against NRTI was the most frequent (81.3%, 26/32), followed by
PI (25.0%) and NNRTI (12.5%). Thymidine analogue mutations
(TAMs) were predominantly detected in TCs with TDR (81.3%,
26/32), mainly represented by the revertant at position 215
(59.4%, 19/32), followed by the mutations K219QR (18.8%),
L210W (15.6%) and M41L (6.3%). Mutations for NNRTI and PI
were I54V, N88D (each 15.6%), K103N (12.5%) and M46IL
(9.4%).
The characteristics of the Leuven ND cohort patients involved
in TCs were evaluated. Patients carrying TDR were significantly
more associated with TCs compared to patients without TDR
(OR: 1.95, see Table 1 and Table S1) and the association
remained when considering only larger clusters by excluding pairs
(OR: 2.86, 95% CI 1.59–5.01, p=,0.001). Similarly, when
including only TCs with TDR-OT, TDR remained significantly
Figure 1. Temporal trends and factors associated with transmitted drug resistance (TDR). (A) Trends of prevalence of TDR (percentage)
and the 95% confidence intervals (light shading) among newly diagnosed HIV-1 patients at ARC Leuven (Belgium) from 1998 to 2012 are shown for
the overall-TDR, NRTI-TDR, NNRTI-TDR, PI-TDR in blue, MSM overall-TDR and Belgian overall-TDR in red. (B) The significant variables associated with
TDR in the univariate analysis were included in the Bayesian network, the number next to the arcs represents the bootstrap support. Abbreviations:
NRTI: nucleoside reverse transcriptase inhibitors, NNRTI: non-nucleoside reverse transcriptase inhibitors, MSM: men who have sex with men, PI:
protease inhibitors.
doi:10.1371/journal.pone.0101738.g001
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associated with TCs (OR: 2.44, 95% CI 1.32–4.36, p = 0.002, see
Table S1). 32 out of 75 TDR patients were involved in TCs
(42.6%, 95% CI 32.1–53.9), while of the 703 patients without
TDR, only 194 were found in TCs (27.6%, 95% CI 24.4–31.0). As
expected, Leuven ND cohort patients with TDR and involved in
TCs were significantly more of Belgian origin (90.6% versus
65.5%; OR: 4.84, 95% CI 1.41–25.78, p = 0.005), infected with
subtype B (90.6% versus 63.9%; OR: 5.42, 95% CI 1.59–28.85,
p = 0.001) and characterized with MSM risk factor (78.1% versus
52.6%; OR: 2.71, 95% CI 1.07–7.84, p = 0.03) than their
counterparts without TDR (see Table S1). When we focussed on
predictors for TCs with TDR by including the data of controls,
subtype B remained significantly associated with TCs with TDR
(77.4% versus 65.1%, OR: 1.83 95% CI 1.03–3.35, p = 0.036).
However, TCs of patients with TDR were larger than TCs
without TDR (median 3.5 vs. 2 patients per TC, OR: 1.43 95%
CI 1.08–1.91, p = 0.001). Belgium as sampling country or as
country of origin and heterosexual contact were then more
frequent in the group of TCs that included solely patients without
evidence of TDR. Multivariate analysis did not show any
significant factor associated with patients in TCs with TDR versus
other TCs. Finally, we also performed separate analyses on TCs
with TDR-OT (see Table S1). The same variables remained
significantly associated with TCs in the univariate analysis, with
the exception of recent infection that became significant. The
median of the TCs with TDR-OT was larger than TCs without
TDR (5.5 versus 2 patients per TCs, OR: 2.01 (1.29–3.11).
Likewise, none of the variables were significant in the multivariate
analysis.
The characteristics of the Leuven TDR patients involved in
TCs are shown in Table 2. Five pairs included mainly naive MSM
originating from Belgium, infected with a subtype B strain carrying
one of the 215 revertants, whereas two pairs with subtype C and
CRF01_AE strains displaying mutations at PR position 46
included heterosexual Belgians with a foreign partner. Two large
subtype B TCs with TDR included 9 or more patients. Cluster
number 5 was composed of nine therapy-naive individuals
originating from Belgium with MSM as a risk factor and
diagnosed between 2007 and 2012. Seven of them displayed a
revertant at RT position 215 while two strains had no TDR.
Cluster number 13 (Figure 2B) included 26 naive patients mainly
from United Kingdom and countries of western and southern
Europe, western Asia and America. The main mode of
transmission was MSM infected with viruses carrying mutations
at position 219, except for six individuals who mainly originated
from Cyprus and did not display any mutations. The remaining
subtype B TCs were composed of three to six individuals. All had
at least one individual originating from Belgium and one from
another country. For instance, cluster number 1 included one
patient originating from Belgium and two patients from Russia
and Pakistan but infected in other countries like Finland and
Spain. One peculiar subtype B cluster with extensive NRTI and PI
resistance (cluster number 3) contained 6 therapy-naive MSM with
TDR all with a Belgian connection, either infected in Belgium or
originating from Belgium. On the other hand, the largest cluster of
non-B subtypes was composed of 17 individuals infected with
CRF02_AG and sampled in different countries from Central-
eastern Asia and Eastern Europe and characterized by different
risks factors including heterosexual orientation, intravenous drug
Figure 2. Examples of subtype B transmission clusters (TCs) with TDR: A maximum likelihood (ML) tree per subtype was
constructed, and TCs were confirmed by Bayesian Phylogenetic analyses. (A) The ML tree for subtype B (Leuven ND cohort and control
sequences) with the TCs colored in dark red. (B) The largest TC of subtype B: composed of therapy-naive patients, several nationalities and mutations
at RT position 219; bootstrap values above 98% are shown. Abbreviations: AR: Argentina, CY: Cyprus, GE: Germany, IT: Italy, UK: United Kingdom, USA:
United States of America, black diamond: men who have sex with men, asterisk: posterior distribution equal to 1 in the Bayesian phylogenetic
analysis.
doi:10.1371/journal.pone.0101738.g002
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user (IVDU) or vertical transmission. The resistance pattern was
also heterogeneous in this cluster. The majority of patients did not
display TDR mutations, whereas one naive patient sampled in
Belgium and originating from Kazakhstan displayed a mixture of
K219RK, and one patient who was tested in Russia was probably
treated and displayed high-level resistance against NRTI and
NNRTI.
Since the definition of clustering is still a matter of debate,
additional analyses were performed to assess the impact of the
genetic distance on the identification of TCs with values of 0.015,
0.03 and 0.045. As a result, the number of TCs with TDR
decreased to 9, 13 and 17, respectively, including 22.7%, 29.3%
and 36.0% of the 75 patients with TDR. The number of TCs that
included TDR patients was larger with the genetic distance 0.045
because the cluster with 9 individuals identified as number 5 in
Table 2 was split in one pair (ARCL-16-TDR and ARCL-18-
TDR) and one cluster with the remaining patients. With the
stringent criteria of 0.015, TDR was still associated with TCs (OR:
2.56 05% CI 1.32–4.76, p= 0.003). Subtype B infection remained
as the factor associated with TCs with TDR (p= 0.002), whereas
sociodemographic factors such as Belgian nationality and MSM
contact were not significantly linked.
Potential Impact Of TDR On First-Line Regimen
For each patient with TDR, we analysed the genotypic
susceptibility score (GSS) of the three regimens most frequently
prescribed during the year the patient was diagnosed, and for each
patient who in the meantime had started treatment we also
estimated the GSS of the first-line therapy received. Rega
algorithm 9.1.0 was used for these analyses, which has a
recommended GSS for patients with TDR. This recommendation
was introduced in March 2007 and suggests a regimen with GSS
of$3.5 when TDR is detected, thereby suggesting a triple therapy
with a fully active boosted PI which receives a score 1.5, but not
with an NNRTI which receives a score of 1 when fully active.
Amongst the 636 patients who started ART, the GSS of the
actual prescribed first-line regimen was $3.5 in 261 patients
(41.0%), 3 in 357 patients (56.1%), and ,3 in 18 patients (2.8%).
The latter group included five patients without TDR, of which
three patients were treated with bi-therapy in 1998, one with bi-
therapy including a PI in 2002 and one with a mono PI regimen in
2010. Although the demographic characteristics were similar
between the patients with a GSS $3 and ,3, the latter group
more often started ART before 2002 (8/18, p,0.001).
In the group of patients with viruses carrying TDR, 60 started
therapy before the end of 2012. The GSS was $3.5 in 34 patients
(56.7%), equal to 3 in 13 patients (21.7%), and ,3 in 13 patients
(21.7%). The latter group displayed resistance only to NRTIs (6/
13), only to PI (2/13) or dual resistance (5/13).
Sustained undetectable viral load during the first-line therapy
was reached in 83.3% (50/60) of the TDR patients, whereas 3.3%
of the patients (2/60) had sustained low level viremia without
evidence of virological rebound above 500 copies/ml. Four
patients (6.7%) had early changes in ART due to toxicity and 1
patient (1.7%) died shortly after therapy initiation. Only 5.1% of
the patients (3/60) displayed virological failure and the emergence
of major NNRTI resistance-related mutations. Two of these
patients displayed evidence of only NRTI TDR mutations at
baseline and received a NRTI+NNRTI regimen with a GSS equal
to 3. The third patient started a NRTI+NNRTI therapy with a
GSS equal to 1 in 2004, two days after the first contact date and
two weeks before the drug resistance results were available. In this
patient, the therapy was quickly changed after receiving the
baseline drug resistance report indicating NRTI and NNRTI
TDR mutations and observing no virological response. Subse-
quent drug resistance testing on a later sample revealed further
accumulation of NNRTI resistance.
To appreciate the value of baseline drug resistance testing, the
GSS was calculated for the three most frequently prescribed first-
line regimens in patients displaying TDR in our cohort per year
(see Table S2). Theoretically, 49.3% of TDR patients (37/75) were
likely to receive a potential suboptimal regimen (GSS,3) if
baseline drug resistance testing had not been available to the
treating physician. However, the frequency of these patients is
decreasing over time (p = 0.002). Up until 2003, the most common
first-line regimens included a thymidine analogue with either a
NNRTI- or unboosted PI. Thereafter, tenofovir or abacavir were
more commonly used as supporting NRTI, but a GSS,3 was still
mainly observed for NRTI+NNRTI regimens. A low GSS under a
boosted PI based regimen would only have accounted for
approximately 15% of the TDR cases per year between 2005
and 2011.
Discussion
The TDR surveillance in the 778 included patients who were
newly diagnosed with HIV-1 at our clinic in Leuven showed a
stable overall prevalence of 9.6% between 1998 and 2012. This
result is in line with the 9.5% of the latest national survey that
included 285 patients who were newly diagnosed in Belgium
between 2003 and 2006 [11]. It was also consistent with the stable
overall TDR levels of 9.7% in Spain and of 9.0% in France, results
from national surveys with a similar design and time frame as our
study [34,39], and with the overall trend of 8.9% in Europe
between 2002 and 2007 [26,40]. However, the overall TDR in our
local epidemic was higher than the 5.6% between 2003 and 2010
in Sweden [5] and the 6.5% between 2001 and 2009 in Ghent
(Belgium) [4]. These regional differences highlight the importance
of studying local epidemics and suggest that TDR prevalence may
vary within a single country. Indeed, our findings may not be
generalizable to the HIV-1 epidemic in Belgium because our
cohort has a higher prevalence of MSM and of individuals
originating from Belgium. It should be pointed out, however, that
the demographic characteristics data of our study population was
more complete than the national database for which nationality
and mode of transmission were not available in approximately
25% of the cases. Although our study could have overestimated
the level of TDR, due to patients who were unwilling to disclose
their ART status, measures were taken to decrease the number of
misclassifications. Patient records were exhaustively revised by
clinicians and virologists, and individuals with evidence of drug
resistance and viral load profiles suggestive of treatment were not
considered drug naive.
While subtype B, being MSM, male gender, originating from
Belgium, recently infected, and involvement in TCs were all
significant predictors for TDR, only subtype B remained
significantly associated in the multivariate analysis. Bayesian
analyses however, showed the dependency of this factor on being
of Belgian origin and MSM. Similarly when subtype B was
excluded, male gender became directly associated with TDR with
low support but significantly dependent on Belgian origin and
MSM. These findings are in agreement with previous reports from
other Belgian, European and American studies [4,5,11,39,41]. In
a recent study, the association of subtype with country of sampling,
risk group and gender has been interpreted as evidence for highly
compartmentalized epidemics in Europe [42]. Therefore, the early
introduction of subtype B in European MSM and their broad
access to HIV care and ART for decades might explain the single
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direct association of subtype B with TDR in many resource-rich
settings. Nevertheless, recent studies revealed an increasing
prevalence of TDR among Sub-Saharan African migrants residing
in Spain and Sweden, potentially linked to the increasing drug
resistance levels in Africa [5,43]. However in our cohort, Sub-
Saharan African patients were still associated with less TDR and
we did not observe a time trend in those patients (data not shown).
Fluctuations in TDR levels were observed over the entire study
period, but the only significant trend was a parabolic trend
detected for transmitted NNRTI resistance. The overall NNRTI
TDR prevalence was 2.2%, with a maximum of 6.5% in 2008-
2009. This parabolic trend, mainly linked to the detection of
K103N and to a Belgian origin, was not observed among recently
infected patients. Although a parabolic trend with a peak in 2004
was also described in the SPREAD study that included data up
until 2005 [26], the same surveillance up to 2007 showed a linear
increase over time [40] potentially associated with the frequent use
of NNRTI in first-line regimens as the authors suggested.
Similarly, the local change of prescribing practices to more potent
regimens in later years, use of drug resistance testing and the
longer time period analyzed in this study could explain the
parabolic trend. In the total cohort, TDR associated with NRTI
and PI resistance fluctuated around 6.5% and 2.2%, respectively.
Among recently infected patients, NRTI- and PI-TDR levels
increased to 12.4% and 6.7% respectively. This increase was not
observed for NNRTI resistance, presumably due to the lower
impact of NNRTI mutations on viral fitness with consequently a
lower likelihood of reversion to wild-type and of a TDR
underestimation by population-based Sanger sequencing in
chronically infected patients.
Singletons were predominantly detected in our cohort, with
TAMs as the most commonly observed. Although the use of
zidovudine has decreased over the last few years, we did not find
any time trend for TAMs. The peak in NNRTI TDR in 2008 was
not related to clustered transmission of TDR or migration from
other countries as has been suggested in other settings [12,43].
However, it might have been linked with the enhanced use of
NNRTI-containing combinations in the years before. From 2009
onwards, the most commonly prescribed regimen was the potent
combination tenofovir+emtricitabine+efavirenz. Up until 2012, no
other available NNRTI- or PI/ritonavir-based regimen had
proven superior to this regimen with respect to virologic responses.
If resistance testing had not been performed and patients with
TDR would have received one of the preferred first-line regimens
at that time, approximately half of them would likely have received
a regimen in which the virus had lost susceptibility to at least one
of the prescribed drugs. Irrespective of the detected TDR by
population-based Sanger sequencing, all of them would have had
a higher risk of virological failure, as NNRTI-based regimes were
commonly prescribed from 2002 onwards [8]. However, 83% of
the patients with TDR and who started ART achieved undetect-
able viral load thanks to the prescription of potent regimens
enabled by the availability of drug resistance results. Only 3
patients with baseline resistance to NRTI had virological failure
with development of NNRTI resistance after the initiation of a
NRTI+NNRTI regimen.
In this cohort, 42.6% of the TDR patients were involved in
TCs, which included nine clusters and seven pairs. Because we
were interested in observing TCs over a period of 15 years, a
genetic distance of 0.06 substitutions per site and a bootstrap
support of $98% were used to define TCs. These TCs were also
confirmed using Bayesian phylogenetic techniques, indicating that
the obtained results were robust [4,7,34]. Although, the compar-
ison between studies of transmission networks is difficult due to the
differences in sampling, phylogenetic techniques and the lack of a
standardized TC definition, our results were in line with a study
carried out in Ghent (Belgium) in which 18 out of 33 (55%) TDR
patients were involved in pairs or larger clusters [4]. When a more
stringent criterion of 0.015 genetic distance was used, the
percentage of TDR patients involved in TCs decreased to
approximately 23%. In general, some conclusions can be drawn
from the TCs analyses. First, none of the factors were significantly
associated with TCs with TDR in the multivariate model,
although a dependency between subtype B and clustering was
found in the Bayesian network and TDR was significantly
associated with TCs in the univariate analysis. Therefore we were
unable to identify a non-sequence based predictor of being in TCs
with TDR, even though the odds were higher for patients who
were MSM and originating from Belgium. This result is similar to
other studies performed in Europe [4,34]. Second, TAMs were
more frequently found in TCs and this was also observed in the
Ghent cohort and other settings [3,4,7]. Third, TCs with TDR
involved mainly therapy-naive individuals, chronically or recently
infected, rather than ART-experienced patients, which could
suggest that drug naive people, potentially unaware of their HIV
seropositive status, are the main source of TDR instead of patients
failing ART [3,6,7]. Fourth, 7 out of 16 TCs with TDR involved
patients of different nationalities. Although, we were not able to
retrace the country of infection in many instances, this may imply
that migration plays an important role in the local spread of
subtype B as previously described [44], but also of TDR. Fifth,
spread of non-B subtypes in the local epidemic was still limited and
was related with heterosexuals as has been described in other
epidemics [6]. They were also not prone to spread TDR. They
often involved Belgians and other nationalities that could imply a
limited intermixing of the HIV-1 epidemic between locals and
immigrants.
Although we used all the sequences available in public databases
and from a collaborative European dataset, for 7 TCs with TDR
we did not find evidence that patients other than the ones followed
at our clinic were involved in transmission networks. Similarly, 6
TCs with TDR patients from the Leuven ND cohort included only
a single patient with TDR, and for these patients, no evidence of
onward transmission of TDR is available. When 3 or more
patients in a TC had the same TDR mutation profile, we indicated
the cluster as TDR-OT, since this is suggestive of onward
transmission of TDR, although we cannot exclude that all these
TDR patients received their resistance from a treated patient. The
association between TDR and TCs remained, also for those TCs
with TDR-OT. Since 27% of the patients from the Leuven ND
cohort were involved in those TCs, this could imply an important
role of local transmission on the spread of TDR. Nevertheless, we
cannot exclude the possibility that the networks might include
other intermediary individuals who were not sampled or unaware
of their seropositive status, known limitations of phylogenetic
analyses.
Singletons and the TAM 215 were predominant in TCs, but the
clinical impact on the current first-line therapies remains limited.
However, two TCs that involved MSM individuals originating
from Belgium with viruses carrying the K103N were detected. The
latest diagnosis date was 2009 in these TCs, suggesting that in our
local epidemic this mutation was not involved in a recent spread in
contrast to a reported outbreak in Namur (Belgium) [12].
Continuous monitoring of the spread of this mutation is required
to establish the impact on current practices. On the other hand,
two large clusters were detected with the TAM 219 and they
involved different nationalities from Europe, Asia and America.
One of these TCs contained one patient living in Belgium but
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originating from Kazakhstan, and control sequences from
Uzbekistan that were part of an outbreak of CRF02_AG among
IVDU [45]. Our analyses revealed the involvement of other
countries and risk groups and the absence of K219R in many of
the clustered sequences. The other large cluster included MSM
individuals infected with subtype B and control sequences mainly
from United Kingdom [46] and other countries in Europe. The
majority of strains in this cluster displayed K219Q with only a few
strains displaying K219R or no TDR.
In summary, this study showed a stable trend of almost 10%
overall TDR between 1998 and 2012 in our Leuven (Belgium)
cohort. TDR associated with NNRTI resistance displayed a
parabolic trend that overlapped with an up-and-down NNRTI
TDR trend in Belgians and with the trend of K103N. Our cohort
was mainly composed of chronically infected patients and around
43% of the patients with TDR were involved in transmission
networks, suggesting public health policies that target early
diagnoses of recently infected patients are needed. Although the
main factor related with TDR was subtype B, this variable was
dependent on Belgian nationality and MSM mode of transmission.
While these variables were also associated with being in TCs with
TDR, we were unable to significantly identify a population that
could be targeted for future TDR prevention policies. More local,
national and international surveillance studies are needed to
confirm the significance and durability of our observations, as
changes in TDR levels and patterns are not straightforward to
predict due to potential changes in prevention, testing and
treatment strategies and changes in other potentially important
drivers, such as e.g. behaviour and migration.
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